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 CHAPTER I 
 
INTRODUCTION 
 
Introduction to influenza 
     Influenza is one of the most well-known viruses and infectious diseases because of its global 
spread and seasonal patterns. Influenzas are enveloped viruses that contain 7-8 negative-sense, 
single-stranded RNA segments, which code for up to 14 different proteins (Figure 1.1). Based on 
immunologic and biologic properties, influenza viruses are divided into three main types: A, B, 
and C.1 Influenza A, the major genera infecting humans, is further divided into subtypes and 
named based on the two major membrane glycoproteins: hemagglutinin (HA) and neuraminidase 
(NA). Eighteen HA and 11 NA subtypes have been identified thus far, however not all types cause 
human infection.2  
 
 
Figure 1.1 Influenza virus structure.3  Reprinted with permission from AAAS. 
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     Each year 3-5 million infections and 250,000-500,000 deaths associated with seasonal 
influenza outbreaks occur worldwide.4 While there is a seasonal influenza vaccine, it has to be 
updated each year to match the strains circulating in the population.5 Influenza viruses have no 
RNA polymerase proofreading activity, which yields an error rate of approximately one mutation 
per replicated genome.6 As mutations build up (antigenic drift), the virus can escape immune 
surveillance and require a new vaccine. Additionally, the segmented nature of the RNA genome 
allows for major antigenic changes through reassortment of co-infecting viruses, typically in an 
intermediate host (antigenic shift).7 This introduces new HA and/or NA subtypes into a naïve 
human population, which can lead to pandemics (Figure 1.2). 
 
 
 
Figure 1.2 Timeline and evolution of pandemic influenza viruses.8  Pandemics in the 20th century were caused 
by various reassortments with between birds, pigs, and humans. The color of the proteins and gene segments 
represent the originating species: pink = avian, green = human, yellow = human, blue = swine, purple = swine. Future 
pandemic viruses could emerge from antigenic drift, antigenic shift, or re-emergence of old strains. Reprinted from 
Trends in Microbiology, with permission from Elsevier. 
 
     The 1918 Spanish Influenza (H1N1) pandemic infected 20-40% of the world’s population and 
killed approximately 50 million people, making it the worst influenza pandemic on record.9 Three 
other influenza pandemics occurred in the 20th century and one in the 21st century. Fortunately, 
these pandemics have not been as catastrophic. All five of these pandemic influenza viruses had 
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some form of avian origin.10-12 Today, the biggest potential pandemics are highly pathogenic avian 
influenza (HPAI) viruses. The first direct HPAI transmission from birds to humans occurred in 
1997 in Hong Kong with H5N1.13 Since then, there have been 856 confirmed human cases and 
a 53% mortality rate (Figure 1.3).14 Almost all of the cases have occurred from direct bird-to-
human transmission. The failure of the viruses to be readily transmitted from human to human 
has kept it from becoming a pandemic. 
 
 
Figure 1.3 Locations of confirmed human cases for avian influenza A (H5N1).14 
 
     H5N1 is a very diverse avian influenza subtype. The World Health Organization (WHO) has 
created a unified nomenclature system for the many clades and sub-clades of H5N1 that is 
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continuously updated when clades diverge (Figure 1.4).15-16 Given how quickly H5N1 has 
diversified in ten years, it is reasonable to worry about if the mutations acquired over time will 
eventually lead to human-to-human transmissibility in the near future. In fact, Herfst et al. showed 
that only five mutations were necessary for H5N1 to become airborne and transmissible between 
ferrets, an accepted model for human transmissibility.17 
 
 
Figure 1.4. Evolution of the H5 hemagglutinin protein.  Over time, the WHO has divided the clades into second 
order, third order, etc. clades based on nucleotide divergence in the H5 HA protein.15 
 
Immune responses to infections and vaccines 
     The human immune system is a complex collection of different organs, cell types, and effector 
molecules, that recognize, neutralize, and eliminate infectious microorganisms, such as the 
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influenza virus.18 This complex system also recognizes and responds identically to microbial 
antigens in vaccines to produce immunological protection against the naturally occurring 
pathogenic organisms. The immune system is divided into two branches: the innate and adaptive 
systems. Both branches are defined by specialized cell types and functions (Figure 1.5) 
 
 
Figure 1.5 Overview of the immune response timeline after a vaccine is given.Cell icons reproduced from 
Janeway’s Immunobiology by Murphy, Kenneth et al. with permission of Garland Sciences via Copyright Clearance 
Center. 
 
     The innate immune system acts as the first line of defense against infectious agents. It 
responds rapidly, but does not lead to long lasting, protective immunity against the pathogen. 
Innate cells, including neutrophils, macrophages, natural killer cells (NK), and dendritic cells (DC), 
rely on a limited number of receptors and secreted proteins to recognize and respond to common 
foreign antigenic features termed pathogen associated molecular patterns (PAMPs).18 Microbial 
products including lipopolysaccharides, peptidoglycans, bacterial RNA and DNA, and lipoteichoic 
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acid are examples of PAMPs recognized by the host’s innate pattern recognition receptors 
(PRRs). When pathogens are detected, they are phagocytized and degraded by the innate cells. 
The activated innate cells secrete numerous cytokines and chemokines that, in turn, activate and 
recruit other immune cells to the site of infection. NK cells, while innate in nature, are derived from 
the lymphoid lineage, while the other innate cell types differentiate from the myeloid lineage. A 
unique feature of NK cells is their ability to recognize stressed cells and directly induce apoptosis 
in cells that are missing key cell surface receptors.18  
     Macrophages and DCs, also called antigen-presenting cells, display peptides from the 
destroyed pathogen on their cell surface using the major histocompatibility complex (MHC) protein 
complex. The MHC is a group of cell surface proteins that controls a large portion of the immune 
system in all vertebrates. The MHC binds pathogen-derived peptide fragments and displays them 
on the host’s cell surface for T cells to recognize.18 In a healthy cell, the proteasome degrades 
intracellular proteins into short peptides and amino acids for recycling and building of new 
proteins. Some of these peptides are transported to the endoplasmic reticulum, where they are 
associated with MHC class I molecules and are presented on the cell’s surface in the MHC 
complex, which indicates the cell is healthy.19 MHC class II receptors display peptides derived 
from extracellular proteins that have been phagocytosed and digested in the lysosomes of the 
host cell. Antigen-presenting cells migrate to the lymph nodes where they present peptides in the 
context of MHC to naïve, antigen-specific T cells, thus activating them.18 
      Compared to the innate immune response, an adaptive immune response takes longer to 
generate, but is highly specific to the particular antigen and pathogen. Critically important, the 
adaptive immune system provides long-lasting protection against the pathogen, which is the 
ultimate goal of vaccination. There are two broad classes of adaptive responses. First, B 
lymphocytes are responsible for the humoral antibody response.18 Each B cell has a unique B-
cell receptor on its surface, which binds to one particular antigen. Naïve B cells whose receptors 
bind antigen and receive a secondary signal from a T-helper cell differentiate into either plasma 
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cells or memory B cells.18 Plasma cells proliferate and secrete large amounts of antibodies that 
recognize the targeted pathogen, neutralize it, and mark it for destruction. Next, T lymphocytes 
are responsible for cell-mediated immunity, which recognizes and destroys infected host cells. 
Several subsets of T cells exist, each with a different function. T-helper cells assist other cells, 
such as B cells, macrophages, and cytotoxic T cells, in their functions. This type of T cell becomes 
activated from interaction with MHC class II complexes. Cytotoxic T cells destroy infected host 
cells by recognizing foreign antigens displayed in the context of the MHC class I receptor on the 
surface of the infected cell. Finally, regulatory T cells are critical for the maintenance of tolerance 
by shutting down cell-mediated immunity at the end of the infection. Long-lived memory B and T 
cells enable the immune system to rapidly respond to and neutralize secondary infections by 
pathogens that have previously been encountered (Figure 1.6).18 The protective function of the 
memory adaptive immune response includes neutralizing the pathogens before they can enter 
host cells, as well as recognizing and destroying pathogen-infected cells before the pathogen can 
multiply. Vaccines mimic pathogenic infections by stimulating the immune system to respond and 
acquire immunological memory. 
 
 
Figure 1.6 The principle of vaccine induced immunological memory as illustrated with a tetanus toxoid 
vaccine.  Vaccination with a chemically modified tetanus toxin produces a toxoid, which has no toxicity, but retains its 
epitopes. A primary antibody response is formed against this toxoid. Later when a natural infection of tetanus toxin 
occurs, B cells are restimulated and produce a faster and more intense secondary antibody response to the original 
epitope. From Roitt et al. 2001.20 
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A brief history of influenza vaccines  
     Vaccinating against the influenza virus is the primary approach for controlling the infection. As 
vaccines mimic natural pathogenic infections by stimulating the immune system to respond and 
acquire immunological memory, inactivated and live attenuated vaccines have been developed.21 
A live attenuated influenza vaccine (LAIV) was first developed in 1936,22-23 followed by an 
inactivated influenza vaccine in the 1940s.24 Live attenuated vaccines are passed through a 
foreign host to become less pathogenic, while inactivated vaccines use heat or formaldehyde to 
kill the pathogen.9 Over time, whole-virus vaccines have been largely replaced with purified split 
virus and subunit vaccines in order to reduce reactogenicity. Split virus vaccines have the virus 
disrupted by a detergent, while subunit vaccines are further purified to include only the portion of 
the pathogen that stimulates the immune system, such as the HA protein of influenza viruses. 
Today, the main seasonal influenza vaccine available is an inactivated trivalent influenza vaccine 
(TIV), which includes representative strains for A/H1N1, A/H3N2, and B virus.21 The specific 
strains are selected based on the surveillance of the circulating viruses from the previous year.25 
Quadrivalent vaccines, which contain both lineages of B virus, are also available, however these 
are not yet as widespread.26  
     Pandemic influenza vaccines historically have been developed using the same technology as 
the inactivated seasonal vaccines. The viruses are grown in the allantoic cavities of embryonated 
chicken eggs, harvested as liquid, undergo inactivation with formalin or β-propiolactone, and are 
further purified to remove unwanted proteins and other molecules.9 However, vaccine 
development for avian influenzas has been hindered due to the virus being rapidly lethal to eggs, 
the system in which these viruses are grown.21 Therefore, the product obtained is poorly 
immunogenic. An inactivated split-virus influenza A/Vietnam (H5N1) vaccine prepared by Sanofi 
Pasteur requires two 90 µg doses given 28 days apart to stimulate an antibody response in 57% 
of young healthy adults.27 For comparison, standard seasonal vaccines include just 15 µg of HA 
protein per strain.  
9 
 
     Research toward growing viruses for vaccines in continuous cell lines is ongoing in order to 
eliminate the need for eggs.28-30 This would allow for increased reproducibility, reduced risk of 
animal-derived protein products in the vaccines, and allow individuals allergic to eggs to be 
vaccinated. Two cell lines are the main focus of research: African green monkey kidney cells 
(Vero) and Madin-Darby canine kidney cells (MDCK). A comparison study of these two cell lines 
infected with a human influenza virus identified 55 proteins and 32 proteins, respectively, which 
were shown to be differentially expressed through 2-dimensional difference gel electrophoresis 
(2D-DIGE) and nano-liquid chromatography (LC) - electrospray ionization (ESI)-MS/MS.29 The 
Vero cells showed a stronger stress response to the virus, which may increase cell apoptosis 
early before enough product is generated. MDCK cells did not show stress responses. Vaccines 
produced from both cell lines have been in clinical trials showing similar immunogenicity and 
safety metrics to traditional egg manufacturing methods.31-34 In 2012 the FDA approved the 
Flucelvax (Novartis) vaccine, which uses MDCK cells for manufacture. Further, in August 2016, 
the FDA approved the use of cell-based candidate vaccine viruses in the production of 
Flucelvax,35 which could pave the way for avian influenza vaccines to be produced from these 
cells. 
     An additional benefit of producing pandemic avian influenza vaccine viruses in cell lines is that 
these methods may produce more immunogenic strains. Clinical trials of a Vero cell-derived whole 
virus H5N1 vaccine have shown that subjects showed protective responses after two 7.5 µg or 
3.75 µg doses given 21 days apart.33-34 However, it may be years before pandemic avian influenza 
vaccines produced using this method are licensed for widespread use. Therefore, other methods 
of enhancing the immunogenicity to vaccine antigens need to be developed. 
 
Vaccine adjuvants 
     Adjuvants are one approach to enhance the immunogenicity to vaccine antigens. Adjuvants 
are added to vaccines in order to increase the stimulation of the immune response by either 
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enhancing antigen presentation or providing costimulatory signals.36 Adjuvants have been called 
the “dirty little secret” of vaccines by the scientific community due to how they were discovered.37 
In 1930, Glenny and colleagues noticed that after precipitating diphtheria toxoid with aluminum 
sulfate and injecting the “dirty” vaccine into guinea pigs, there was a much greater immune 
response than to the toxoid alone.38-39 Using an adjuvant, the amount of antigen can be decreased 
(dose-sparing). In addition, adjuvanted vaccines can improve the immune response in populations 
who respond poorly to vaccines, such as elderly and immunocompromised individuals.36 
     Several types of immunologic adjuvants exist depending on the mechanism used to stimulate 
the immune response.40 Inorganic aluminum salts, typically aluminum phosphate and aluminum 
hydroxide (termed alum), are the most widely used adjuvants in human vaccines.41 Alum has 
been shown to activate complement42 and the Nalp3 inflammasome,43 but the precise mechanism 
behind the action of alum adjuvants is unknown. It has been hypothesized that the antigen 
adsorbs on the alum particles, which prolongs its availability to antigen presenting cells.41 
However, it has also been shown that alum causes inflammation at the injection site, resulting in 
antigen presenting cells being recruited to the area.41 
     In addition to alum, monophosphoryl lipid A (MPL) is an adjuvant used in licensed U.S. 
vaccines. MPL is derived from the lipopolysaccharide (LPS) of Salmonella Minnesota R595,44 but 
has only ~0.1% of the toxicity of LPS.45-47 MPL works by signaling through Toll-like receptor 4 
(TLR4) to induce a balanced Th1/Th2 immune response.48 MPL generally is used in combination 
with other compounds as an adjuvant system, rather than alone.47 As AS04, MPL is adsorbed 
onto alum and is included in the licensed HPV vaccine Cervarix (GlaxoSmithKline).48 Additionally, 
MPL is found with QS21, a plant saponin, in AS02 and AS01, where AS01 also contains 
liposomes.47, 49 Most recently, the WHO announced that pilot projects of the Mosquirix 
(RTS,S/AS01) vaccine against malaria will be conducted in sub-Saharan African countries to 
assess the efficacy of the vaccine in the field, which may help it get licensed.50-51 
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     Oil-in-water emulsion adjuvants are another class that are used, particularly in instances when 
alum adjuvants have proven insufficient. They are thought to increase the trafficking of DCs and 
macrophages to the lymph nodes.41 In addition, they are thought to increase the release of 
cytokines and chemokines from innate cells at the injection site, thus recruiting B and T cells to 
the site. MF59 (Novartis), a squalene-based adjuvant, appeared for the first time in a U.S. 
seasonal flu vaccine (FLUAD) during the 2016-2017 season after being licensed in 2015.52  
Another oil-in-water emulsion adjuvant, AS03 (squalene + α-tocopherol, GlaxoSmithKline), is 
included in an H5N1 vaccine in the U.S. National Stockpile in case of a pandemic.53 
     Many other types of adjuvants are being developed with the hope of being able to more finely 
tune the immune response for each pathogen. The saponin QS-21 has been shown to activate 
human monocyte-derived dendritic cells and promote expression of IL-1β.54 Synthetic 
oligodeoxynucleotides containing unmethylated CpG motifs (CpG adjuvants) target TLR9 and 
enhance humoral immunity.55 Cytokine mixtures,56 bacterial endotoxins, D-tetrapeptide-based 
hydrogels,57 and others have also been investigated to direct the immune response.58 
 
Systems biology in the study of vaccines 
     Historically, vaccines have been developed empirically using observational knowledge of 
natural infections and immunity classically illustrated by Edward Jenner’s smallpox vaccine in 
1798.59 Jenner used moderately harmful cowpox to immunize against the much more dangerous 
smallpox (Variola) disease. Jenner obtained this idea through a combination of village folklore 
about milkmaids not becoming infected with smallpox because of previous exposure to cowpox 
and a conversation in 1763 with Dr. John Fewster who speculated that cowpox might protect 
against smallpox.60 When this approach proved successful, more controlled, and scientific 
experiments were developed to lessen the pathogenicity of specific disease-causing vaccines.59 
Louis Pasteur first showed the attenuation of infectious pathogens by passage in tissue or cell 
cultures during the development of a chicken cholera vaccine in the late 1870s.59 Since then, a 
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number of successful vaccines have been developed using attenuated pathogens or even just 
killed pathogens. However, due to the empirical nature of vaccine development, not much was 
understood about how these vaccines were conferring protection. Still, immunologists found 
methods to assess the efficacy of vaccines. 
     Correlates of protection, a measurable immune response that is statistically related and 
responsible for protection, were identified for each vaccine.61 Antigen-specific antibody titers 
against the vaccine have been the gold standard for correlates of protection for most pathogens.61-
62
 Vaccine-specific antibody levels are measured through standardized serological methods 
including ELISA to determine binding antibody titers, as well as neutralization and 
hemagglutination inhibition (HAI) assays. These methods result in a single value representing the 
full immune response. For example, following influenza vaccination, a serum HAI antibody level 
greater than 1:40 dilution against the hemagglutinin protein is considered protective.62 However, 
a single value threshold may not be sufficient as a correlate of protection due to the natural 
variability of human biology. In addition, measuring antibody response may not always be the best 
or only correlate of protection. T cell response is another form of protection that is currently used 
for the varicella zoster63 and Bacillus Calmette-Guerin (BCG)64 vaccines. CD4+ T-cell proliferation 
assays are the correlate of protection for the zoster vaccine, while interferon levels produced by 
CD4+ T cells are measured after BCG vaccination.64 Identifying correlates that are not based on 
antibodies tends to be more time consuming, expensive, and difficult to perform and interpret 
compared to antibody assays. 
     In response to such limitations and difficulties to identify and measure vaccine correlates of 
protection, current vaccine research has seen a large push toward systems biology studies to 
study global immune responses to vaccines. Systems biology is an interdisciplinary approach, 
typically combining multiple –omics fields, that aims to explain complex interactions between all 
components in biological systems.65 This approach (termed systems vaccinology) allows for the 
mechanisms of vaccines to be better understood in order to develop better vaccines and to assess 
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the efficacy of current vaccines. One goal of systems vaccinology is to predict vaccine 
immunogenicity and efficacy without relying on the current correlates of protection that are not 
necessarily the best indicators of protection.65  
     It is hypothesized that dynamic blood transcriptomes and proteomes will show immune 
response events that correlate with traditional correlates of protection. The first vaccine to be 
studied this way was the yellow fever vaccine, YF-17D.66-67 Considered one of the most successful 
vaccines ever developed, YF-17D provided a good model vaccine to determine the utility of 
applying systems approaches to vaccines.65 Using RNA microarrays, Querec et al. identified 
translation initiation factor EIF2AK4 as being correlated with protective cell-mediated and antibody 
responses, thus providing a predictive signature.66 Similar studies for TIV68-69 and meningococcal 
conjugate vaccines70 have also identified specific gene signatures correlated either positively or 
negatively with ultimate antibody responses. Any of these signatures could potentially be 
classified as correlates of protection if they pass validation. Most interestingly, very early gene 
expression patterns have been identified as being associated with later antibody responses.69, 71 
Bucasas et al.69 and Nakaya et al.71 identified interferon signaling and antigen presentation 
pathways up-regulated within the first 24 hours after vaccination. This is a very significant finding 
for the area of pandemic vaccines, where early determination of a person’s ability to develop long-
term protection is beneficial. These systems vaccinology studies have offered insights into how 
protective immunity is generated by investigating multiple immune system components, including 
mRNA transcripts, antibody responses, and proteins, to obtain a comprehensive assessment of 
the response to vaccines.65, 72 
 
Proteomics in systems vaccinology 
     While transcriptomic studies are currently expanding our knowledge base about the response 
to vaccines, systems vaccinology is largely ignoring the proteomics piece of the puzzle. 
Transcriptomics and proteomics are closely related in that they measure dynamic expression 
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patterns in response to stimuli. However, multiple studies demonstrate that mRNA and protein 
expression do not correlate at a given time or even over time.73-75 By excluding proteomic data, 
important information about the immune response and possible correlates of protection are 
potentially missed. 
     Initial proteomic studies have taken an almost identical approach to RNA studies and used 
protein and peptide microarrays. Davies et al. printed the entire proteome of vaccinia virus on 
microarray chips and then probed the chips with serum from vaccinated individuals.76 Antibodies 
in the serum bound to proteins on the chip were observed using fluorescent secondary antibodies 
to obtain a quantitative measurement. Price et al. found similar results using both whole protein 
and peptide microarrays for influenza. In addition, peptide-array reactivity significantly correlated 
with age and neutralization titer.77 It also has been proposed that certain biomarkers present prior 
to vaccination can also predict later vaccine response. Using peptide microarrays, four viral 
influenza hemagglutinin peptides were identified with expression levels that correlated to the pre-
vaccination HAI titer.78 This allowed for a model that successfully identified “good” and “poor” 
responders to an influenza vaccine based on their baseline antibody repertoire. It is important to 
note, though, that these studies tested only the antibody repertoire, a small portion of the immune 
system’s proteome response, to vaccines.  
 
Quantitative Proteomic Methods and iTRAQ 
     Gel-based proteomic methods largely dominated the proteomics field until mass spectrometry 
(MS)-based methods were introduced.79 MS allows for the high-throughput detection of ionized 
gas-phase analytes based on their mass-to-charge ratio (m/z). Electrospray ionization (ESI) is 
one available method to ionize the analytes.80 As ESI ionizes analytes from solution, it can easily 
be combined with liquid separation methods, such as liquid chromatography (LC).81-83 This is 
especially beneficial for highly complex proteomics samples.84 After ionization, analytes are 
manipulated by electric and/or magnetic fields in order to separate them by their m/z for detection. 
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Tandem mass spectrometry (MS/MS) can also be performed to obtain more structural information 
about the analytes.85 In MS/MS, a precursor ion is selected, isolated, and fragmented into product 
ions, which are then detected. This can be done in time within one trapping analyzer or in space 
with hybrid instruments containing multiple analyzers in series. In the case of proteomics, the 
starting sample is typically a mix of peptides derived from enzyme digested proteins. When these 
peptides undergo MS/MS, sequence information can be extracted from their spectra because 
peptides fragment at predictable locations, with b- and y-ions being the most common (Figure 
1.7).84 Further, the peptides can then be mapped back onto the proteins from databases in order 
to determine which proteins were present in the original sample.86  
 
 
Figure 1.7 Peptide fragmentation locations. 
 
     Currently, proteomics methods are focused on quantitative studies rather than just protein 
identifications.87-88 Multiple methods have been developed for quantitation of proteins using MS, 
each offering benefits and limitations (Figure 1.8).89 Generally, these methods are divided 
between label-free and label-based methods. Label-free methods first allowed for the comparison 
of the same proteins across different experiments in their natural state. The area under the curve 
obtained as peptides elute or spectral counting are two methods for label-free quantitation,90 
however high reproducibility is required for the different samples to be compared.91  
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Figure 1.8 Comparison of quantitative proteomic mass spectrometry methods.  Each method indicates when 
samples are labeled (shown by blue [light] and red [heavy]). The exception is label-free quantitation, which analyzes 
each sample individually and compares the data using AUC, spectral counting, etc. Samples are labeled in vivo in 
metabolic labeling, combined, and processed for analysis. In enzymatic and chemical labeling, protein extraction 
occurs prior to labeling. Enzymatic labeling adds the isotopes during digestion. With chemical labeling, the peptides 
are labeled after digestion. Isobaric tags, a subcategory of chemical labeling, requires LC-MS/MS to generate 
cleaved tag spectra in the MS2 for quantitation. Known amounts of spiked heavy peptides are added to unlabeled 
samples, which allows for a standard curve to be made. This leads to absolute quantitation. Adapted from Thermo.92 
 
     Stable isotope-labeling methods were developed to overcome the label-free limitations and 
offer higher accuracy of measurements, but do require additional steps and higher cost. Label-
based methods make use of stable heavy isotopes (13C, 15N, 18O) to produce mass shifts of 
peptide peaks in the mass spectrum, while maintaining the original isotope pattern.91 These heavy 
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isotopes largely do not affect the behavior of the peptides and proteins during chromatography or 
in the mass spectrometer. Therefore, the relative-abundance ratios (peak intensities) of peptides 
can be compared between the different labeled samples to obtain quantitative information.  
     The simplest labeling method involves the spike-in of isotope labeled standards, which allows 
for absolute quantitation (AQUA). However, heavy-labeled peptides have to be synthesized for 
each peptide being quantified, which can be costly.93 Isotope labels can also be covalently linked 
to the proteins and peptides. In this case, the isotope labels are introduced metabolically, 
enzymatically, or chemically.82 Stable isotope labeling by amino acids in cell culture (SILAC) is 
the most common method for metabolically labeling proteins.94 SILAC uses 13C6-Lys and 13C6- 
and 15N4-Arg containing cell media to label proteins in vivo. While this reduces the variability by 
introducing the labels early on, this method is only possible with experiments involving growing 
cells.95 Enzymatic labeling introduces either 18O or 16O into peptides during proteolysis, so no 
additional steps are needed.96 However, these labels lead to small mass shifts, so high-resolution 
instruments are required. Chemical labeling, however, is the most common approach for label-
based proteomics methods, due to the fact that any sample can be labeled.91 This method 
involves the derivatization of peptides with isotopically labeled tags. ICAT (isotope-coded affinity 
tags)97, TMT (tandem mass tags)98, and iTRAQ (isobaric tags for relative and absolute 
quantitation)99 are all different methods that utilize chemical labeling for quantitation and each 
allow for different multiplexing capabilities. Weaknesses associated with chemical labeling include 
incomplete labeling reactions and potential for side reactions.95 
     The iTRAQ method is advantageous because it allows for the simultaneous analysis of up to 
eight different samples within one experiment.99-100 Each reagent contains a peptide reactive 
group, balance group, and reporter group (Figure 1.9A), but overall each reagent has the same 
molecular weight and produce identical mass shifts. The N-hydroxysuccinimide ester portion of 
the peptide reactive group reacts with primary amines to label peptides with an isobaric tag. Each 
sample is labeled with a different reagent, containing different distributions of heavy isotopes in 
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the reporter group, and mixed. Tagged peptides with identical sequences co-elute and are 
detected as a single precursor ion (Figure 1.9B). Upon fragmentation of a tagged peptide ion, the 
reporter ions are measured in the m/z 113-121 range of the MS/MS spectrum. The relative 
intensities of these reporter ions are proportional to the relative abundances of the labeled peptide 
between the different samples.  
     The various MS-based quantitative proteomics methods allow for a higher throughput 
assessment of a system’s proteome than previous quantitation methods. By applying an iTRAQ 
strategy in systems vaccinology studies, a more global and quantitative view of the immune 
response can be achieved.  
 
 
Figure 1.9 iTRAQ labeling method.  (A) General structure of the individual iTRAQ reagents includes the peptide 
reactive group (right), balance group (middle), and reporter group. (B) Identical labeled peptides co-elute and are 
detected as one precursor peak in the MS spectrum. After fragmentation, reporter ions are detected in the low mass 
range of the MS/MS spectrum, which allows for the quantitative information to be extracted. 
 
Scope of this work 
     The goal of this dissertation is to develop and optimize a method for assessing the proteomic 
response in individual immune cells following vaccination and then apply that method to an 
adjuvanted influenza vaccine clinical trial in order to better understand the mechanism of action 
of the adjuvant. Chapter II describes the development and optimization of the quantitative 
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proteomic method to investigate the immune response in purified immune cells across time. The 
optimized method multiplexed the same cell type at various time points together using 8-plex 
iTRAQ. This also serves as a proof-of-concept study showing that by analyzing individual immune 
cell types, more proteins are identified compared to traditional whole blood or PBMC samples, 
allowing for a more complete picture of the immune response to be obtained. Chapter III discusses 
the proteomic results obtained from the AS03-adjuvanted H5N1 clinical trial, which used the 
optimized method developed in Chapter II. A comparison of these proteomic results to results 
from a transcriptomics study conducted in parallel is also included. These chapters showcase one 
of the first times quantitative shotgun proteomics has been used to assess the immune response 
to a vaccine. By doing so, a more complete understanding of the immune response and vaccine 
mechanism can be obtained. 
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 CHAPTER II 
 
A CELL-BASED SYSTEMS BIOLOGY ASSESSMENT OF HUMAN BLOOD TO MONITOR 
PROTEOMIC IMMUNE RESPONSES AFTER INFLUENZA VACCINATION 
 
Introduction 
     Systems biology is a comprehensive approach to describe complex interactions between 
multiple components in a biological system.1 Using high-dimensional molecular approaches, 
systems biology identifies changes caused by perturbations such as infection or vaccination, 
combined with extensive computation analysis to model and predict responses.1 In the context of 
vaccinology, systems biology offers an approach to dissect the human immune response after 
immunization by correlating changes in the transcriptome or proteome with antibody or cell-
mediated immune responses, in order to make predictions about vaccine efficacy and potentially 
adverse events, such as pain, headache, fever, and fatigue.2-3  
     Systems biology studies with influenza vaccines have identified modules of genes that 
positively correlated with protective immune responses.4-5 For example, interferon-responsive 
genes that were up-regulated at early time points after TIV positively correlated with robust HAI 
titers.4-5 Nakaya et al. found that an elevated antibody response to TIV, but not LAIV, correlated 
with up-regulation of B cell-specific transcripts, including immunoglobulins and the TNFRSF17 
surface receptor.6 Using the Nakaya dataset, Tan et al. identified immunoglobulin and 
complement genes as well as proliferation-associated genes to be predictors of protective 
antibody production in response to TIV.7 They concluded that enrichment of these gene sets at 7 
days post-TIV vaccination was likely due to an increase of proliferating plasmablasts in subjects 
with elevated antibody response.7 
     In addition to studying post-vaccination responses, predictive correlates identified prior to 
vaccination have also been studied. Tsang et al. showed that baseline proportions of 126 immune 
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cell sub-populations in the blood could predict influenza vaccine-induced antibody responses.8 
Furman et al. identified several additional baseline predictors of protective immunity, including the 
frequency of CD8+ T cells and NK cells, as well as multiple differentially expressed gene 
modules.9 These included genes associated with: 1) apoptotic pathways; 2) cell survival and 
proliferation; 3) cell-to-cell signaling; 4) RNA post-transcriptional modification; and 5) 
carbohydrate metabolism.9  
     Despite insights to the global human immune responses to influenza vaccines obtained from 
these and other studies, the majority of systems biology studies are limited in scope to total RNA 
from whole blood or peripheral blood mononuclear cells (PBMC).4, 7-11 Blood is comprised of many 
hematopoietic cell types that are present in varying proportions (Figure 2.1) and therefore, 
responses elicited from under-represented cell types are likely masked by those of predominant 
cells.12 Nakaya et al. observed this when transcription factor XBP-1 was upregulated in sorted B 
cells, but not PBMC, after TIV vaccination.6 XBP-1 is necessary for the terminal differentiation of 
antibody-forming plasma cells, and therefore an important factor for developing protective 
immunity.6 Additionally, when utilizing PMBC to monitor the immune response, the contributions 
of polymorphonuclear (PMN) cells – the prime contributors to innate immunity – are ignored, as 
these cells are separated out. Furthermore, an immune response represents a highly coordinated 
effort from multiple hematopoietic cell types – each with their own inherent programming.13 
Therefore, it is vitally important to analyze and model individual immune cell types in response to 
vaccination. 
    To develop a comprehensive systems biology model for studying immune responses following 
vaccination, we developed an efficient protocol to quantitatively analyze five purified immune cell 
types from human blood that contribute to both innate and adaptive immune responses: T cells, 
B cells, NK cells, monocytes, and neutrophils. Unlike previous systems vaccinology studies, my 
protocol uses quantitative proteomics to monitor changes in protein expression prior to and after 
TIV vaccination. My results reveal that protein expression profiles from each sorted cell type differ 
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significantly from the profile obtained from PBMC. Comparison of differentially expressed proteins 
after vaccination with 2011-2012 seasonal TIV further shows considerable differences between 
PBMC and sorted cells. Together, my data suggest that important cell type-specific information is 
gained when purified cells rather than PBMC or whole blood are sampled in systems studies. 
 
 
Figure 2.1 Breakdown of the components in blood.  Immune cells, found in the leukocytes category represent a 
very small portion of a blood sample. Additionally, these immune cells have different concentrations compared to one 
another.14  
 
Methods and Materials 
Seasonal TIV vaccination of human volunteers and blood collection 
     Volunteer recruitment and vaccination protocols for this study were approved by the Vanderbilt 
Institutional Review Board (IRB#111030 “CLR-03 2011-Immune Cells and Soluble Factors from 
Healthy Donor”). After obtaining written informed consent, two subjects were vaccinated with a 
single dose of 2011-2012 seasonal trivalent inactivated influenza vaccine (TIV) (strains included: 
A/California/7/09 (H1N1), A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008). Blood samples (90 
mL) from the two vaccinated subjects were processed prior to vaccination (day 0) and at days 1, 
3, and 7 post-vaccination for downstream quantitative proteomic analysis.  
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Immune cell isolation 
     Freshly collected whole blood was fractionated into PBMCs and PMNs over a Ficoll density 
gradient (GE Healthcare, Marlborough, MA). PBMC and PMN fractions were then subjected to 
magnetic-activated cell sorting (MACS) to positively select CD3+ T cells, CD14+ monocytes, 
CD15+ neutrophils, CD19+ B cells or negatively enrich for CD3-CD14-CD15-CD19- NK and mDC 
(Figure 2.2). MACS-enriched cells were further subjected to fluorescence-activated cell sorting 
(FACS) to achieve ≥98% purity (Figure 2.2). Recovery of sorted mDC cells was insufficient for 
proteomic analysis (1X106 cells needed) and therefore proteomic analysis was not performed on 
this cell type.  
 
 
Figure 2.2 Flow cytometry analysis of immune cell types purified from human blood. PMN and PBMC cell 
fractions from a single representative subject were subjected to CD15+, CD3+, CD19+, and CD14+ positive selection 
or CD19-CD15-CdD14-CD3- enrichment (top panels) via magnetic sorting (MACS). MACS-enriched cells were 
stained with a cocktail of antibodies and subjected to FACS (bottom panels) to obtain highly purified neutrophil, T cell, 
B cell, monocyte, and NK populations for systems analysis.  
 
iTRAQ experiment preparation 
     Protein extracts from PBMC and sorted immune cells (1x106 cells) from two vaccinated human 
subjects were prepared by ultrasonicating cells in lysis buffer (50% trifluoroethanol 50 mM 
HEPES). The protein amounts were quantified using a BCA assay. An immune cell common 
standard (ICCS) control sample composed of protein extracts from PBMC and CD15+ cells (80% 
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and 20%, respectively, by protein weight) was included in duplicate in all 8-plex iTRAQ 
experiments. Ten micrograms of protein per sample was reduced by 50 mM tris(2-
carboxyethyl)phosphine (TCEP), cysteine blocked by 200 mM methyl methanethiosulfonate 
(MMTS), and digested with trypsin (1:50 trypsin:protein) overnight.15-18 The peptides were 
desalted through solid phase extraction with a reverse phase microtrap column (Michrom 
BioResources, Auburn, CA). The peptides were resolubilized in 7 µL 500 mM triethylammonium 
bicarbonate. Twelve microliters of iTRAQ reagent (AB Sciex, Framingham, MA) were added to 
the peptide samples. The labeling reactions were incubated with shaking for 2 h, pooled together, 
frozen, and lyophilized. The iTRAQ labeled samples were resolubilized in buffer A (5% 
acetonitrile/0.1% formic acid in water) to 0.5 µg/µL and analyzed by MudPIT using an Eksigent 2-
D nanoLC pump coupled to a nanoESI-LTQ-Orbtirap XL mass spectrometer (Thermo Scientific, 
Waltham, MA). The precursor ions were analyzed in the Orbitrap followed by 4 CID fragment ion 
scans in the ion trap to identify the peptides. The precursor ions were then fragmented by HCD 
to measure reporter ion intensities in the Orbitrap.19-21 
 
Quantitative proteomic analysis 
     For each precursor ion, the CID and HCD spectra were merged using Proteome Discoverer 
v1.3 (Thermo Scientific, Waltham, MA). The merged fragmentation spectra were searched 
against a forward and reverse concatenated human Ensembl protein and common contaminants 
database (gene model 74) using the Sequest database search engine running under Proteome 
Discoverer.22-23 Precursor mass tolerance was set to 20 ppm and fragment mass tolerance to 0.8 
Da. iTRAQ modification of N-terminus and ε-amine of lysines and β-methylthiolation of cysteines 
were used as static/constant modifications of the peptides. Oxidation of methionine and 
tryptophan and deamidation of asparagine and glutamine were used as dynamic/variable 
modifications of the peptides. Protein assembly, reporter ion quantitation, and statistical analysis 
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were performed with a 5% peptide and protein FDR using ProteoIQ v2.61 (Premier Biosoft, Palo 
Alto, CA).  
 
Comparative and differential analysis 
     Prior to differential analysis, missing values and contaminating keratin proteins were removed 
from the protein lists. A ≥1.25 fold change (calculated in ProteoIQ) in expression between pair-
wise comparisons (days 0-1, 0-3, and 0-7) was considered significant. Comparative analysis of 
the proteomic profiles between cell types was performed using Spearman correlation coefficients. 
Principal component analysis (PCA) was performed in R and plotted using the rgl package.24 
Hierarchical clustering analysis, dendograms, and heatmaps were generated using Cluster3.0 
and Java Treeview, respectively.25-26 A Unix bash shell command was used to identify 
differentially expressed proteins shared between individuals and cell types, as well as to create 
lists of proteins for heat maps. 
 
Visualization of proteins across the human genome 
     Genome-wide visualization of relative protein expression from PBMC and each purified 
immune cell type was generated using the open-source Circos software package.27 The genome 
location for individual protein data points was mapped using BioMart.28  
 
Network analysis 
     Differentially expressed proteins identified in both subjects after vaccination were imported into 
Ingenuity Pathway Analysis (Qiagen, Alameda, CA) to identify the most significantly affected 
unique canonical pathways, biological functions, and networks between time points. 
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Data Availability 
     The raw proteomics data and unfiltered database search results are available via the 
ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) with the dataset 
identifier PXD001657 and DOI 10.6019/PXD001657.  
 
Results and Discussion 
Protein quantification from purified cells 
     Prior to performing quantitative proteomics, protein lysates from PBMC and sorted cells were 
quantified. The different cell types (1x106 cells) generated between 30-80 µg protein/sample 
(Figure 2.3). Neutrophils contained the highest amount of protein, followed by monocytes, while 
lymphocytes contained the least. As monocytes and neutrophils are much larger than 
lymphocytes,29 it is reasonable to see higher protein amounts from these cell types since the 
assays were performed based on cell number and not cell volume. Lundberg et al. previously 
showed a correlation between cell size and protein expression levels.30 To remove this bias from 
later analyses, experiments were done on normalized protein weights rather than cell number. 
 
 
Figure 2.3 Adequate protein quantity is obtained from sorted immune cells for proteomics applications. Total 
protein isolated from sorted immune cells (1x106 each cell type) from a single vaccinated subject was quantified. 
 
Evaluation of proteomics data quality 
     A slope of the regression line >0.8 between the technical replicates of the common control 
(ICCS) based upon pseudospectral counts was required as a quality control threshold (Figure 
2.4A). A plot of log2 fold changes against pseudospectral counts was used to assess the effect of 
 35 
 
sampling over the observed fold changes. The symmetric distribution of log2 fold changes versus 
pseudospectral counts suggests the differential expression analysis was unbiased by protein 
abundances (Figure 2.4B). Distribution of relative expression across different samples was 
visualized using cluster dot plots to see if obvious differences occurred between samples (Figure 
2.4C). The ICCS iTRAQ channels showed a wider range of expression values (last two columns) 
compared to the purified cell types, likely due to being a compilation of cell types. Experiments 
where the purified cell types showed similar protein expression distributions were considered in 
compliance. 
 
 
Figure 2.4 Proteomics quality control.  (a) Scatter plot showing the protein abundances measured in two technical 
replicates of the ICCS common control. Each dot represents an individual protein. X-axis represents the protein 
abundances measured in replicate 2. Y-axis represents the protein abundances in replicate 1. (b) Scatter plot 
showing the distribution of fold changes of proteins with respect to their abundances. Each dot represents an 
individual protein. X-axis represents protein abundance. Y-axis represents fold changes. (c) Cluster dot plot showing 
the distribution of fold changes in different iTRAQ channels. Each dot represents an individual protein and the lines 
represent patterns of expression change. 
 
Comparison of two iTRAQ labeling strategies 
     Two iTRAQ labeling strategies were tested to determine the optimal pooling strategy for 
detecting proteomic changes after vaccination (Figure 2.5). In strategy 1, all six cell types at a 
single time point were multiplexed into one experiment. In strategy 2, all four time points from a 
single cell type were multiplexed into an experiment. Strategy 1 is advantageous because the 
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technical experimental variation between cell types at each time point would be minimized. 
However, since the MS/MS method selects peptides for fragmentation and therefore identification 
and quantitation based upon their abundance in the sample proteins present in higher amounts 
across the samples would be preferentially quantified. Thus, differentially changing proteins with 
low expression from a single cell-type might not be quantified. Further, by increasing the 
complexity of the sample pool through multiplexing lysates from six different cell types, co-
fragmentation of co-eluting peptides might cause an increase in iTRAQ signal interference, and 
therefore possibly negate the effects of purifying the cells. In contrast, strategy 2 does not have 
the potential signal interference problems because the sample complexity is reduced due to 
similar proteomes being pooled together. This would also ensure quantitation of a larger fraction 
of cell type-specific proteins. However, strategy 2 may detect artifacts due to technical 
experimental variation. 
  
 
Figure 2.5 Two iTRAQ strategies for quantitative proteomic analysis of immune cells after vaccination.  
Experimental design. In strategy 1, multiple immune cell types from one time point were multiplexed together in the 
experiment. In strategy 2, different time points from the same immune cell type were multiplexed tougher. An immune 
cell common standard (ICCS) was used to normalize reporter ion intensities across the experiments. 
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      The two strategies were compared with both unsupervised hierarchical clustering and PCA 
(Figure 2.6). In strategy 1, the cell types did not completely cluster together in the unsupervised 
hierarchical clustering analysis. However, the cell types in strategy 2 did cluster together. 
Additionally, the heatmap shows distinct protein expression patterns for the different cell types in 
strategy 2, while strategy 1 has very similar patterns for the cells derived from the PBMC fraction 
(monocytes, NK cells, B cells, and T cells). The neutrophil samples show a relatively different 
clustering compared to the other cell types, as they originate from the PMN blood fraction. This is 
also observed in the PCA plots (Figure 2.6B). There is poor clustering of the cell types in strategy 
1 and the different cell types fail to separate. In contrast, strategy 2’s PCA plot shows distinct 
clustering of the cell types (Figure 2.6B). The neutrophil samples clustering the furthest away 
indicating their different protein expression. The possibility of these results being caused by batch 
effects was discounted as the samples from each individual iTRAQ experiment using strategy 1 
did not cluster together by either hierarchical clustering or PCA. Overall, strategy 2 produced cell-
type specific clustering and protein expression patterns by both methods, while strategy 1 did not. 
Therefore, strategy 2 was considered the optimal approach and employed for the remaining 
proteomic analysis. 
 
 
Figure 2.6 Comparison of global proteome analysis for two iTRAQ strategies.(a) Unsupervised hierarchical 
clustering analysis and (b) PCA of pseudo-spectral counts from one subject generated using strategy 1 (left panels; 
5,676 proteins, filtered to remove zero values and contaminating keratins) or strategy 2 (right panels, 3,852 proteins, 
filtered to remove zero values and contaminating keratins) reveals that cell-types cluster together and display distinct 
cell-type specific patterns of protein expression using strategy 2, but not with strategy 1. 
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Proteomic profiles of two TIV-vaccinated subjects 
    The proteomes of PBMC and five purified immune cell types from two subjects before (day 0) 
and after TIV vaccination (days 1, 3, and 7) were analyzed by MS to identify changes in the 
immune response. Approximately 7000 proteins were identified in 44 protein samples (Table A-1). 
After removing zero values (identified but not quantified proteins) and contaminating keratins, 
approximately 4000 proteins from each subject were retained for further analysis (Table A-2 - 
Table A-3). The PBMC and purified immune cell baseline (day 0) proteomes from one vaccinated 
subject (HD31) plotted over the length of the human genome showed activity across the majority 
of the genome indicating unbiased genome coverage (Figure 2.7). This plot also showed distinct 
proteomic profiles between the different cell types at baseline. The results agreed with the 
observations made during the iTRAQ pooling strategies experiments.  
 
 
Figure 2.7 Circos representation of baseline proteomic profiles of PBMC and individual immune cell types.  
Bars on the outside of the circle represent individual chromosomes. The heat-map color scaling parameter was set to 
“scale_log_base = 10” to allow for optimal color space.  
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     Pair-wise comparisons of baseline proteomic data (day 0) from one subject showed poor 
correlation between PBMC and sorted cells (Figure 2.8A). The highest correlation was observed 
between monocytes and PBMC. However a Spearman correlation coefficient of 0.72 suggests a 
poor correlation. PCA revealed that all cell types clustered distinctly from each other (Figure 2.8B). 
Semi-supervised hierarchical clustering analysis of identified proteins showed that each cell type 
displayed a distinct protein expression profile that differed from both PBMC and the other cell 
types (Figure 2.8C). This indicates that the immune cell purification strategy employed allowed 
for the identification of proteins that are masked in the PBMC sample. As current vaccine studies 
use either whole blood or PBMCs to assess the vaccine response, these low abundant proteins 
would be missed in the analyses and therefore a full picture of the response to vaccines would 
not yet been synthesized.  
 
 
Figure 2.8 Proteomic analysis of purified immune cells in subject HD31 after TIV vaccination.  (a) Pair-wise 
comparison of day 0 protein profiles (3,852 proteins, filtered to remove zero values and contaminating keratins) from 
subject HD31 shows that proteomes of sorted cells correlate poorly with PBMC. (b) PCA of protein profiles from 
subject HD31 at four time points shows that purified immune cell types cluster into distinct groups. (c) Semi-
supervised hierarchical clustering analysis of relative protein expression from a vaccinated individual reveals that 
purified immune cells have distinct proteomic expression profiles compared to PBMC. Data was centered across 
protein and cell type; red = up, black = no change, green = down. 
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Figure 2.9 Proteomic analysis of purified immune cells in subject HD30 after TIV vaccination.  (a) Pair-wise 
comparison of day 0 protein profiles from subject HD30 shows that proteomes of sorted cells correlate poorly with 
PBMC. (b) PCA of protein profiles from subject HD30 at four time points shows that purified immune cell types cluster 
into distinct groups. (c) Semi-supervised hierarchical clustering analysis of relative protein expression from a 
vaccinated individual reveals that purified immune cells have distinct proteomic expression profiles compared to 
PBMC. Data was centered across protein and cell type; red = up, black = no change, green = down. 
 
     The proteome of the second vaccinated subject (HD30) also showed distinct protein expression 
profiles among the different cell types and a lack of correlation between the different cell types 
(Figure 2.9). However, PCA of the proteomics data for both subjects showed that while the cell 
types at all time points clustered similarly on a per-subject basis, the cells from the two subjects 
did not cluster together (Figure 2.10). Overall, intra-individual variability in the cell type responses 
from subject HD31 is smaller than the intra-individual variability in subject HD30 and the inter-
individual variability between the two. This indicates that either different subsamples of the 
proteome were identified from each subject or the same subsample of identified proteins were 
identified in both subjects but were responding at different levels. Either possibility is likely due to 
biological variability between the proteomes of the two subjects. It has been estimated that 20-
40% of immune variation is due to heritable factors and 5% to intrinsic factors,31 leaving a large 
portion of immune variation due to environmental and other factors.32 While these estimates are 
based on leukocyte population subsets and function, it can be extrapolated that this variation also 
occurs on the protein level as the proteins do the work in the cell. 
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Figure 2.10 Principal component analysis reveals poor correlation of proteomes between subjects. Proteins 
(5,304 total proteins, filtered to remove zero values and contaminating keratins) from subject 1 (HD31; large circles) 
and subject 2 (HD30; small circles) were clustered in the same experiment. PC1 = 77.19%, PC2 = 6.99%, PC3 = 
5.23%. 
 
     Previous studies investigating inter-individual proteome variability in various biological 
matrices showed protein abundance variance ranging between 10% and 148%.31-33  While none 
of these studies investigated the variability of purified cell populations, one study measured the 
mean variation to be 28% in the PBMC proteome of 24 individuals.31 Our study of two subjects 
showed average CV values ranging between 43-57% for the pseudospectral counts of individual 
immune cell types at day 0. These higher CV values are likely due to a small sample size. 
However, the maximum protein CV for the cell types was 133%, which is in agreement with 
previous reported values.31-33 This high variability may pose a challenge when identifying shared 
protein responses. Indeed, less than 20% of differentially expressed (DE) proteins responding in 
the same direction were shared between both subjects for most cell types and time points (Table 
2.1). The proof-of-concept study showed additional unique protein identifications on a cell-type 
level obtained from purifying immune cells for proteomic vaccine studies. With only two subjects, 
the statistical power is not sufficient to allow for biological conclusions, only observations. A larger 
sample size would be needed to extract specific biological information. 
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Table 2.1 Shared DE proteins. 
  
HD30 HD31 Shared 
Cell type Time point Up Down Up Down Up Down 
PBMC 
d0-1 292 200 369 216 9 13 
d0-3 375 171 340 523 79 27 
d0-7 254 323 499 366 51 25 
T cell 
d0-1 347 220 116 806 1 93 
d0-3 419 48 248 837 19 1 
d0-7 665 37 24 661 0 3 
B cell 
d0-1 N/A N/A 227 505 N/A N/A 
d0-3 N/A N/A 265 517 N/A N/A 
d0-7 N/A N/A 170 442 N/A N/A 
NK 
d0-1 216 255 455 249 8 11 
d0-3 176 193 157 642 7 38 
d0-7 256 376 231 467 8 26 
Monocyte 
d0-1 529 547 127 399 4 35 
d0-3 310 952 262 390 16 97 
d0-7 374 581 200 334 14 44 
Neutrophil 
d0-1 118 151 172 119 0 5 
d0-3 109 120 119 206 11 8 
d0-7 128 77 84 238 6 12 
 
Differential analysis of proteins from two TIV-vaccinated subjects 
     For comparison of proteomic changes in PBMC and sorted immune cells, DE proteins ≥1.25 
fold after vaccination were investigated. While standard methods for determining fold change 
typically use a 2x fold change threshold, this level failed to identify significant numbers of shared 
DE proteins between both subjects. I hypothesize that this is likely due to iTRAQ under-reporting 
fold changes that has been previously reported.34 By choosing the 1.25 threshold, comprehensive 
lists of DE proteins from each cell type that were shared between both subjects at each time point 
were obtained. There was little correlation between PBMC and purified immune cell types when 
comparing DE proteins (Table 2.2). The greatest overlap occurred between monocytes and 
PBMC at day 3 with 25% of the proteins being shared. This is expected as monocytes and PBMCs 
had high Spearman correlation coefficients as discussed earlier. Interestingly, this comparison 
also indicates a time trend in the number of DE proteins identified, with the most identified at day 
3 in all cell types.  
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Table 2.2 Comparison of differentially expressed proteins in PBMC and individual immune cell types. 
 Day 0-1 Day 0-3 Day 0-7 
 
# proteins 
identified  * 
# (%) 
shared with 
PBMC 
# proteins 
identified * 
# (%) 
shared with 
PBMC 
# proteins 
identified  
* 
# (%) 
shared 
with PBMC 
PBMC 585 - 863 - 865 - 
T cell 922 41 (7.0%) 1085 132 (15.3%) 685 74 (8.6%) 
B cell 732 75 (12.8%) 782 40 (4.6%) 612 89 (10.3%) 
NK 704 71 (12.1%) 799 141 (16.3%) 698 
129 
(14.9%) 
Monocyte 526 36 (6.2%) 652 222 (25.7%) 534 
163 
(18.8%) 
Neutrophil 291 48 (8.2%) 325 84 (9.7%) 322 42 (4.9%) 
 
     Circos was used to plot DE proteins over the length of the human genome and to visualize 
overlap of DE proteins at three time points after TIV vaccination (Figure 2.11). The plots showed 
a lack of substantial overlap in DE proteins between PBMC and each cell type at each time point, 
as indicated by there being more grey lines than red.  
 
 
Figure 2.11 Visualization of differentially expressed proteins in PBMC and individual immune cell types. 
Circos plots of DE proteins from a vaccinated subject at (a) day 1, (b) day 3, and (c) day 7 post-TIV vaccination. For 
each cell type, the colored bar on the outer circle represents the entire human genome; segments within the bars 
divide the genomes into chromosomes. Red lines indicate DE proteins that are shared between PBMC and purified 
immune cell types. Grey lines indicate DE proteins that are shared between the purified immune cell types. 
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     Finally, semi-supervised hierarchical clustering revealed little overlap in the shared DE 
proteins from each cell type at each time point (Figure 2.12). This analysis suggest variability 
between the two subjects’ innate immune cell proteomes. This is most noticeable in NK cells at 
day 7, where a subset of proteins are up-regulated in one donor while down-regulated in the 
second donor (Figure 2.12C). However, the majority of the shared DE proteins are responding in 
the same direction just at different intensities when comparing between donors. Histone proteins 
are one example of this, as they are largely up-regulated in the majority of the cell types for both 
donors. This is expected because histones have been observed to increase circulation in 
response to stress, infection, and inflammation.35  
 
 
Figure 2.12 Unique modules of proteins are differentially expressed in each immune cell type after TIV 
vaccination.  Log2 fold change values of shared DE proteins in each cell type from both subjects were clustered at 
(a) day 1 (196 proteins), (b) day 3 (263 proteins), and (c) day 7 (199) proteins post-vaccination. Very little overlap of 
differentially expressed proteins is observed between cell types; red = up, yellow = no change, blue = down. B cell 
data was derived from only one subject due to insufficient recovery of B cells from the second subject. 
 
     Lists of significant DE proteins were functionally analyzed using Ingenuity Pathway Analysis 
(IPA) to identify the most significant biological interactions following vaccination. The top network 
identified showed unique biological networks induced in each cell type and time point. These 
results support the observed different responses from these purified immune cells (Figure 2.13-
Figure 2.15). The network annotations and the top canonical pathways identified from each cell 
type and time point were determined (Table A-4). Each cell type had different function annotations 
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derived from the networks. Most of these were generic functions, such as cellular assembly, cell 
cycle, and cellular movement. However, inflammatory response and immune cell trafficking were 
identified for monocytes at day 1 and NK cells at day 3, respectively, showing that proteome 
analysis of the immune response of individual immune cell populations can identify important 
immune responses. 
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Figure 2.13 Networks derived from DE proteins at d1 post-TIV vaccination. DE proteins identified in both subjects at day 1 post-vaccination were imported 
into IPA, and the top network identified in each cell type is displayed (*multiple ENSPs mapped to these proteins). Very little overlap of individual proteins or 
biological networks that are activated is observed between cell types. B cell data was derived from only one subject due to insufficient B cell recovery from the 
second subject. 
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Figure 2.14 Networks derived from DE proteins at d3 post-TIV vaccination. DE proteins identified in both subjects at day 3 post-vaccination were imported 
into IPA, and the top network identified in each cell type is displayed (*multiple ENSPs mapped to these proteins). Very little overlap of individual proteins or 
biological networks that are activated is observed between cell types. B cell data was derived from only one subject due to insufficient B cell recovery from the 
second subject 
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Figure 2.15 Networks derived from DE proteins at d7 post-TIV vaccination. DE proteins identified in both subjects at day 1 post-vaccination were imported 
into IPA, and the top network identified in each cell type is displayed (*multiple ENSPs mapped to these proteins). Very little overlap of individual proteins or 
biological networks that are activated is observed between cell types. B cell data was derived from only one subject due to insufficient B cell recovery from the 
second subject.
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Conclusions 
     The goal of this study was to develop methods and establish protocols that can be used in 
future systems vaccinology studies. By utilizing an efficient cell-sorting protocol, sufficient 
numbers of five immune cell types purified from freshly collected human whole blood were 
obtained for quantitative proteomic analysis. Additionally, this study optimized the strategy to 
generate and analyze the quantitative proteomics data. Differential analysis for each human 
primary immune cell type revealed unique proteomic expression profiles as well as changing 
biological networks during the early response after vaccination. The methods and strategies 
developed in this project provided a unique and important opportunity to investigate the 
quantitative and qualitative differences between human PBMC and individual immune cell types. 
Only a small fraction of DE proteins identified in the purified immune cell types were also identified 
in the PBMC fraction. Thus, by analyzing each cell type individually, cell-specific proteomic 
contributions to the immune response following vaccination were identified. This cell type-specific 
information, coupled with unbiased systems biology approaches, provides a more comprehensive 
and robust approach to monitor and eventually model vaccine and infectious disease responses. 
The approach developed in this pilot project will help guide future systems biology studies aimed 
at modeling and predicting complex responses to vaccines and vaccine components involving 
interactions between multiple cell types. 
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 CHAPTER III 
 
QUANTITATIVE PROTEOMIC ANALYSIS OF HUMAN IMMUNE CELLS IN RESPONSE TO 
AS03-ADJUVANTED H5N1 VACCINATION 
 
Introduction 
     Developing vaccines against highly pathogenic avian influenza H5N1 is a critically important 
public health priority due to the high morbidity and mortality associated with influenza infection.1 
However, vaccine development has been hindered by the poor immunogenicity of the H5N1 HA 
protein when compared with seasonal influenza vaccines.2 Oil-in-water emulsion adjuvants have 
demonstrated great promise in enhancing antibody responses at low antigen doses.3-4 Adjuvant 
system 03 (AS03)5-6, an α-tocopherol-based oil-in-water emulsion adjuvant, is one such adjuvant. 
Alpha-tocopherol, an isoform of vitamin E, is a fat soluble antioxidant that works in the glutathione 
peroxidase pathway to disable the production of free radicals in tissues.7 Dietary vitamin E 
supplementation has been shown to aid the immune response, particularly with earlier antibody 
production to certain pathogens and neutrophil and macrophage phagocytosis and chemotaxis.8-
11
 However, little is known about the benefits of vitamin E as an injectable. The other main 
ingredients in AS03 are squalene and polysorbate 80 (polyoxyethylene sorbitan-20 monooleate).5 
Squalene is a triterpene collected from shark liver, but also is produced in human liver. It is an 
essential molecule used for the synthesis of cholesterol, vitamin D, and other steroid hormones 
and is commonly used in many cosmetics, medications, and other adjuvants.3 Finally, polysorbate 
80 is an emulsifier used in the pharmaceutical and food industries to stabilize aqueous 
formations.3  
     AS03 has been shown to markedly enhance antibody responses.3-4 HAI and neutralizing (Nt) 
antibody titers were significantly increased following two doses of an AS03-adjuvanted H5N1 
inactivated, split-virion vaccine, including when dose-sparing vaccines were used (Figure 3.1).3-4 
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The geometric mean titers (GMTs) showed that an adjuvant effect was observed after both doses, 
but especially after the second. Overall, the addition of the adjuvant allowed for lower amounts of 
antigen per dose and more protection while being generally well tolerated, with few severe 
reactions and adverse events.4-5, 12-17  
 
 
Figure 3.1. AS03-adjuvanted H5N1 vaccination enhances the antibody response. (A) Homologous 
Hemagglutination-inhibiting and (B) neutralizing antibody titers in human volunteers after two administrations of a 
nonadjuvanted or an AS03-adjuvanted H5N1 vaccine. Different doses of influenza antigen were used (from 3.75 to 
30 µg).3  
 
     AS03 has also been shown to increase the frequency of H5N1-specific memory B cells and 
CD4+ T cell responses, and to induce both cross-reactive antibody and CD4+ T cell responses 
when administered with H5N1 vaccine.16 In mouse models, AS03 increased production of 
monocyte- and neutrophil-recruiting chemokines, promoted the migration of antigen presenting 
cells to the draining lymph nodes, and enhanced antigen uptake by monocytes.15 Recently, it was 
reported that injection of AS03 in rabbits induced a transient inflammatory response as measured 
by an increase in neutrophil number in the blood.17 Additionally, early changes in cytokine and 
chemokine levels after AS03-adjuvanted H1N1 vaccination were attributed to mouse 
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monocytes.18 While AS03 enhances the immune response to H5N1 vaccine antigens, the 
underlying molecular mechanisms are still poorly understood. 
     One of the concerns regarding the H5N1 vaccines is safety since higher doses are required to 
elicit a protective response. AS03-adjuvanted vaccines are well tolerated in the healthy adult 
population, although there are more incidences of local and systemic reactogenicity, such as 
injection site pain, muscle ache, headache, and fatigue.3 A concerning discovery, however, was 
an increased incidence of narcolepsy in patients aged 4-19 after receiving PandemrixTM, a 
monovalent H1N1 vaccine adjuvanted with AS03 licensed in Europe for the 2009-2010 influenza 
season.19-20 Epidemiologic studies indicated a 6 - 13-fold increased risk among the vaccinated, 
compared to nonvaccinated adolescents.21 However, a recent study implicates antibodies to the 
influenza nucleoprotein as the narcolepsy cause, due to their cross-reactivity with human neural 
hypocretin receptor 2.22 However, the possible contribution of adjuvants to autoimmune diseases 
and general safety of adjuvants remain a concern.23 These findings demonstrate the necessity in 
comprehensively understanding the mechanisms of action of AS03. 
     Systems vaccinology allows the human immune response to be comprehensively studied by 
combining –omics analysis with humoral and cell-mediated immune responses to increase our 
understanding of the mechanisms by which vaccines and adjuvants confer protection.24-28 Such 
studies typically focus only on transcriptome analysis. However, a comprehensive systems 
vaccinology approach that understands both transcriptomics and proteomics could enhance the 
understanding of vaccine responses. 
     We developed a systems biology approach to study the transient immune response following 
vaccination with a seasonal, inactivated influenza vaccine (trivalent) at the individual primary 
immune cell type-level.29 This cell-based approach provided a more comprehensive 
understanding of the human immune response to vaccination compared to using PBMCs.29 
Additionally, we analyzed both transcriptomic and proteomic responses to a seasonal influenza 
vaccine.29 Using the same immune cell-based approach, a randomized, double-blinded, 
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controlled, Phase I prospective clinical trial to assess the molecular immune responses of an 
intramuscular split-virus (SV), influenza A/H5N1 (A/Indonesia/05/2005) vaccine given with or 
without AS03 adjuvant was conducted. Here the changes in the immune cell proteome in 
responses to these well tolerated vaccines are assessed. 
 
Methods and Materials 
Clinical study design 
     Twenty healthy adult volunteers aged 19 – 39 years were enrolled in a randomized, double-
blinded, controlled Phase I clinical trial designed to determine safety, reactogenicity, and 
immunogenicity of an inactivated subvirion monovalent influenza A/H5N1 (A/Indonesia/05/2005) 
vaccine given with or without the AS03 adjuvant. Each subject received two 0.5 mL intramuscular 
injection doses of 3.75 µg HA per dose with either PBS (SV-PBS) or AS03 adjuvant (4.86 mg 
polysorbate 80, 11.86 mg α-tocopherol, and 10.69 mg squalene) (SV-AS03) 28 days apart 
(vaccine product description in APPENDIX B). Permuted block randomization with random block 
sizes of 2 and 4 were applied to improve balance between the vaccine groups. All protocols and 
consent forms were approved by the Vanderbilt University Institutional Review Board (IRB# 
120404 "VTEU 02-2011- A Randomized, Double-Blinded, Controlled, Phase I Study in Healthy 
Adults to Assess the Safety, Reactogenicity, and Immunogenicity of Intramuscular Subvirion 
Inactivated Monovalent Influenza A/H5N1 Virus Vaccine Administered With and Without AS03 
Adjuvant: Standard and Systems Biology Analyses (DMID 10-0074)”). 
     Peripheral blood samples (100 mL) were collected on days -28, -14, and 0, prior to the first 
vaccine dose for baseline assessment, and days 1, 3, 7, and 28 post-vaccination for serology, 
RNA-seq,30 and proteomics analysis. A final blood sample was collected on Day 56 (28 days after 
the second vaccine dose) for serological analysis only (see APPENDIX B).  
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Immune cell purification 
     Purified immune cell populations were isolated from whole blood samples as previously 
described in Chapter II and published protocols.29 Briefly, PBMC and PMN fractions were isolated 
using a Ficoll-paque PLUS (GE Healthcare) separation. These fractions were subjected to 
magnetic bead separation followed by FACS on a BD FACSArialII flow cytometry to acquire ≥98% 
pure cell populations of neutrophils, monocytes, NK cells, B cells, and T cells for proteomic 
analysis.  
 
Immune serologic assays 
     H5-specific HAI and Nt assays were performed at Days 0 (prior to first vaccination), 1, 3, 7, 
and 28 (prior to the second vaccination) after the initial vaccine dose and 28 days (Day 56) after 
the second vaccine dose.31 Titers below the limit of detection (1:10) were given a value of 1:5 
prior to statistical analysis. The proportion of subjects achieving serum HAI and Nt antibody titers 
of 1:40 or greater, and a 4-fold or greater increase in antibodies were calculated for each time 
point. 
 
Quantitative proteomic analysis 
     Quantitative mass spectrometry was performed on protein extracts from sorted immune cells 
as previously described.29 Briefly, protein extracts were obtained using a modified lysis buffer 
(50% trifluoroethanol 50 mM HEPES)32 and quantified by BCA analysis.33 Due to insufficient 
amount of collected protein, 17 samples were removed from analysis at this stage (Table 3.1).  
An immune cell common standard (ICCS) control sample was prepared using 80% PBMC and 
20% neutrophil protein extracts (by weight) and included in all iTRAQ experiments as a reference 
channel. For each subject and cell type, 10 µg of reduced, alkylated, and trypsinized protein 
extracts were labeled with 8plex iTRAQ tags (AB Sciex), pooled, and analyzed by MudPIT using 
an Eksigent 2-D nanoLC pump coupled to a nanoESI-LTQ-Orbitrap XL mass spectrometer 
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(Thermo Scientific).29 Precursor ions were analyzed in the Orbitrap followed by 4 CID fragment 
ion scans in the ion trap for peptide identification. The precursor ions were then fragmented by 
HCD to measure the reporter ion intensities in the Orbitrap.29  
 
Table 3.1 Proteomics samples for which no iTRAQ results were reported due to insufficient amounts of 
protein 
Subject ID Cell Type Study Day 
A B cells Day -14 
A T cell Day 3 
F B cells Day 3 
H B cells Day -28 
H B cells Day 0 
H B cells Day 28 
I B cells Day -28 
I NK cells Day 0 
I NK cells Day 1 
I NK cells Day 3 
L Monocytes Day 3 
L T cells Day 7 
N NK cells Day 28 
O B cells Day -14 
O T cells Day -14 
Q NK cells Day 1 
 
 
Quality Control of Protein Samples 
     Two S. cerevisiae proteins (enolase and alcohol dehydrogenase) were added to each sample 
prior to digestion to act as markers for errors in digestion and iTRAQ labeling. Prior to iTRAQ 
labeling, 1 µg of each the trypsin-digested protein samples was combined with 0.100 fmol glu-1-
fibrinopeptide B (glufib) and run on an LTQ mass spectrometer (Thermo Scientific) as quality 
control. Previously, the stability of the instrument was assessed for its ability to handle the number 
of samples (APPENDIX C). The raw files were converted to mzxml files and searched against the 
human protein database using X!Tandem within the Global Proteome Machine (GPM).34 Samples 
where the internal standards were identified and showed similar protein numbers to the ICCS 
control samples were deemed sufficient for iTRAQ labeling and further analysis. Samples that 
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were outside of the acceptable limits were checked by visual inspection, re-quantified by BCA, 
re-digested, and re-checked for compliance. 
     Each iTRAQ experiment was assessed for consistency as well. The reporter ion intensities for 
all identified peptides of the two yeast proteins were compared within each subject level 
experiment. Additionally, the pseudo-spectral counts for yeast proteins as a whole were compared 
across all 20 experiments for each cell type. Samples that showed values inconsistent with others 
of the same cell type were checked statistically to determine if they were true outliers and re-
analyzed if there was enough material.   
 
Peptide and protein quantitation 
     The CID and HCD spectra were merged for each precursor ion, using Proteome Discoverer 
v1.3 (Thermo Scientific). The merged spectra were searched against a forward and reverse 
concatenated human Ensembl protein database containing 169,816 sequences (gene model 74) 
using the Sequest database search engine within Proteome Discoverer.35-36 The precursor mass 
tolerance and fragment mass tolerance were set to 20 ppm and 0.8 Da, respectively. Static 
modifications of the peptides were set to iTRAQ modification of N-terminus and ε-amines of 
lysines and β-methylthiolation of cysteines. Additionally, oxidation of methionine and tryptophan 
and deamidation of asparagine and glutamine were used as dynamic modifications.  
     Protein assembly, reporter ion quantitation and statistical analysis were performed with a 5% 
peptide and protein FDR using ProteoIQ v2.61 (Premier Biosoft). Peptide intensities within each 
8-plex iTRAQ experiment were normalized so that the sum of reporter ion intensities was the 
same across all channels within the experiment. For each 8-plex iTRAQ experiment, protein level 
quantifications were calculated for each experimental channel by calculating the median of the 
log2 ratios (experimental channel intensity divided by the ICCS reference channel intensity) for all 
assigned peptides. The ICCS channel was chosen as reference after comparing the number of 
quantitative values obtained when it was used as a reference versus Day 0 as a reference (see 
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APPENDIX B). Peptides with missing experimental or reference reporter ion intensities or with 
intensities below the threshold (intensity < 10) were not included in the median calculations. 
Indistinguishable proteins with identical median ratios across all subjects and time points were 
collapsed into one representative Ensembl protein ID with the longest protein sequence.  
 
Analysis datasets 
     PCA and 1-Spearman correlation distance were used to identify outlying samples (Figure B-1). 
Seventeen samples, including 4 baseline samples, were flagged as strong outliers based on their 
placement compared to other cell type samples (Table 3.2). Among these outliers, 7 (41%) were 
attributable to one neutrophil iTRAQ experiment.  
 
Table 3.2 Outlying proteomics samples 
Subject ID Experiment ID Cell type Study Visit Day 
A A_NK_3 NK-cells Day 3 
B B_Neu_5 Neutrophils Day 28 
C C_Neu_4 Neutrophils Day 7 
H H_B_2 B-cells Day 1 
I I_Neu_A Neutrophils Day -28 
I I_Neu_B Neutrophils Day -14 
I I_Neu_1 Neutrophils Day 0 
I I_Neu_2 Neutrophils Day 1 
I I_Neu_3 Neutrophils Day 3 
I I_Neu_4 Neutrophils Day 7 
I I_Neu_5 Neutrophils Day 28 
L L_B_1 B-cells Day 0 
L L_B_3 B-cells Day 3 
L L_B_5 B-cells Day 28 
N N_Neu_4 Neutrophils Day 7 
R R_B_5 B-cells Day 28 
R R_Mono_2 Monocytes Day 1 
 
 
     Protein ratio distributions across samples were median-normalized within the cell type group 
to reduce systematic variability between the iTRAQ experiments (see APPENDIX B) (Figure B-2 
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- Figure B-3). For multivariate data visualization, missing protein ratios within cell type were 
imputed using the k-nearest neighbors algorithm (k=5) using the impute package in R (version 
1.34.0). Proteins identified in at least 75% of samples within each cell type were considered and 
only samples for which at least 20% of proteins were non-missing were included in the imputation 
step. Resulting imputed per-cell type data matrices were also merged to generate a combined set 
(all cell types together) using zero log2 ratios to align disparate proteins between cell types. 
     The Ensembl protein database (Ensemble Version 74) was clustered using CD-HIT software 
(Version 4.6.1, 08/27/2012) to derive a set of protein families based on 50% protein sequence 
identity. One representative Ensembl protein ID with the longest protein sequence was selected 
as the protein family name.  
 
Significant Proteins 
     Differentially abundant (DA) proteins were identified through the use of an exact two-sided 2-
sample permutation test of the mean difference (coin R package, version 1.0.23) for each post-
vaccination day and cell type combination, if proteins had at least 3 non-missing fold changes for 
each treatment group. Proteins were considered significant if p ≤0.05 and the mean treatment 
fold changes differed by 1.2 fold. Significantly DA proteins and subjects were clustered by their 
baseline log2 fold change values using pairwise uncentered Pearson correlation distances and 
complete linkage clustering. Proteins missing from individual samples were given a value of 0.  
 
Gene set enrichment analysis 
     Protein accessions were mapped to their corresponding Ensembl Gene IDs. Gene sets and 
databases were obtained from the KEGG database (version 70.0) and MSigDB (Version 4.0). The 
goseq package in R (version 1.12.0) was used to evaluate gene set enrichment using the 
hypergeometric distribution to assess significance with the Benjamini-Hochberg correction 
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applied to adjust for multiple testing.37 Gene sets with a FDR of ≤0.05 that contained genes 
encoding for at least two significant protein families were considered significantly enriched. 
 
Protein-protein interaction networks 
     Uniprot IDs and gene symbols for the DA proteins were obtained using the Uniprot retrieve/ID 
mapping tool. Known human-human and human-influenza A protein-protein interactions were 
extracted from the IntAct database. The list of interactions was filtered for nodes with a distance 
of 1 to significantly DA proteins and the networks were visualized using Cytoscape (version 3.1.1). 
 
Regularized logistic regression analysis 
     A regularized logistic regression model was fit for monocytes (day 1, 3, 7, and 28) and 
neutrophils (day 1 and 3) to identify protein responses that are correlated with seroprotection (HAI 
≥1:40) at any post-vaccination day using the gimnet R package (version 2.0-2). Only these cell 
types were included because they had a sufficiently large number of protein families with non-
missing values for at least 9 of the subjects in each treatment group. An elastic net regularization 
step (combination of L1 Lasso and L2 ridge penalization, α=0.5) was included to avoid overfitting. 
Leave-one-out cross validation was used to determine the optimum parameters which minimized 
the mean misclassification error between seroprotection response groups. 
 
Results and Discussion 
Protective antibody responses 
     HAI and Nt antibody titers were determined in order to assess the protective response obtained 
from each vaccine. Titers did not increase from baseline during the first 7 days after vaccination 
in either SV-AS03 or SV-PBS groups (Figure 3.2A). At day 28, there was no significant difference 
in the mean HAI GMT between groups, with no subjects showing an HAI response in the PBS 
group, while one subject in the SV-AS03 group exhibited an HAI titer ≥1:40 and a >4-fold rise in 
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titer (Figure 3.2B). By day 56, 9 subjects in the SV-AS03 group achieved seroconversion and 
seroprotection for HAI titers, while none of the SV-PBS group subjects reached seroprotection 
titers, resulting in a significant difference between the two groups (p<0.001). For the Nt assay, at 
days 28 and 56, the SV-AS03 group showed significantly higher GMT titers compared to SV-PBS 
(p=0.015 and p<0.001, respectively). All subjects within the SV-AS03 group showed 
seroconversion and seroprotection at day 56, contrasting to the 3 subjects in the SV-PBS group. 
As the vaccines used in this study were identical in composition to those used in previous studies, 
these results were anticipated. Overall, this indicates that the SV-AS03 vaccine is eliciting 
protective immune responses, while the SV-PBS vaccine failed to produce a significant response. 
 
 
Figure 3.2 AS03-adjuvanted H5N1 vaccination induced a protective immune response relative to non-
adjuvanted vaccine.  (A) HAI and Nt antibody GMT and 95% CI at each time point by vaccine group; p-values are 
based on two-sided t-test on the log scale adjusting for unequal variances if necessary. No multiple testing 
adjustment was carried out. (B) HAI and Nt titers in individual subjects at days 28 and 56 by vaccine group; titer is 
represented by bar height (left y-axis) while fold change from baseline is shown as a connected black line (right y-
axis), cut-offs are indicated by grey lines (solid: 1:40 titer, dashed: 4-fold change).30 
    
iTRAQ experiments 
     In order to identify the molecular mechanisms responsible for the differences seen in antibody 
responses between the SV-AS03 and SV-PBS vaccine groups, quantitative proteomic analysis 
was performed. An average of 2,900 proteins from 450 protein groups were identified in each 8-
plex iTRAQ experiment. While identified proteins in each cell type did not largely differ in physical 
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properties (Figure 3.3), the number of identified proteins was higher in monocytes compared to 
the other immune cell types. This is consistent with previous reports suggesting that monocytes 
play an important role in responding to AS03.15, 18 
 
 
Figure 3.3 Experimental summary statistics by cell type.  *: restricted to the representative protein in a protein 
group for which at least one of the 7 iTRAQ channels was quantified. Cell types across the bottom: B cells, 
Monocytes, Neutrophils, NK cells, T cells. 
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     Using the top hit per protein group, the main analysis set was comprised of quantifications for 
3,247 proteins (1,580 protein families based on 50% sequence identity) compared to the immune 
cell common standard.  Broken down by cell type, 533 (T cells), 665 (NK cells), 813 (B cells), 860 
(neutrophils), and 1,252 (monocytes) protein families were identified. Many proteins were only 
quantifiable in a subset of samples and we observed different levels of quantification sensitivity 
for the five cell types (Figure 3.4). For example, while 17.1% and 10.4% of monocyte and 
neutrophil proteins were quantified in at least 90% (126 out of 140) of their respective samples, 
the percentage ranged from 1.1-2.5% for the other cell types, indicating lower proteome coverage 
for those cell types (Figure 3.4). This could be due to the prevalence of highly abundant proteins 
diluting the low abundant signals, variability between subjects, different proteins being identified 
at different time points, or the common phenomenon of missing peptides in iTRAQ experiments.38-
39
 Additionally, pooling the identified proteins from all cell types and time points showed higher 
levels of missing samples, indicating that disparate protein sets were identified across cell types. 
This is generally expected as the five immune cell types have different functions and timelines in 
the immune response. 
 
 
Figure 3.4 Empirical cumulative distribution function plots of protein missingness across samples. Table on 
bottom indicates the number of samples that could be missing corresponding to the percentages. 
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 Multiple baseline time points enhance sensitivity  
     Vaccine studies traditionally use only one collected sample prior to vaccination as the baseline 
measurement. While this reduces sample numbers and costs to both researchers and volunteers, 
this practice may be allowing more inconsistency into the study because of the inherent variability 
of human biology. Variation in the three pre-vaccination time points was largely due to the immune 
cell type, similar to the variation in all time points (Figure 3.5). 
   
 
Figure 3.5 Baseline variability shown by PCA biplots. Variation at (A) pre-vaccination time points and (B) all time 
points is driven by cell type.  
 
  To assess the impact of using multiple baseline time points on the number of proteins identified, 
the results from all three baseline measures (day -28, -14, and 0) were compared to one (day 0),  
and two (day -14 and day 0) baseline measures for monocytes and neutrophils, as these cell 
types had the most proteins identified. With each additional baseline measurement included, the 
sensitivity of the protein identifications increased, as shown by the height of the bars (Figure 3.6). 
In almost all cases, including two baseline measures had at least 80% protein identification 
overlap with the three baseline measure dataset. Additionally, including more baseline measures 
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reduces the number of false positives in the data sets as the FDR is consistently higher when 
fewer baseline measurements are used (Figure 3.6). Monocytes at day 3 is the most striking 
example of the loss in sensitivity that occurs when fewer baseline measurements are collected. 
With fold change of >1.2, which this study used as a threshold, the sensitivity decreased from 
approximately 0.95 down to 0.45 when the number of baseline measures was reduced from two 
to one. Overall, the difference in sensitivity between using three and two baseline measures is 
relatively small. While increasing the number of baseline measurements also increases both the 
time and money costs for these studies, it gives more confidence in the results as well as 
potentially more identified proteins. Here, all three baseline measurements were averaged and 
used for the remaining analysis.
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Figure 3.6 Effect of multiple baseline timepoints.  Protein identification sensitivity for experiments using one (grey) or two (blue) baseline measures were 
compared to using all three for multiple fold change cutoffs. The FDR was also calculated for each case and is shown inside the bars. Different possible fold 
change cutoffs are across the bottom. The number of proteins identified at each fold change cutoff is shown by the n value either below the plots (three baseline 
time points) or inside the bars (one and two baseline time points) 
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AS03-modulated protein responses across time 
     To compare the protein log2 fold changes from baseline between the SV-AS03 and control SV-
PBS vaccine groups, significant DA proteins were determined using a per-protein permutation 
test (p≤0.05) and treatment fold change cutoff of ≥1.2 fold for each cell type at days 1, 3, 7, and 
28 post-vaccination. The number of DA proteins (protein families) identified between the two 
vaccine groups for each cell type was: T cells: 60 (28); NK cells: 80 (40); B cells: 109 (50); 
neutrophils: 100 (55); and monocytes: 172 (108) (Table B-1 – Table B-20). Little overlap of DA 
proteins between post-vaccination time points within the same cell type was observed (Figure 
3.7).29 Lee et al. showed a similar transient response in mice infected with Brucella abortus.40 
They observed more proteins at the individual time points rather than shared between time points, 
which supports our hypothesis that different subsets of proteins are being activated at different 
times and that our selected time points were too far apart to show the overlap.  
     Of the 188 unique DA protein families, 64 (34%) were reported for at least two cell types, with 
TUBB3 (tubulin, beta 3 class III) family-related proteins being differentially abundant in all five cell 
types (Table B-21). Additionally, proteins in the HLA (major histocompatibility complex, class I) 
family were significantly differentially abundant in all cell types, except T cells and pyruvate kinase 
members were found for all immune cells except NK cells. 
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Figure 3.7 Venn diagrams of differentially abundant proteins by cell type 
 
     Overall, the observed vaccine effect between the SV-AS03 and SV-PBS groups was strongest 
for monocytes at day 1 and 3, both in terms of number (24 and 33) and percentage of protein 
families (77%) with higher responses in the SV-AS03 group (Figure 3.8). Additionally, differential 
protein responses in B cells at days 1 and 3 were primarily increased for the SV-AS03 group, 
which is likely associated with the B cells acting in their role as antigen presenting cells, as these 
time points are too early for the B cell antibody production. Finally, at day 1, neutrophils had a 
higher fraction of protein families that were elevated from baseline for the SV-AS03 group. The 
prevalence of increased proteomic responses in the SV-AS03 group for these time points 
suggests that AS03 induces early responses rather than bolstering the later responses.  
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     Homologous proteins including many HLA-protein family members tended to cluster within 
their cell type based on their baseline fold changes (Figure 3.8). One exception was observed in 
NK cells at day 3, where HLA proteins clustered separately. Baseline response time trends for 
DA proteins from the HLA protein family showed that the mean response was higher in the SV-
AS03 compared to the SV-PBS vaccine group in monocytes, neutrophils, and B cells (Figure 3.9). 
For all three cell types, an initial peak response was observed at day 3 for the SV-AS03 group 
with responses returning to near-baseline levels by day 7. In contrast to the other two cell types, 
neutrophils showed an additional increase in response for the SV-AS03 group at day 28, however 
there was an increase in unidentified proteins for a number of subjects at that time point. For NK 
cells, while HLA DA proteins showed consistent baseline trends with a peak at day 3, responses 
in the SV-PBS group were much more divergent with an overall higher mean response at day 1 
compared to the SV-AS03 group, which could potentially be due to noise in those signals. 
Interestingly, there is an increase in HLA protein expression in the SV-PBS group from B cells, 
indicating that the unadjuvanted vaccine may be inducing HLA proteins in B cells only. This could 
be a possible mechanism for how a few of the subjects in the SV-PBS group showed 
seroconversion in their Nt titers, however this would need to be validated.  
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Figure 3.8 Heatmaps of DA protein baseline log2 fold changes for each cell type at each post-vaccination time 
point.  Dendrograms were obtained using complete linkage clustering of uncentered pairwise Pearson correlation 
distances between log2 fold changes. Llog2 fold changes of 0 were imputed for missing values. Protein cluster 
membership (50% sequence identity) is along the protein dendrogram on the left side; vaccine group membership is 
highlighted below the subject dendrogram at the top. Red: up-regulated from baseline; green: down-regulated from 
baseline; grey: missing observations. Larger versions of these heatmaps available in Appendix B 
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Figure 3.9 HLA Class I family time trends of mean log2 fold changes from baseline by vaccine group.  Data 
only includes cell types with differentially abundant HLA proteins.  Individual HLA family protein time trends are 
plotted in lighter colors. The mean log2 fold changes across all HLA protein family members are in bold. 
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AS03-induces antigen processing and presentation pathways 
     Gene set enrichment analysis showed that genes encoding for DA proteins are involved in a 
range of biological processes including protein metabolism, tubulin folding, platelet activation, and 
immune system-related processes (Table B-22 -Table B-33). Antigen processing and 
presentation-related pathways were enriched in monocytes and neutrophils at day 3, including 
Class I MHC-mediated antigen processing and presentation, Antigen processing and cross 
presentation, and ER phagosome pathways (source: Reactome, Figure 3.10). This strongly 
suggests that SV-AS03 enhances antigen presentation at early time points, which is essential for 
the ultimate production of antibodies and activation of cytotoxic T-cells. Unexpectedly, Antigen 
presentation folding assembly and peptide loading of class I MHC was enriched for B cells at day 
7, with the proteins being upregulated in the SV-AS03 group. While B cells are a professional 
APC, they usually present antigen to helper T cells via the MHC class II complex.41 However, Hon 
et al. and others have shown that B cells are able to also participate in cross-presentation to 
present antigen to cytotoxic T cells via the MHC class I complex, which could be happening 
here.41-42   
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Figure 3.10 Heatmap of enriched MSigDB Reactome pathways.  Gene sets significantly enriched in at least two 
conditions (cell type/time point combinations) are shown. Cells are color-coded by the Jaccard similarity index. 
Numbers in the cells represent the DA protein families in a set. Cells with protein family numbers in brackets indicate 
significantly enriched sets. Sets were clustered on the Jaccard distance between their binary enrichment pattern. 
 
Antigen presentation and oxidative stress response proteins predict seroprotection status 
     To identify AS03-modulated protein families that are predictive of seroprotection status (HAI 
titer ≥1:40) at day 56, regularized logistic regression analysis was performed using imputed 
protein family baseline responses as predictors (Table B-34 - Table B-37). To reduce the impact 
of missing observations on the imputation process, the analysis was performed on the most 
complete datasets (monocytes and neutrophils) and proteins with quantifications for 9 of 10 
subjects in each vaccine group. MPO (myeloperoxidase) and SOD2 (superoxide dismutase 2) 
protein families, which are involved in inflammation and oxidative stress responses, were among 
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those identified as positive predictors of seroprotection in monocytes at day 1 (Table B-34). 
Surprisingly, while similar inflammation and oxidative stress-related protein families, including 
NCF4 (neutrophil cytosolic factor 4) and GZMB (granzyme B), were identified as predictors in 
neutrophils at day 1, they were negative predictors (Table B-37). In fact, the majority of the 
proteins included in the day 1 neutrophil model for seroprotection prediction were negative 
predictors, indicating that early time point neutrophils were potentially reducing the antibody 
response. Yang et al. previously reported that depletion of neutrophils following an adjuvanted 
vaccination actually increase the CD4+ T cell and antibody responses in mice.43 While they were 
using neither AS03 nor H5N1 in their vaccinations, this could explain the negative association 
observed in the neutrophils.  
     Four of the 12 selected protein families identified as predictors of seroprotection in monocytes 
at day 3 were related to Class I MHC-mediated antigen processing and presentation including 
HLA (major histocompatibility complex, class I family), PSME 1 and PSME 2 (PA28 alpha/beta 
proteasome activator subunit families), as well as ITGB5 (integrin, beta 5 family) (Table B-35). 
For all these protein families, an increase in fold change from baseline resulted in an increased 
likelihood of seroprotection. Changes in PSME2 had the highest impact. The monocyte day 3 
protein-protein interaction network (Figure 3.11) shows HLA and proteasome family proteins 
separated by two intermediate nodes indicating their close functional relationship. However, it 
remains unclear by what mechanism up-regulation of HLA class I molecules, proteasome 
activators, and other inflammation proteins enhance seroprotection.  
 
Comparison of proteomic and transcriptomic data 
     Differentially expressed (DE) genes (SV-AS03 vs. SV-PBS) identified in the transcriptomics 
study conducted in parallel30 were compared to the proteomics results. Twenty-three DA protein 
families were associated with DE genes identified for any cell type-time point combination (Table 
3.3). Interestingly, increased PSME1 and PSME2 proteomic responses for the SV-AS03 group in  
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Figure 3.11 Monocyte day 3 protein-protein interaction network.  Human-human and human-Influenza A 
experimental interactions for which at least one interacting partner was differentially abundant between vaccine 
groups are shown. The mean log2 fold change between vaccine groups was used if multiple Ensembl protein IDs 
mapped to one UniProt ID. 
 
monocytes at day 3 corresponded with increased transcriptomic changes in the genes encoding 
these proteins in monocytes at day 1. Change in PSME2 were significant in both the proteomic 
and transcriptomic studies. While HLA Class I protein encoding genes were slightly up-regulated 
but not significantly differentially expressed in the SV-AS03 group in monocytes, the Class I MHC-
mediated antigen processing and presentation pathway was significantly enriched in DE genes 
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up-regulated in SV-AS03 group at day 1.30 Together these findings imply a delayed Class I-related 
antigen presentation response on the protein level (day 3) following an initial transcriptomics 
response at 24h post-vaccination. A post-transcriptional regulation mechanism may be 
modulating the expression of antigen processing and presentation proteins in monocytes.44 
     As anticipated, very few of the differential protein families (12%, 23 of 188) were identified in 
the transcriptomics analysis for any cell type-time point combination. This lack of shared 
responses has been seen in previous comparison studies45-46 and likely stems from translational 
control of gene expression, degradation of mRNA prior to translation, post-translational 
modifications of proteins, bias towards highly abundant proteins, small sample size, and general 
noise in the data.47 Despite the lack of individual shared responses, the proteomic analysis on the 
pathway level confirmed the enrichment of the Class I antigen processing and presentation 
pathway at day 1 based on transcriptomics results for monocytes and neutrophils albeit two days 
later (day 3, Figure 3.10).  
 
Conclusion 
     The goal of this study was to investigate the changes in immune cell proteomes after H5N1 
vaccination with or without AS03 in order to better understand the mechanisms by which AS03 
enhances protection. Even with a small sample size, this study highlights the strengths of 
assessing proteomic responses of multiple individual immune cell types in parallel by 
demonstrating a transient response to the AS03-adjuvanted influenza vaccine shown by 
modifications of the immune cell’s proteomic profiles across the entire immune response. 
Furthermore, this study identified a strong antigen processing and presentation response at early 
time points that could also predict later seroprotection. In summary, the application of a cell-based 
proteomics approach allows a more granular assessment of immune cell-specific responses that, 
compared with transcriptomics results, revealed additional aspects of the immune responses to 
AS03-adjuvanted influenza vaccine.  
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Table 3.3 Proteins encoded by genes determined to be differentially expressed in a parallel RNA-Seq 
experiment. Protein families that contained at least one differentially abundant protein and at least one protein that 
was encoded by a differentially expressed gene were included.  
Protein Family ID Gene ID Gene Name Gene Description 
ENSP00000346550 ENSG00000138772 ANXA3 Annexin A3 
ENSP00000310219 ENSG00000126803 HSPA2 Heat shock 70kDa protein 2 
ENSP00000363071 ENSG00000026025 VIM Vimentin 
ENSP00000357283 ENSG00000113368 LMNB1 Lamin B1 
ENSP00000249750 ENSG00000128918 ALDH1A2 Aldehyde dehydrogenase 1 
family, member A2 
ENSP00000446252 ENSG00000112096 SOD2 Superoxide dismutase 2, 
mitochondrial 
ENSP00000379038 ENSG00000025708 TYMP Thymidine phosphorylase 
ENSP00000468041 ENSG00000126247 CAPNS1 Calpain, small subunit 1 
ENSP00000433138 ENSG00000137752 CASP1 Caspase 1, apoptosis-related 
cysteine peptidase 
ENSP00000372155 ENSG00000092010 PSME1 Proteasome (prosome, 
macropain) activator subunit 1 
(PA28 alpha) 
ENSP00000216802 ENSG00000100911 PSME2 Proteasome (prosome, 
macropain) activator subunit 2 
(PA28 beta) 
ENSP00000226299 ENSG00000002549 LAP3 Leucine aminopeptidase 3 
ENSP00000362409 ENSG00000136830 FAM129B Family with sequence similarity 
129, member B 
ENSP00000345023 ENSG00000065621 GSTO2 Glutathione S-transferase 
omega 2 
ENSP00000053867 ENSG00000030582 GRN Granulin 
ENSP00000378669 ENSG00000109107 ALDOC Aldolase C, fructose-
bisphosphate 
ENSP00000221992 ENSG00000007306 CEACAM7 Carcinoembryonic antigen-
related cell adhesion molecule 7 
ENSP00000423563 ENSG00000263521 HIST2H2AC Histone cluster 2, H2ac 
ENSP00000386881 ENSG00000135636 DYSF Dysferlin 
ENSP00000222553 ENSG00000105835 NAMPT Nicotinamide 
phosphoribosyltransferase 
ENSP00000289473 ENSG00000158517 NCF1 Neutrophil cytosolic factor 1 
ENSP00000394842 ENSG00000115271 GCA Grancalcin, EF-hand calcium 
binding protein 
ENSP00000357721 ENSG00000143546 S100A8 S100 calcium binding protein A8 
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 CHAPTER IV 
 
CONCLUSIONS AND PERSPECTIVES 
 
Summary 
     Vaccines have significantly reduced world-wide mortality caused by infectious diseases by 
producing long-term immunological memory.1 As a result, vaccines have been one of the most 
cost-effective advancements in medicine, particularly with influenza. Seasonal influenza 
outbreaks cause 3-5 million infections worldwide and the associated vaccines are typically 70-
80% effective.2-3 However, pandemic influenza vaccines, particularly avian influenzas, tend to not 
be particularly effective for unknown reasons.3 Therefore, vaccine manufacturers have started 
using adjuvants to enhance the protective response from the vaccine and to help reduce the 
amount of antigen required.4 While this approach has worked with moderate success for such 
adjuvants like monophosphoryl lipid A in the HPV vaccine and MF59 in one seasonal influenza 
vaccine,5 the adjuvant AS03 has shown slower success due to initial safety issues.6-7 By being 
associated with an increased risk of narcolepsy in children, even when more recent reports have 
implicated other causes,8-10 AS03 has yet to be approved for the general public.  
     Studies examining how AS03 and its components work have largely been conducted using 
animal models.11-12 However, they are not necessarily a good analogy for human studies.13-15 
Therefore, we sought to investigate the molecular mechanisms of AS03 on a cell-population level 
using a human cohort. First, cell purification and protein quantitation multiplexing strategies 
needed for a large study were developed, as described in Chapter II. Using both MACS and 
FACS, highly purified immune cell populations were collected for proteomics analysis, along with 
the standard PBMC fraction for comparison. By comparing two competing iTRAQ multiplexing 
strategies, it was shown that pooling together the same cell types at different time points was 
superior to pooling different cell types at the same time point, in terms of identifying cell-type 
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specific protein responses. Further, the fraction of shared differentially expressed proteins from 
each immune cell population with the unpurified immune cells was very small, indicating a more 
complete data set was obtained from the purified cells. 
     Chapter II introduced one of the first examples of using quantitative shotgun proteomic 
analysis in a systems vaccinology study. The majority of systems vaccinology reviews have 
discussed the benefit of including proteomics data, but fail to provide any such example.16-18 
Instead, they describe numerous studies utilizing transcriptomics and antibody responses.19-24 
Genomics, transcriptomics, and proteomics complement each other.25 While the genome is static, 
transcriptomics and proteomics dynamically respond to environmental changes. Even so, the 
correlation between transcriptomics and proteomics can be low due to post-transcriptional 
regulatory mechanisms.26 By including proteomics data, we can obtain a more comprehensive 
picture of the immune response following vaccination.  
     Building on the methods developed in Chapter II, Chapter III reported the results from a Phase 
I prospective clinical trial assessing the molecular immune responses of an H5N1 vaccine given 
with our without AS03 adjuvant. This trial represents the first instance of AS03 being investigated 
in humans by systems biology methods. Distinct responses were observed in all cell types, but 
monocytes demonstrated the strongest differential signal, followed by neutrophils. Antigen 
processing and presentation pathways were shown to be enriched in these cell types at early time 
points for both proteomic and transcriptomic analysis. Prediction models identified inflammation 
and oxidative stress proteins at day 1, as well as immunoproteasome subunits at day 3, as 
predictors of later seroprotective antibody responses. However, the correlation of these proteins 
to seroprotective antibody responses needs to be validated in a larger study. Once confirmed, 
this set of proteins could potentially be used to assess the effectiveness of the AS03-H5N1 
vaccine. This would be especially important during a pandemic outbreak to determine if a person 
would ultimately achieve protection or if the dose would be better going to someone else. 
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Study Limitations 
     Although the research described here identified many proteome changes in the immune 
response to influenza vaccines, some limitations were unavoidable. First, the small sample size 
of 2 subjects in Chapter II and 10 subjects per group in Chapter III limits the generalizability of our 
results. However, these studies demonstrate the strengths of analyzing proteomic responses in 
systems vaccinology studies. By including proteomics, additional aspects of the immune response 
were identified as compared to transcriptomics and serological analysis conducted alone, allowing 
for a more comprehensive picture of the immune response. Second, since this pilot study and 
clinical trial was conceptualized, designed, and conducted, new mass spectrometry methods 
using MS327 and MultiNotch MS328 for iTRAQ analysis have been published. These methods 
show a reduction in the ratio distortion seen in iTRAQ experiments and allow for more proteins to 
be quantified overall. While we were unable to adopt the newer methods in these studies, due to 
the limitations on altering protocols after they are approved and the trial begins, future systems 
vaccinology studies will greatly benefit from these enhancements. This, however, does not 
discredit the observations made here; it just suggests that additional information could have been 
obtained. Finally, the immune cells used in these studies were purified from venous whole blood, 
rather than a combination of venous blood, lymphoid tissues, and muscle tissue at the site of 
injection. After APCs come in contact with a pathogen, they migrate to the lymph nodes in order 
to activate the adaptive immune response.29 By sampling only blood, “fresh” immune cells are 
likely being sampled more than any activated ones over time, leading to important signals being 
diluted. Blood is a relatively quick and easy sample to collect and it was not possible to collect 
lymphoid and muscle tissue from healthy human subjects. Even with using only blood, models of 
protein combinations that could predict later seroprotection status were identified. It is reasonable 
to hypothesize that these models, based on blood, may be useful in the case of a H5N1 pandemic 
outbreak in order to quickly identify those who will achieve protection from the vaccine. 
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Future Directions 
Protein Validation Studies 
     The clinical trial described in Chapter III identified hundreds of proteins that were differentially 
expressed between subjects who received AS03-H5N1 and those who received the control PBS-
H5N1 vaccine. A small subset of these proteins were further selected in prediction models for 
seroprotection. However, in order for these proteins and models to be fully applied as correlates 
of protection, they must be validated and confirmed. The Link lab is currently working on methods 
to validate both the proteomics and transcriptomics results using a human monocyte THP-1 cell 
line.  
     Western blotting has historically been considered the gold standard for validating protein 
quantitation, however the field is moving more toward multiple reaction monitoring (MRM) for 
validation, as it is more reliable, reproducible, and accurate.30 MRM is a targeted mass 
spectrometry approach that measures only the precursor and fragment ions of analytes of interest 
as transitions.31 During MRM method development, a list of proteins of interest are imported into 
Skyline,32 where the program fragments the proteins in silico and provides lists of possible 
transitions based on spectral libraries. This list is then narrowed down to pick at least three 
proteotypic peptides per protein and at least three transitions per peptide for scouting runs. 
Scouting runs test the detectability, stability, and reproducibility of the transitions. The MRM 
transition list is then reduced further iteratively until a final method is produced. Finally, synthetic 
peptides corresponding to the proteins of interest are used as internal standards to obtain the 
quantitative information. Currently, the initial transition list for the scouting runs has been made 
for validation of the monocyte data. However, there are a number of steps to be completed before 
the method will be usable for the validation of the clinical trial proteins. Further, this process will 
need to be completed for the neutrophil results, if not all the remaining cell types. 
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Metabolomics 
     Metabolomics is considered the “final frontier” in systems biology.17, 33 Therefore, investigating 
the metabolomic response to an AS03-adjuvanted H5N1 vaccine is a logical step for further 
understanding how it works. Metabolomics is the method of measuring and identifying small 
molecules, typically under 2000 Da. As the components of AS03 are all small molecules, it is 
possible to hypothesize that the degradation products could be measured throughout the immune 
response allowing for a better understanding of both the immune response and the 
pharmacokinetics of the adjuvant. Million Tegenge and Robert Mitkus created a physiologically 
based pharmacokinetic model which predicted that α–tocopherol would peak in serum at 8 hours, 
rapidly transfer to draining lymph nodes, and be stored in adipose tissue.34 However, their model 
was based on data collected from studies conducted in sheep and required a number of informed 
assumptions regarding human biology. By using metabolomics, the components of AS03 could 
be followed after vaccination to fully understand how they work, rather than relying on 
assumptions.  
     Further, the AS03-adjuvant degradation products could also be stimulating the immune 
response themselves, as metabolites can regulate signal transduction and regulate immune 
functions.17, 35 The application of metabolomics to studying vaccines is relatively new, however 
one study identified sets of metabolites that differentiated between vaccinated and unvaccinated 
cows.36 Similar to our proteomics analysis, the metabolites identified would also need to be 
validated. 
 
AS03 Mechanism of Action 
     Understanding the exact mechanism of how AS03 works is vitally important for it to be licensed 
for general use. The best way to investigate this would be to compare the response of AS03 alone 
to the response of the AS03-H5N1 vaccine and the response of an unadjuvanted H5N1 vaccine. 
This three-way comparison would help identify which signals stem from AS03, rather than the 
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normal response to an antigen. Ethical concerns prohibit the use of AS03 alone without a vaccine 
in humans, as it has not been assessed for safety in that manner. Therefore, these experiment 
will have be carried out in cell culture and animal models. While the methods outlined in Chapters 
II-III can and should be applied to these experiments, the data obtained will not be fully 
comparable to the human results.  
     In order to get the most complete understanding of the AS03 mechanism of action, all of the 
omics data from the human clinical trial and any cell culture/animal model experiments would 
need to be compared and integrated. This is the area where systems vaccinology faces the most 
challenges ahead. Individual omics studies generate enormous amounts of data and systems 
vaccinology aims to integrate many different types of omics studies (Figure 4.1). Effectively 
combining multiple omics datasets requires understanding each one individually statistically and 
biologically, as they all come with their own background and experimental noise, complexity, and 
format.37-38 While there are tools to aid in the integration of multiple data types, they mainly are 
derived from methods for analyzing one data type and therefore do not completely bridge the 
gap.38 Furthermore, these methods are mathematically complex to both operate and understand. 
Until a tool that will effectively combine all omics data types is developed, it will be difficult to 
produce a complete mechanism of action for AS03 or any other adjuvant. 
 
 
 92 
 
 
Figure 4.1 Overview of systems vaccinology methods. Systems vaccinology aims to collect and integrate data 
from all components of the immune response. A combination of standardized immune serologic assays with the high-
throughput transcriptomic, proteomic, and metabolomic measurements will provide the opportunity to predict 
immunologic protection from vaccines.17 Reprinted from Seminars in Immunology, with permission from Elsevier. 
 
Conclusion 
     Applying quantitative proteomics to the field of systems vaccinology represents a step forward 
for understanding the immune response to vaccines on a granular level. Overall, the methods in 
this dissertation outline the benefit of both separating the individual immune cell populations and 
using quantitative proteomics to study the immune response to vaccines. Many differences were 
observed when the responses from purified individual immune cell types were compared to PBMC 
after a seasonal influenza vaccine. Each individual immune cell type showed unique biological 
networks associated with their differential proteins. Further, when the developed methods were 
applied during a clinical trial of an AS03-adjuvanted H5N1 vaccine, monocytes and neutrophils 
showed significant upregulation of antigen processing and presentation proteins, which 
corresponded to similar results observed at the transcriptomics level. The approaches outlined 
here can guide future systems biology studies aimed at modeling and predicting complex 
responses to vaccines, vaccine adjuvants, or even natural infections between multiple cell types. 
 93 
 
References 
1. Germain, R. N., Vaccines and the Future of Human Immunology. Immunity 2010, 33, 441-
450. 
2. Kreijtz, J. H. C. M.; Fouchier, R. A. M.; Rimmelzwaan, G. F., Immune responses to 
influenza virus infection. Virus Res 2011, 162, 19-30. 
3. Gottlieb, T.; Ben-Yedidia, T., Epitope-based approaches to a universal influenza vaccine. 
J Autoimmun 2014, 54, 15-20. 
4. Vogel, F. R.; Hem, S. L., Immunologic Adjuvants. In Vaccines, Expert Consult, 5th ed.; El: 
China, 2008; pp 59-71. 
5. Centers for Disease Control and Prevention Vaccine Adjuvants. 
https://www.cdc.gov/vaccinesafety/concerns/adjuvants.html (accessed December 12, 
2016). 
6. Nohynek, H.; Jokinen, J.; Partinen, M.; Vaarala, O.; Kirjavainen, T.; Sundman, J.; 
Himanen, S.; Hublin, C.; Julkunen, I.; Olsen, P.; Saarenpaa-Heikkila, O.; Kilpi, T., AS03 
adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of 
childhood narcolepsy in Finland. PLoS ONE 2012, 7 (3), e33536. 
7. Ahmed, S. S.; Schur, P. H.; MacDonald, N. E.; Steinman, L., Narcolepsy, 2009 A(H1N1) 
pandemic influenza, and pandemic influenza vaccinations: what is known and unknown 
about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. J 
Autoimmun 2014, 50, 1-11. 
8. Vaarala, O.; Vuorela, A.; Partinen, M.; Baumann, M.; Freitag, T. L.; Meri, S.; Saavalainen, 
P.; Jauhiainen, M.; Soliymani, R.; Kirjavainen, T.; Olsen, P.; Saarenpaa-Heikkila, O.; 
Rouvinen, J.; Roivainen, M.; Nohynek, H.; Jokinen, J.; Julkunen, I.; Kilpi, T., Antigenic 
Differences between AS03 Adjuvanted Influenza A (H1N1) Pandemic Vaccines: 
Implications for Pandemrix-Associated Narcolepsy Risk. PLoS ONE 2014, 9 (12), 
e114361. 
9. Ahmed, S. S.; Volkmuth, W.; Duca, J.; Corti, L.; Pallaoro, M.; Pezzicoli, A.; Karle, A.; Rigat, 
F.; Rappuoli, R.; Narashimhan, V.; Julkunen, I.; Vuorela, A.; Vaarala, O.; Nohynek, H.; 
Pasini, F. L.; Montomoli, E.; Trombetta, C.; Adams, C. M.; Rothbard, J.; Steinman, L., 
Antibodies to influenza neucleoprotein cross-react with human hypocretin receptor 2. 
Science Translational Medicine 2015, 7 (294), 29ra105. 
10. Ambati, A.; Poiret, T.; Svahn, B. M.; Valentini, D.; Khademi, M.; Kockum, I.; Lima, I.; 
Arnheim-Dahlstrom, L.; Lamb, F.; Fink, K.; Meng, Q.; Kumar, A.; Rane, L.; Olsson, T.; 
Maeurer, M., Increased beta-haemolytic group A streptococcal M6 serotype and 
streptodornase B-specific cellular immune responses in Swedish narcolepsy cases. 
Journal of internal medicine 2015, 278 (3), 264-276. 
11. Morel, S.; Didierlaurent, A.; Bourguignon, P.; Delhaye, S.; Baras, B.; Jacob, V.; Planty, C.; 
Elouahabi, A.; Harvengt, P.; Carlsen, H.; Kielland, A.; Chomez, P.; Garçon, N.; Van 
Mechelen, M., Adjuvant System AS03 containing α-tocopherol modulates innate immune 
response and leads to improved adaptive immunity. Vaccine 2011, 29, 2461-2473. 
 94 
 
12. Segal, L.; Wouters, S.; Morelle, D.; Gautier, G.; Le Gal, J.; Martin, T.; Kuper, F.; Destexhe, 
E.; Didierlaurent, A. M.; Garcon, N., Non-clinical safety and biodistribution of AS03-
adjuvanted inactivated pandemic influenza vaccines. Journal of applied toxicology : JAT 
2015, 35 (12), 1564-1576. 
13. Mestas, J.; Hughes, C. C. W., Of Mice and Not Men: Differences between Mouse and 
Human Immunology. J Immunol  2004, 172 (5), 2731-2738. 
14. Su, L. F.; Han, A.; McGuire, H. M.; Furman, D.; Newell, E. W.; Davis, M. M., The promised 
land of human immunology. Cold Spring Harbor symposia on quantitative biology 2013, 
78, 203-13. 
15. Beura, L. K.; Hamilton, S. E.; Bi, K.; Schenkel, J. M.; Odumade, O. A.; Casey, K. A.; 
Thompson, E. A.; Fraser, K. A.; Rosato, P. C.; Filali-Mouhim, A.; Sekaly, R. P.; Jenkins, 
M. K.; Vezys, V.; Haining, W. N.; Jameson, S. C.; Masopust, D., Normalizing the 
environment recapitulates adult human immune traits in laboratory mice. Nature 2016, 
532 (7600), 512-6. 
16. Pulendran, B.; Li, S.; Nakaya, H. I., Systems vaccinology. Immunity 2010, 33, 516-529. 
17. Li, S.; Nakaya, H. I.; Kazmin, D. A.; Oh, J. Z.; Pulendran, B., Systems biological 
approaches to measure and understand vaccine immunity in humans. Semin Immunol 
2013, 25, 209-218. 
18. Buonaguro, L.; Wang, E.; Tornesello, M. L.; Buonaguro, F. M.; Marincola, F. M., Systems 
biology applied to vaccine and immunotherapy development. BMC Systems Biology 2011, 
5, 146. 
19. Li, S.; Rouphael, N.; Duraisingham, S.; Romero-Steiner, S.; Presnell, S.; Davis, C.; 
Schmidt, D. S.; Johnson, S. E.; Milton, A.; Rajam, G.; Kasturi, S.; Carlone, G. M.; Quinn, 
C.; Chaussabel, D.; Palucka, A. K.; Mulligan, M. J.; Ahmed, R.; Stephens, D. S.; Nakaya, 
H. I.; Pulendran, B., Molecular signatures of antibody responses derived from a systems 
biology study of five human vaccines. Nat Immunol 2014, 15, 195-204. 
20. Nakaya, H. I.; Clutterbuck, E.; Kazmin, D.; Wang, L.; Cortese, M.; Bosinger, S. E.; Patel, 
N. B.; Zak, D. E.; Aderem, A.; Dong, T.; Del Giudice, G.; Rappuoli, R.; Cerundolo, V.; 
Pollard, A. J.; Pulendran, B.; Siegrist, C. A., Systems biology of immunity to MF59-
adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood. 
Proceedings of the National Academy of Sciences of the United States of America 2016. 
21. Nakaya, H. I.; Hagan, T.; Duraisingham, S. S.; Lee, E. K.; Kwissa, M.; Rouphael, N.; 
Frasca, D.; Gersten, M.; Mehta, A. K.; Gaujoux, R.; Li, G. M.; Gupta, S.; Ahmed, R.; 
Mulligan, M. J.; Shen-Orr, S.; Blomberg, B. B.; Subramaniam, S.; Pulendran, B., Systems 
Analysis of Immunity to Influenza Vaccination across Multiple Years and in Diverse 
Populations Reveals Shared Molecular Signatures. Immunity 2015, 43 (6), 1186-98. 
22. Nakaya, H. I.; Wrammert, J.; Lee, E. K.; Racioppi, L.; Marie-Kunze, S.; Haining, W. N.; 
Means, A. R.; Kasturi, S. P.; Khan, N.; Li, G.-M.; McCausland, M.; Kanchan, V.; Kokko, K. 
E.; Li, S.; Elbein, R.; Mehta, A. K.; Aderem, A.; Subbarao, K.; Ahmed, R.; Pulendran, B., 
Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 2011, 12, 
786-795. 
 95 
 
23. Querec, T. D.; Akondy, R. S.; Lee, E. K.; Cao, W.; Nakaya, H. I.; Teuwen, D.; Pirani, A.; 
Gernert, K.; Deng, J.; Marzolf, B.; Kennedy, K.; Wu, H.; Bennouna, S.; Oluoch, H.; Miller, 
J.; Vencio, R. Z.; Mulligan, M.; Aderem, A.; Ahmed, R.; Pulendran, B., Systems biology 
approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 
2009, 10, 116-125. 
24. Tan, Y.; Tamayo, P.; Nakaya, H.; Pulendran, B.; Mesirov, J. P.; Haining, W. N., Gene 
signatures related to B-cell proliferation predict influenza vaccine-induced antibody 
response. European Journal of Immunology 2014, 44, 285-295. 
25. Adamczyk-Poplawska, M.; Markowicz, S.; Jagusztyn-Krynicka, E. K., Proteomics for 
development of vaccine. J Proteomics 2011, 74, 2596-2616. 
26. Vogel, C.; Marcotte, E. M., Insights into the regulation of protein abundance from 
proteomic and transcriptomic analyses. Nature reviews. Genetics 2012, 13 (4), 227-32. 
27. Ting, L.; Rad, R.; Gygi, S. P.; Haas, W., MS3 eliminates ratio distortion in isobaric 
multiplexed quantitative proteomics. Nat Methods 2011, 8 (11), 937-40. 
28. McAlister, G. C.; Nusinow, D. P.; Jedrychowski, M. P.; Wuhr, M.; Huttlin, E. L.; Erickson, 
B. K.; Rad, R.; Haas, W.; Gygi, S. P., MultiNotch MS3 enables accurate, sensitive, and 
multiplexed detection of differential expression across cancer cell line proteomes. Anal 
Chem 2014, 86 (14), 7150-8. 
29. Murphy, K., Janeway's Immunobiology. 8th ed.; Garland Science: London, 2012. 
30. Aebersold, R.; Burlingame, A. L.; Bradshaw, R. A., Western Blots versus Selected 
Reaction Monitoring Assays: Time to Turn the Tables? Molecular & Cellular Proteomics 
2013, 12, 2381-2382. 
31. Kitteringham, N. R.; Jenkins, R. E.; Lane, C. S.; Elliott, V. L.; Park, B. K., Multiple reaction 
monitoring for quantitative biomarker analysis in proteomics and metabolomics. J 
Chromatogr B Biomed Sci Appl 2009, 877, 1229-1239. 
32. MacLean, B.; Tomazela, D. M.; Shulman, N.; Chambers, M.; Finney, G. L.; Frewen, B.; 
Kern, R.; Tabb, D. L.; Liebler, D. C.; MacCoss, M. J., Skyline: an open source document 
editor for creating and analyzing targeted proteomics experiments. Bioinformatics 2010, 
26 (7), 966-8. 
33. Veenstra, T. D., Metabolomics: the final frontier? Genome Medicine 2012, 4, 40. 
34. Tegenge, M. A.; Mitkus, R. J., A first-generation physiologically based pharmacokinetic 
(PBPK) model of alpha-tocopherol in human influenza vaccine adjuvant. Regulatory 
toxicology and pharmacology : RTP 2015, 71 (3), 353-364. 
35. Wellen, K. E.; Thompson, C. B., A two-way street: reciprocal regulation of metabolism and 
signalling. Nature reviews. Molecular cell biology 2012, 13 (4), 270-6. 
36. Gray, D. W.; Welsh, M. D.; Doherty, S.; Mansoor, F.; Chevallier, O. P.; Elliott, C. T.; 
Mooney, M. H., Identification of systemic immune response markers through metabolomic 
 96 
 
profiling of plasma from calves given an intra-nasally delivered respiratory vaccine. 
Veterinary research 2015, 46, 7. 
37. Buescher, J. M.; Driggers, E. M., Integration of omics: more than the sum of its parts. 
Cancer & metabolism 2016, 4, 4. 
38. Gligorijevic, V.; Przulj, N., Methods for biological data integration: perspectives and 
challenges. Journal of the Royal Society, Interface 2015, 12 (112). 
 
 97 
 
APPENDIX A 
 
SUPPORTING INFORMATION: CHAPTER II 
 
The following three tables are too large to be included in this document, but can be accessed 
from the provided links. Each file reports normalized pseudospectral counts (NPSC) that were 
calculated in ProteoIQ. A value of zero indicates a protein was identified but not quantified, while 
an NA value indicates a protein was not identified in that sample at all.  
 
Table A-1 Normalized protein expression in human immune cells prior to and post-TIV vaccination. 
Link https://drive.google.com/open?id=1GECKcX6pPg-NcgKJ9ixvdxThs1h-yxdOKNHVcOOyfgQ 
 
Table A-2 Normalized protein expression in human immune cells prior to and post-TIV vaccination filtered to 
remove zero values and contaminating keratins from subject HD30 
Link https://drive.google.com/open?id=18dUgJPractjufwTe88Spa1r0Am-fSa_dvHsrfQSbtys 
 
Table A-3 Normalized protein expression in human immune cells prior to and post-TIV vaccination filtered to 
remove zero values and contaminating keratins from subject HD31 
Link https://drive.google.com/open?id=1AtnZoC1HHwfPq5oN74ww2MO_ZfAdm8r25oVOx
adff-0 
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Table A-4 Top networks and pathways identified in TIV-vaccinated subjects 
 Top Network Description Top Canonical Pathway 
d0-1 
PBMC Hematological disease, reproductive system development 
and function, cellular assembly and organization Granzyme A signaling 
T cell Endocrine system development and function, molecular transport, small molecule biochemistry 
Mechanisms of viral exit 
from host cells 
B cell Cellular assembly and organization, cellular function and 
maintenance, nervous system development and function 
Pyruvate fermentation to 
lactate 
NK Cellular assembly and organization, DNA replication, 
recombination and repair, post-translational modification Granzyme A signaling 
Monocyte Dermatological disease and conditions, antimicrobial 
response, inflammatory response 
Methylglyoaxal 
degradation III 
Neutrophil Hematological system development and function, tissue 
morphology, cellular development RhoGDI signaling 
d0-3 
PBMC 
Cellular assembly and organization, DNA replication, 
recombination and repair, connective tissue development 
and function 
Granzyme A signaling 
T cell Hereditary disorder, metabolic disease, neurological disorder 
Inhibition of angiogenesis 
by TSP1 
B cell Protein synthesis, RNA post-transcriptional modification, 
molecular transport 
Lipid antigen 
presentation by CD1 
NK Cellular movement, hematological system development and function, immune cell trafficking 
Actin cytoskeleton 
signaling 
Monocyte Cancer, endocrine system disorders, hematological disease Sertoli cell-sertoli cell junction signaling 
Neutrophil Cell morphology, hereditary disorder, nervous system development and function 
Pentose phosphate 
pathway (non-oxidative) 
d0-7 
PBMC Cellular assembly and organization, DNA replication, 
recombination and repair, cell cycle Granzyme A signaling 
T cell Cell death and survival, embryonic development, post translational modification 
Oxidative 
phosphorylation 
B cell Nucleic acid metabolism, cardiac arrhythmia, cardiovascular disease Mitochondrial dysfunction 
NK Free radical scavenging, molecular transport, cellular 
assembly and organization 
Regulation of actin-based 
motility by Rho 
Monocyte Cell death and survival, cellular compromise, protein trafficking 
Neuroprotective role of 
THOP1 in Alzheimer’s 
disease 
Neutrophil Cellular assembly and organization, cellular function and 
maintenance, neurological disease 
Amyotropic lateral 
sclerosis signaling 
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APPENDIX B 
 
SUPPORTING INFORMATION: CHAPTER III 
 
Supplemental Methods 
Ethics statement 
     This study was approved by the Vanderbilt University Institutional Review Board, and the study 
was conducted in accordance with Good Clinical Practice, the Declaration of Helsinki, the US 
Code of Federal Regulations for the Protection of Human Subjects, and the Department of Health 
and Human Services Belmont Report. The study is registered on ClinicalTrials.gov (No. 
NCT01573312). All subjects provided written informed consent prior to initiation of study 
procedures. Subjects were assigned de-identified code numbers and their privacy strictly held in 
trust by study personnel, sponsors, and their agents. This confidentiality extends to cover testing 
of biological samples, in addition to the clinical information related to participants.  
 
Study products 
     Inactivated monovalent influenza A/Indonesia/05/2005 H5N1 split-virus vaccine at a dosage 
of 3.75 mcg and phosphate buffered saline (PBS) diluent were both manufactured by Sanofi 
Pasteur. The AS03 adjuvant was manufactured by GlaxoSmithKline (GSK) and contained 4.86 
mg polysorbate 80, 11.86 mg α-tocopherol, and 10.69 mg squalene in an oil-in-water emulsion. 
The vaccine and adjuvant were provided by the US Department of Health and Human Services 
Biomedical Advanced Research and Development Authority from the National Pre-pandemic 
Influenza Vaccine Stockpile. 
 
 
 
 100 
 
Analysis population 
     The systems biology analysis population included all subjects who met all inclusion and 
exclusion criteria, who contributed at least one pre-vaccination blood sample (at Day -28, -14, or 
0) and at least one post-vaccination blood sample (at Day 1, 3, 7, or 28) for which valid results 
were reported. The analyses included subjects by study product actually received. This population 
included 20 subjects (10 for each treatment group) including a subject in the SV-AS03 vaccine 
group, who received the second vaccination (Day 28) out-of-window. Time points with outlying 
measurements were identified separately for each assay. 
 
Reference Channel Selection 
     In order to determine the most advantageous method for normalizing the data within ProteoIQ, 
randomly selected donors and cell type data were analyzed first using Day 0 as the reference 
channel and second with ICCS as the reference channel. The log2 ratios were exported for each 
method and plotted against each other in R (Figure B-11A). While both methods showed 
moderate correlation for peptides quantitated in both experiments (Figure B-11B), the experiment 
using ICCS as the reference channel showed more quantitated peptides overall. Further, a Bland-
Altman plot showing the agreement between the two methods (Figure B-11C) showed a slight 
bias towards higher quantitation values in the method using ICCS as the reference, however with 
a value of 0.03122, the bias was small enough to not be considered. Therefore, the remaining 
analyses were performed using ICCS selected as the reference channel.  
 
Normalization 
     To account for systematic differences in the protein ratio distributions between iTRAQ 
experiments for the same cell type, protein ratios were normalized within cell type on the log2 
scale to align the medians of the protein ratio distributions across cell type samples. The following 
steps were taken for each cell type: 
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(1) For each sample (140 per cell type), the median of the protein ratio distribution was 
determined using the quantifications obtained from the reference (top) protein within a 
protein group 
(2) The median of all the sample medians calculated in (1) was obtained 
(3) A sample specific scaling factor was then calculated as the difference between the cell 
type-specific median obtained in (2) and the sample-specific median obtained in (1) 
(4) The protein ratio distribution for each sample was then normalized by adding the scaling 
factor determined in (3). 
Subject specific log2 protein fold changes from baseline were calculated for each subject and 
post-vaccination day by subtracting the mean of the normalized log2 baseline ratios from each of 
the subject’s post-vaccination day ratios. 
 
Supplementary Results 
Quality Control 
     Due to the large number of experiments, samples were checked for consistency at different 
times during analysis. After digestion, the number of peptides and proteins identified helped 
determine if there were losses during the desalting step by solid phase extraction or if the original 
quantitation of protein was incorrect (Figure B-9). After each iTRAQ experiment, the two yeast 
proteins were used to determine if there was inconsistency within the experiment (Figure 
B-10A,B), indicating errors in labeling efficiency. The yeast proteins were also used after all 20 
experiments of the same cell type were run to determine if any experiments appeared as outliers 
(Figure B-10C,D). 
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Supplementary Figures and Tables  
 
 
 
 
Figure B-1 PCA plots identified outliers in data from each cell type.  Bivariate 99.6% confidence ellipses for 
standardized variables are shown. Strong outliers are highlighted in blue. 
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Figure B-2 Boxplots of log2 ICCS ratios before median normalization.Outliers are omitted for clarity. 
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Figure B-3 Boxplots of log2 ICCS ratios after median normalization.Median normalization within cell type aligned 
protein ratio distributions, while retaining cell-type median centers Outliers are omitted for clarity. 
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Figure B-4  Heatmaps of DA protein baseline log2 fold changes for B cells at each post-vaccination time 
point.   Dendrograms were obtained using complete linkage clustering of uncentered pairwise Pearson correlation 
distances between log2 fold changes. Llog2 fold changes of 0 were imputed for missing values. Protein cluster 
membership (50% sequence identity) is along the protein dendrogram on the left side; vaccine group membership is 
highlighted below the subject dendrogram at the top. Red: up-regulated from baseline; green: down-regulated from 
baseline; grey: missing observations. 
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Figure B-5 Heatmaps of DA protein baseline log2 fold changes for monocytes at each post-vaccination time 
point.Dendrograms were obtained using complete linkage clustering of uncentered pairwise Pearson correlation 
distances between log2 fold changes. Llog2 fold changes of 0 were imputed for missing values. Protein cluster 
membership (50% sequence identity) is along the protein dendrogram on the left side; vaccine group membership is 
highlighted below the subject dendrogram at the top. Red: up-regulated from baseline; green: down-regulated from 
baseline; grey: missing observations 
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Figure B-6 Heatmaps of DA protein baseline log2 fold changes for neutrophils at each post-vaccination time 
point.Dendrograms were obtained using complete linkage clustering of uncentered pairwise Pearson correlation 
distances between log2 fold changes. Llog2 fold changes of 0 were imputed for missing values. Protein cluster 
membership (50% sequence identity) is along the protein dendrogram on the left side; vaccine group membership is 
highlighted below the subject dendrogram at the top. Red: up-regulated from baseline; green: down-regulated from 
baseline; grey: missing observations 
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Figure B-7 Heatmaps of DA protein baseline log2 fold changes for NK cells at each post-vaccination time 
point.Dendrograms were obtained using complete linkage clustering of uncentered pairwise Pearson correlation 
distances between log2 fold changes. Llog2 fold changes of 0 were imputed for missing values. Protein cluster 
membership (50% sequence identity) is along the protein dendrogram on the left side; vaccine group membership is 
highlighted below the subject dendrogram at the top. Red: up-regulated from baseline; green: down-regulated from 
baseline; grey: missing observations 
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Figure B-8 Heatmaps of DA protein baseline log2 fold changes for T cells at each post-vaccination time 
point,Dendrograms were obtained using complete linkage clustering of uncentered pairwise Pearson correlation 
distances between log2 fold changes. Llog2 fold changes of 0 were imputed for missing values. Protein cluster 
membership (50% sequence identity) is along the protein dendrogram on the left side; vaccine group membership is 
highlighted below the subject dendrogram at the top. Red: up-regulated from baseline; green: down-regulated from 
baseline; grey: missing observations 
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Figure B-9  Neutrophil experiments control chart.  The number of proteins identified in each sample (from 
X!Tandem) were plotted over time. The middle bold dashed line indicates the average number of proteins identified 
across all neutrophil samples. The other lines indicate the 1st and 2nd standard deviation control limits in each 
direction 
 
 
Figure B-10 Boxplots assessing response of internal standard yeast proteins.  The reporter ion intensities of 
the individual peptides of (A) yeast enolase and (B) yeast alcohol dehydrogenase were plotted for each individual 
sample. Similarly, the pseudo-spectral counts on the protein level of (C) yeast enolase and (D) yeast alcohol 
dehydrogenase were compared to identify any inconsistent experiments or samples 
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Figure B-11 Comparison of peptide normalization methods.(A) Exported log2 ratios from an experiment using 
Day 0 as reference versus ICCS as reference showing that there were more peptides quantified when ICCS was the 
reference. ProteoIQ uses values of -10 when quantifications cannot be made. (B) Zoomed in plot of the cluster from 
(A) with a linear regression showing the moderate correlation between the methods. (C) Bland-Altman plot assessing 
the agreement between the two methods. Each point represents a protein. The mean value (bias) was slightly 
increased from 0. The upper and lower limits were defined as the second standard deviations from the mean of the 
difference between methods. 
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Table B-1 Differentially abundant proteins for B cells at Day 1.Proteins with the same ICCS-ratio were grouped 
together and represented by the longest protein in the group. *mean baseline log2 fold change. 
 
 
 
 
Protein ID Gene ID Gene Name Log2 Fold Change z-statistic P Mean [N] (AS03)* Mean [N] (PBS)*
ENSP00000408986 ENSG00000231834 HLA-A 0.7073 2.78929 0.0008 0.28 [8] -0.43 [7]
ENSP00000410645 ENSG00000223980 HLA-A 0.7073 2.78929 0.0008 0.28 [8] -0.43 [7]
ENSP00000390282 ENSG00000237022 HLA-C 0.5543 2.76956 0.003 0.16 [8] -0.39 [7]
ENSP00000433363 ENSG00000206450 HLA-B 0.5601 2.70912 0.0006 0.21 [7] -0.35 [7]
ENSP00000411954 ENSG00000206450 HLA-B 0.4905 2.67166 0.0006 0.17 [7] -0.32 [7]
ENSP00000388526 ENSG00000235657 HLA-A 0.5056 2.64343 0.0053 0.2 [8] -0.3 [9]
ENSP00000352656 ENSG00000206450 HLA-B 0.5395 2.63203 0.0006 0.19 [7] -0.35 [7]
ENSP00000373114 ENSG00000206505 HLA-A 0.4218 2.61053 0.0065 0.22 [8] -0.2 [7]
ENSP00000407494 ENSG00000237022 HLA-C 0.4886 2.57666 0.0061 0.1 [8] -0.39 [7]
ENSP00000430420 ENSG00000197043 ANXA6 0.575 2.53443 0.0048 0.26 [8] -0.32 [8]
ENSP00000397867 ENSG00000228299 HLA-C 0.5173 2.52548 0.0059 0.19 [8] -0.33 [7]
ENSP00000391250 ENSG00000228299 HLA-C 0.5311 2.46462 0.0076 0.2 [7] -0.33 [7]
ENSP00000400410 ENSG00000204525 HLA-C 0.5311 2.46462 0.0076 0.2 [7] -0.33 [7]
ENSP00000366002 ENSG00000206503 HLA-A 0.6111 2.43126 0.004 0.3 [8] -0.31 [7]
ENSP00000377958 ENSG00000115484 CCT4 0.3217 2.42337 0.0087 0.12 [8] -0.21 [8]
ENSP00000403679 ENSG00000196419 XRCC6 0.7217 2.37822 0.0108 0.17 [6] -0.56 [6]
ENSP00000392235 ENSG00000232126 HLA-B 0.3697 2.34576 0.0154 0.2 [8] -0.17 [7]
ENSP00000463482 ENSG00000265434 HLA-ABC 0.5358 2.32412 0.0095 0.31 [8] -0.23 [7]
ENSP00000407431 ENSG00000225691 HLA-C 0.4304 2.31709 0.0159 0.26 [8] -0.17 [7]
ENSP00000449958 ENSG00000111144 LTA4H 0.4526 2.30571 0.0179 0.08 [3] -0.37 [5]
ENSP00000388208 ENSG00000232126 HLA-B 0.3517 2.29162 0.0183 0.18 [8] -0.17 [7]
ENSP00000364805 ENSG00000204390 HSPA1L -1.3723 -2.27956 0.0286 -0.46 [4] 0.92 [3]
ENSP00000366980 ENSG00000197043 ANXA6 0.537 2.27011 0.0112 0.28 [8] -0.26 [8]
ENSP00000359338 ENSG00000122406 RPL5 0.8482 2.25378 0.0159 0.1 [5] -0.75 [5]
ENSP00000339001 ENSG00000196230 TUBB -0.3182 -2.2245 0.0199 -0.03 [8] 0.29 [9]
ENSP00000372819 ENSG00000204525 HLA-C 0.4097 2.20802 0.023 0.17 [8] -0.24 [9]
ENSP00000413992 ENSG00000233841 HLA-C 0.4097 2.20802 0.023 0.17 [8] -0.24 [9]
ENSP00000372975 ENSG00000206435 HLA-C 0.4153 2.20053 0.0163 0.16 [8] -0.26 [7]
ENSP00000293422 ENSG00000092841 MYL6 0.5224 2.19505 0.0169 0.01 [7] -0.51 [6]
ENSP00000408052 ENSG00000136167 LCP1 -0.7035 -2.16541 0.0269 -0.1 [8] 0.6 [7]
ENSP00000298510 ENSG00000165672 PRDX3 0.4812 2.14585 0.0204 0.1 [7] -0.38 [7]
ENSP00000252699 ENSG00000130402 ACTN4 -1.539 -2.12455 0.0265 -0.11 [7] 1.43 [5]
ENSP00000364801 ENSG00000204388 HSPA1B -1.2342 -2.11092 0.0286 -0.44 [4] 0.79 [3]
ENSP00000257860 ENSG00000135406 PRPH 0.6258 2.06843 0.0362 0.23 [8] -0.39 [8]
ENSP00000412426 ENSG00000225691 HLA-C 0.3325 2.05225 0.037 0.16 [8] -0.17 [7]
ENSP00000431347 ENSG00000237022 HLA-C 0.3824 2.03957 0.0354 0.19 [8] -0.19 [7]
ENSP00000362413 ENSG00000102144 PGK1 0.6227 2.00961 0.0305 0.46 [9] -0.16 [8]
ENSP00000444708 ENSG00000102144 PGK1 0.6227 2.00961 0.0305 0.46 [9] -0.16 [8]
ENSP00000349410 ENSG00000115053 NCL 0.3556 1.99868 0.0407 0.15 [9] -0.21 [9]
ENSP00000410661 ENSG00000206452 HLA-C 0.3461 1.99458 0.0268 0.09 [7] -0.26 [7]
ENSP00000260356 ENSG00000137801 THBS1 -2.3392 -1.98503 0.0022 -1.35 [6] 0.99 [5]
ENSP00000452254 ENSG00000072110 ACTN1 1.0923 1.9814 0.0357 0.35 [6] -0.75 [3]
ENSP00000448239 ENSG00000229215 HLA-A 0.3681 1.97925 0.0421 0.18 [8] -0.19 [7]
ENSP00000441750 ENSG00000092841 MYL6 0.4542 1.95809 0.0385 0.01 [7] -0.44 [6]
ENSP00000446721 ENSG00000092841 MYL6 0.4542 1.95809 0.0385 0.01 [7] -0.44 [6]
ENSP00000463939 ENSG00000141522 ARHGDIA -1.0176 -1.87746 0.0286 -0.92 [3] 0.09 [4]
ENSP00000461956 ENSG00000141522 ARHGDIA -1.0176 -1.87746 0.0286 -0.92 [3] 0.09 [4]
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Table B-2 Differentially abundant proteins for B cells at Day 3. Proteins with the same ICCS-ratio were grouped 
together and represented by the longest protein in the group. *mean baseline log2 fold change. 
 
 
 
 
 
Protein ID Gene ID Gene Name Log2 Fold Change z-statistic P Mean [N] (AS03)* Mean [N] (PBS)*
ENSP00000346550 ENSG00000197043 ANXA6 0.4065 3.11319 0.0005 0.29 [9] -0.12 [8]
ENSP00000430517 ENSG00000197043 ANXA6 0.4065 3.11319 0.0005 0.29 [9] -0.12 [8]
ENSP00000348889 ENSG00000197043 ANXA6 0.3741 2.93086 0.0014 0.29 [9] -0.09 [8]
ENSP00000430420 ENSG00000197043 ANXA6 0.412 2.89567 0.0006 0.19 [8] -0.22 [8]
ENSP00000366980 ENSG00000197043 ANXA6 0.3427 2.46452 0.0107 0.2 [8] -0.14 [8]
ENSP00000410645 ENSG00000223980 HLA-A 0.5046 2.44955 0.006 0.3 [9] -0.21 [8]
ENSP00000388526 ENSG00000235657 HLA-A 0.344 2.44792 0.0094 0.21 [9] -0.14 [8]
ENSP00000408986 ENSG00000231834 HLA-A 0.5039 2.44749 0.006 0.3 [9] -0.2 [8]
ENSP00000330054 ENSG00000156508 EEF1A1 -0.755 -2.36715 0.0159 -0.59 [4] 0.17 [5]
ENSP00000217182 ENSG00000101210 EEF1A2 -0.755 -2.36715 0.0159 -0.59 [4] 0.17 [5]
ENSP00000390282 ENSG00000237022 HLA-C 0.4061 2.27519 0.0158 0.19 [9] -0.22 [8]
ENSP00000447571 ENSG00000110955 ATP5B -0.3447 -2.27181 0.0194 0.02 [10] 0.36 [8]
ENSP00000253024 ENSG00000130726 TRIM28 0.5507 2.25803 0.013 0.48 [6] -0.08 [5]
ENSP00000298510 ENSG00000165672 PRDX3 0.3486 2.23207 0.0221 0.13 [7] -0.22 [7]
ENSP00000365439 ENSG00000165119 HNRNPK -0.8702 -2.22366 0.0286 -0.33 [4] 0.54 [4]
ENSP00000386743 ENSG00000014641 MDH1 0.4307 2.19144 0.0265 0.2 [5] -0.24 [7]
ENSP00000446395 ENSG00000014641 MDH1 0.3984 2.17818 0.0278 0.2 [5] -0.2 [7]
ENSP00000366002 ENSG00000206503 HLA-A 0.4861 2.1777 0.0216 0.37 [9] -0.12 [7]
ENSP00000276079 ENSG00000147140 NONO 0.3883 2.11647 0.0316 0.39 [5] 0 [7]
ENSP00000409773 ENSG00000147140 NONO 0.3883 2.11647 0.0316 0.39 [5] 0 [7]
ENSP00000441364 ENSG00000147140 NONO 0.3883 2.11647 0.0316 0.39 [5] 0 [7]
ENSP00000464042 ENSG00000108424 KPNB1 0.2955 2.11637 0.0309 0.12 [7] -0.17 [7]
ENSP00000327054 ENSG00000176619 LMNB2 -0.8584 -2.09801 0.0286 -0.3 [4] 0.56 [6]
ENSP00000431086 ENSG00000197043 ANXA6 0.5696 2.09283 0.0397 0.3 [4] -0.27 [5]
ENSP00000391481 ENSG00000163931 TKT -0.5798 -2.06549 0.0286 -0.17 [4] 0.4 [6]
ENSP00000286788 ENSG00000156261 CCT8 0.4101 2.0442 0.0364 0.25 [7] -0.16 [4]
ENSP00000302935 ENSG00000172349 IL16 0.8634 2.03361 0.0286 0.58 [4] -0.28 [4]
ENSP00000441750 ENSG00000092841 MYL6 0.4417 2.01354 0.0392 0.03 [7] -0.41 [8]
ENSP00000446721 ENSG00000092841 MYL6 0.4417 2.01354 0.0392 0.03 [7] -0.41 [8]
ENSP00000265462 ENSG00000126432 PRDX5 0.9914 2.00997 0.0238 0.27 [4] -0.72 [5]
ENSP00000335334 ENSG00000126432 PRDX5 0.9914 2.00997 0.0238 0.27 [4] -0.72 [5]
ENSP00000342232 ENSG00000130726 TRIM28 0.5497 2.00585 0.0411 0.39 [6] -0.16 [5]
ENSP00000471303 ENSG00000130726 TRIM28 0.5497 2.00585 0.0411 0.39 [6] -0.16 [5]
ENSP00000422615 ENSG00000138668 HNRNPD 0.3642 2.00538 0.0325 0.16 [5] -0.2 [6]
ENSP00000463482 ENSG00000265434 HLA-ABC 0.3945 1.97131 0.0393 0.38 [9] -0.02 [7]
ENSP00000409456 ENSG00000165119 HNRNPK -0.9247 -1.95257 0.0286 -0.39 [3] 0.54 [4]
ENSP00000407431 ENSG00000225691 HLA-C 0.3412 1.92161 0.0477 0.29 [9] -0.05 [7]
ENSP00000466406 ENSG00000074800 ENO1 0.3226 1.91022 0.0497 0.12 [9] -0.2 [8]
ENSP00000434565 ENSG00000109971 HSPA8 -0.9648 -1.903 0.0476 -0.52 [6] 0.44 [3]
ENSP00000244573 ENSG00000124610 HIST1H1A -0.906 -1.82175 0.0286 -0.83 [4] 0.07 [3]
ENSP00000341214 ENSG00000187475 HIST1H1T -0.906 -1.82175 0.0286 -0.83 [4] 0.07 [3]
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Table B-3 Differentially abundant proteins for B cells at Day 7.Proteins with the same ICCS-ratio were grouped 
together and represented by the longest protein in the group. *mean baseline log2 fold change. 
 
 
Table B-4 Differentially abundant proteins from B cells at Day 28.Proteins with the same ICCS-ratio were 
grouped together and represented by the longest protein in the group. *mean baseline log2 fold change. 
 
 
 
Protein ID Gene ID Gene Name Log2 Fold Change z-statistic P Mean [N] (AS03)* Mean [N] (PBS)*
ENSP00000344419 ENSG00000005381 MPO 0.8393 2.56217 0.0054 0.51 [6] -0.33 [9]
ENSP00000446489 ENSG00000110955 ATP5B -0.3238 -2.36343 0.0124 -0.06 [9] 0.26 [9]
ENSP00000219169 ENSG00000102898 NUTF2 -0.3975 -2.27857 0.0238 -0.33 [4] 0.07 [5]
ENSP00000293422 ENSG00000092841 MYL6 0.5626 2.17634 0.0228 0.06 [7] -0.5 [9]
ENSP00000318697 ENSG00000176014 TUBB6 0.3592 2.16016 0.0177 0.05 [7] -0.31 [5]
ENSP00000366002 ENSG00000206503 HLA-A 0.3386 2.13432 0.0297 0.16 [8] -0.18 [8]
ENSP00000457420 ENSG00000067225 PKM -0.4576 -2.1284 0.0313 -0.28 [9] 0.18 [7]
ENSP00000456984 ENSG00000067225 PKM -0.5331 -2.11319 0.0274 -0.27 [9] 0.26 [7]
ENSP00000464359 ENSG00000101608 MYL12A 0.6255 2.10308 0.0306 0.42 [9] -0.2 [10]
ENSP00000441750 ENSG00000092841 MYL6 0.5171 2.10227 0.0267 0.06 [7] -0.46 [9]
ENSP00000446721 ENSG00000092841 MYL6 0.5171 2.10227 0.0267 0.06 [7] -0.46 [9]
ENSP00000311042 ENSG00000173876 TUBB8 0.3636 2.08068 0.03 0.02 [8] -0.34 [6]
ENSP00000451560 ENSG00000198211 TUBB3 0.4552 2.04531 0.0324 0.08 [7] -0.37 [10]
ENSP00000408897 ENSG00000135406 PRPH 0.6509 1.98579 0.0455 -0.03 [7] -0.69 [7]
ENSP00000447571 ENSG00000110955 ATP5B -0.3097 -1.98236 0.0438 0.01 [9] 0.32 [9]
ENSP00000259818 ENSG00000137285 TUBB2B 0.4318 1.98137 0.0392 0.06 [7] -0.37 [10]
ENSP00000252699 ENSG00000130402 ACTN4 -0.5388 -1.97812 0.0455 -0.17 [7] 0.37 [6]
ENSP00000324173 ENSG00000044574 HSPA5 0.5063 1.96433 0.0476 0.13 [5] -0.38 [5]
ENSP00000439497 ENSG00000130402 ACTN4 -0.4252 -1.89806 0.0286 -0.12 [7] 0.3 [6]
ENSP00000369475 ENSG00000057608 GDI2 -0.3427 -1.89183 0.046 -0.16 [7] 0.19 [7]
ENSP00000369528 ENSG00000057608 GDI2 -0.3427 -1.89183 0.046 -0.16 [7] 0.19 [7]
ENSP00000408649 ENSG00000146701 MDH2 0.3102 1.88932 0.0381 -0.17 [4] -0.48 [6]
Protein ID Gene ID Gene Name Log2 Fold Change z-statistic P Mean [N] (AS03)* Mean [N] (PBS)*
ENSP00000391842 ENSG00000026025 VIM 0.5545 2.33097 0.0054 0.44 [8] -0.12 [8]
ENSP00000392541 ENSG00000163631 ALB -1.619 -2.3264 0.0238 -0.18 [5] 1.44 [5]
ENSP00000341826 ENSG00000135486 HNRNPA1 0.6443 2.28261 0.0176 0.08 [7] -0.57 [8]
ENSP00000287613 ENSG00000241553 ARPC4 -0.4291 -2.27666 0.0117 -0.18 [7] 0.25 [7]
ENSP00000416551 ENSG00000164924 YWHAZ -0.7209 -2.24514 0.0211 -0.31 [7] 0.41 [8]
ENSP00000301522 ENSG00000167815 PRDX2 -0.4627 -2.20657 0.0256 -0.42 [7] 0.04 [7]
ENSP00000380033 ENSG00000100201 DDX17 -0.6019 -2.10303 0.0179 -0.13 [5] 0.47 [3]
ENSP00000219169 ENSG00000102898 NUTF2 0.4392 2.07719 0.0333 -0.1 [6] -0.54 [4]
ENSP00000339001 ENSG00000196230 TUBB -0.5617 -2.07438 0.0353 0.17 [9] 0.73 [8]
ENSP00000439189 ENSG00000188219 POTEE 0.6508 2.06758 0.0344 0.16 [9] -0.49 [8]
ENSP00000350052 ENSG00000196604 POTEF 0.6473 2.05982 0.035 0.15 [9] -0.5 [8]
ENSP00000464265 ENSG00000263563 UBBP4 -0.8152 -1.97507 0.0384 -0.57 [8] 0.24 [8]
ENSP00000272317 ENSG00000143947 RPS27A -0.7723 -1.95436 0.0435 -0.52 [8] 0.25 [8]
ENSP00000379278 ENSG00000164924 YWHAZ 1.1055 1.95041 0.0303 0.26 [6] -0.85 [5]
ENSP00000289352 ENSG00000158406 HIST1H4H -0.5368 -1.95034 0.0486 -0.24 [9] 0.3 [8]
ENSP00000327054 ENSG00000176619 LMNB2 -0.6382 -1.93765 0.0159 -0.35 [4] 0.29 [5]
ENSP00000297185 ENSG00000113013 HSPA9 -0.3109 -1.93733 0.0179 -0.05 [5] 0.27 [3]
ENSP00000312206 ENSG00000186442 KRT3 -1.2285 -1.91181 0.0397 -1.08 [5] 0.15 [5]
ENSP00000330101 ENSG00000185069 KRT76 -1.2285 -1.91181 0.0397 -1.08 [5] 0.15 [5]
ENSP00000457332 ENSG00000102879 CORO1A -0.6441 -1.90263 0.0495 -0.51 [7] 0.13 [7]
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Table B-5 Differentially abundant proteins from monocytes cells at Day 1.  Proteins with the same ICCS-ratio 
were grouped together and represented by the longest protein in the group. *mean baseline log2 fold change. 
 
 
 
Protein ID Gene ID Gene Name Log2 Fold Changez-statistic P Mean [N] (AS03)*Mean [N] (PBS)*
ENSP00000444467 ENSG00000127314 RAP1B 0.3222 2.73613 0.002 0.21 [9] -0.11 [10]
ENSP00000385385 ENSG00000143870 PDIA6 0.2653 2.6592 0.0048 0.31 [8] 0.05 [10]
ENSP00000399986 ENSG00000127314 RAP1B 0.3307 2.5679 0.0064 0.27 [9] -0.06 [10]
ENSP00000250559 ENSG00000127314 RAP1B 0.3303 2.56548 0.0065 0.27 [9] -0.06 [10]
ENSP00000440014 ENSG00000127314 RAP1B 0.3303 2.56548 0.0065 0.27 [9] -0.06 [10]
ENSP00000450353 ENSG00000257767 RP11-162P23.2 -0.2933 -2.46851 0.0104 -0.17 [7] 0.12 [8]
ENSP00000364801 ENSG00000204388 HSPA1B 0.284 2.39722 0.0123 0.14 [9] -0.14 [10]
ENSP00000450538 ENSG00000258947 TUBB3 0.8022 2.35603 0.0098 0.57 [4] -0.23 [9]
ENSP00000471786 ENSG00000130755 GMFG 0.3332 2.34175 0.0179 0.28 [3] -0.05 [5]
ENSP00000310749 ENSG00000115756 HPCAL1 0.4947 2.33916 0.0179 0.35 [3] -0.15 [5]
ENSP00000464668 ENSG00000005381 MPO 0.3105 2.33496 0.0138 0.24 [9] -0.07 [10]
ENSP00000348786 ENSG00000116473 RAP1A 0.3204 2.32094 0.0166 0.27 [9] -0.05 [10]
ENSP00000367615 ENSG00000198931 APRT -0.3788 -2.30383 0.0114 -0.19 [5] 0.19 [7]
ENSP00000467932 ENSG00000171403 KRT9 0.9348 2.29994 0.0179 -0.06 [5] -0.99 [3]
ENSP00000216962 ENSG00000100994 PYGB -0.3854 -2.2957 0.0175 -0.17 [7] 0.22 [7]
ENSP00000455692 ENSG00000198931 APRT -0.3741 -2.29467 0.0114 -0.19 [5] 0.18 [7]
ENSP00000460612 ENSG00000185624 P4HB -0.3925 -2.27504 0.0145 -0.41 [9] -0.02 [10]
ENSP00000455749 ENSG00000198931 APRT -0.2876 -2.26845 0.0212 -0.1 [4] 0.18 [7]
ENSP00000356022 ENSG00000112096 SOD2 0.3923 2.23937 0.0174 0.32 [9] -0.07 [9]
ENSP00000434565 ENSG00000109971 HSPA8 0.3659 2.23833 0.0203 0.05 [8] -0.32 [10]
ENSP00000460741 ENSG00000185624 P4HB -0.6968 -2.23562 0.0022 -0.65 [5] 0.05 [6]
ENSP00000337127 ENSG00000112096 SOD2 0.3804 2.22951 0.0179 0.37 [9] -0.01 [9]
ENSP00000252029 ENSG00000025708 TYMP 0.2988 2.20491 0.0202 0.21 [7] -0.09 [8]
ENSP00000298283 ENSG00000165496 RPL10L 0.8138 2.2031 0.0286 0.42 [4] -0.39 [4]
ENSP00000327589 ENSG00000182890 GLUD2 -0.472 -2.17842 0.0238 -0.18 [5] 0.29 [4]
ENSP00000379038 ENSG00000025708 TYMP 0.2924 2.16845 0.0242 0.23 [7] -0.06 [8]
ENSP00000287613 ENSG00000241553 ARPC4 0.3063 2.16014 0.0264 0.15 [9] -0.15 [10]
ENSP00000398632 ENSG00000026508 CD44 0.4384 2.15912 0.0233 0.29 [8] -0.15 [8]
ENSP00000216336 ENSG00000100448 CTSG 0.3307 2.15593 0.0241 0.25 [9] -0.09 [10]
ENSP00000341136 ENSG00000147813 NAPRT1 0.4505 2.14563 0.0238 0.28 [6] -0.17 [6]
ENSP00000246662 ENSG00000171403 KRT9 0.7412 2.1023 0.0238 -0.02 [5] -0.76 [4]
ENSP00000277865 ENSG00000148672 GLUD1 -0.4252 -2.07638 0.028 -0.26 [6] 0.16 [7]
ENSP00000369475 ENSG00000057608 GDI2 -0.3286 -2.06098 0.0269 -0.26 [9] 0.07 [10]
ENSP00000369528 ENSG00000057608 GDI2 -0.3286 -2.06098 0.0269 -0.26 [9] 0.07 [10]
ENSP00000400882 ENSG00000256812 CAPNS2 0.5975 2.03693 0.0333 0.1 [4] -0.5 [6]
ENSP00000403260 ENSG00000137752 CASP1 0.3021 2.03152 0.0339 0.23 [9] -0.07 [8]
ENSP00000408649 ENSG00000146701 MDH2 -0.3035 -2.02767 0.037 -0.19 [8] 0.12 [10]
ENSP00000468041 ENSG00000126247 CAPNS1 0.5156 2.0266 0.0433 0.02 [5] -0.5 [6]
ENSP00000344871 ENSG00000142347 MYO1F 0.3072 2.01814 0.0199 0.23 [9] -0.08 [10]
ENSP00000474036 ENSG00000126247 CAPNS1 0.5785 2.00258 0.0333 0.1 [4] -0.48 [6]
ENSP00000303276 ENSG00000169385 RNASE2 0.3807 1.98863 0.0449 0.16 [7] -0.22 [6]
ENSP00000467670 ENSG00000105220 GPI 0.401 1.98392 0.0444 0.42 [9] 0.02 [9]
ENSP00000465858 ENSG00000105220 GPI 0.3872 1.97961 0.0454 0.41 [9] 0.02 [9]
ENSP00000337448 ENSG00000119383 PPP2R4 0.3159 1.97603 0.0366 0.23 [5] -0.08 [7]
ENSP00000446415 ENSG00000134333 LDHA 0.3857 1.97198 0.0286 0.32 [3] -0.07 [4]
ENSP00000433443 ENSG00000177600 RPLP2 0.4295 1.96727 0.0338 0.26 [7] -0.17 [7]
ENSP00000389906 ENSG00000167004 PDIA3 0.4767 1.71624 0.0238 0.2 [4] -0.27 [5]
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Table B-6 Differentially abundant proteins from monocytes cells at Day 3.  Proteins with the same ICCS-ratio 
were grouped together and represented by the longest protein in the group. *mean baseline log2 fold change. 
 
 
Protein ID Gene ID Gene Name Log2 Fold Change z-statistic P Mean [N] (AS03)* Mean [N] (PBS)*
ENSP00000373114 ENSG00000206505 HLA-A 0.3723 2.77873 0.0014 0.32 [10] -0.06 [9]
ENSP00000349748 ENSG00000116560 SFPQ 0.5827 2.76377 0.0048 0.2 [6] -0.39 [4]
ENSP00000475260 ENSG00000268548 TPI1 -0.3991 -2.6657 0.0037 -0.16 [10] 0.24 [9]
ENSP00000228318 ENSG00000075415 SLC25A3 0.4227 2.60471 0.0041 0.08 [7] -0.35 [6]
ENSP00000206451 ENSG00000092010 PSME1 0.4581 2.60047 0.0028 0.39 [9] -0.07 [9]
ENSP00000450538 ENSG00000258947 TUBB3 0.8854 2.58245 0.0023 0.44 [5] -0.45 [8]
ENSP00000412429 ENSG00000158710 TAGLN2 0.3133 2.5787 0.0049 0.21 [10] -0.11 [9]
ENSP00000216802 ENSG00000100911 PSME2 0.4113 2.56524 0.0071 0.3 [10] -0.11 [9]
ENSP00000436277 ENSG00000137710 RDX 0.3872 2.53423 0.0087 0.17 [8] -0.22 [6]
ENSP00000357076 ENSG00000158710 TAGLN2 0.307 2.50769 0.0073 0.2 [10] -0.11 [9]
ENSP00000444467 ENSG00000127314 RAP1B 0.3021 2.47581 0.0081 0.13 [10] -0.18 [9]
ENSP00000391481 ENSG00000163931 TKT 0.2951 2.4581 0.0091 0.07 [10] -0.22 [9]
ENSP00000417864 ENSG00000140350 ANP32A 0.4417 2.45402 0.0037 0.35 [10] -0.09 [9]
ENSP00000295685 ENSG00000163466 ARPC2 0.3171 2.44811 0.0069 0.07 [10] -0.25 [8]
ENSP00000443599 ENSG00000111669 TPI1 -0.3831 -2.43927 0.0097 -0.15 [10] 0.23 [9]
ENSP00000299767 ENSG00000166598 HSP90B1 0.4754 2.41857 0.0086 0.2 [9] -0.27 [8]
ENSP00000296181 ENSG00000082781 ITGB5 0.3684 2.40465 0.0082 0.09 [10] -0.28 [9]
ENSP00000280326 ENSG00000150753 CCT5 -0.4373 -2.37248 0.0117 -0.16 [8] 0.27 [6]
ENSP00000426923 ENSG00000150753 CCT5 -0.4373 -2.37248 0.0117 -0.16 [8] 0.27 [6]
ENSP00000423318 ENSG00000150753 CCT5 -0.4672 -2.3598 0.0123 -0.19 [8] 0.27 [6]
ENSP00000423052 ENSG00000150753 CCT5 -0.4672 -2.3598 0.0123 -0.19 [8] 0.27 [6]
ENSP00000365439 ENSG00000165119 HNRNPK 0.48 2.3596 0.0139 0.2 [10] -0.28 [7]
ENSP00000366002 ENSG00000206503 HLA-A 0.3415 2.35591 0.0132 0.29 [10] -0.05 [9]
ENSP00000463482 ENSG00000265434 HLA-ABC 0.3408 2.32685 0.0145 0.3 [10] -0.04 [9]
ENSP00000441556 ENSG00000150991 UBC 0.2785 2.32602 0.0137 0.17 [8] -0.11 [6]
ENSP00000325905 ENSG00000115875 SRSF7 0.4814 2.30605 0.0065 0.33 [5] -0.15 [6]
ENSP00000344871 ENSG00000142347 MYO1F 0.3353 2.26809 0.0196 0.28 [10] -0.05 [9]
ENSP00000475184 ENSG00000111669 TPI1 -0.3066 -2.25173 0.0175 -0.07 [10] 0.24 [9]
ENSP00000420213 ENSG00000136068 FLNB 0.4518 2.23644 0.0162 0.12 [7] -0.33 [8]
ENSP00000343027 ENSG00000127955 GNAI1 -0.4598 -2.22209 0.0286 -0.26 [4] 0.2 [4]
ENSP00000429374 ENSG00000008988 RPS20 -0.3586 -2.1927 0.0303 -0.05 [8] 0.31 [3]
ENSP00000226299 ENSG00000002549 LAP3 0.3863 2.18813 0.0246 0.44 [10] 0.06 [9]
ENSP00000442285 ENSG00000142657 PGD 0.2683 2.18268 0.0248 -0.09 [10] -0.36 [9]
ENSP00000473957 ENSG00000165119 HNRNPK 0.7156 2.17693 0.026 0.24 [5] -0.48 [6]
ENSP00000450121 ENSG00000089157 RPLP0 -0.2953 -2.15646 0.0119 -0.43 [6] -0.14 [3]
ENSP00000379038 ENSG00000025708 TYMP 0.3961 2.15537 0.026 0.44 [8] 0.05 [8]
ENSP00000303476 ENSG00000171914 TLN2 0.3402 2.10115 0.022 0.15 [8] -0.19 [6]
ENSP00000344666 ENSG00000186575 NF2 0.3768 2.10033 0.0381 0.25 [6] -0.13 [4]
ENSP00000299427 ENSG00000166340 TPP1 0.3351 2.08515 0.0309 0.2 [9] -0.14 [9]
ENSP00000410572 ENSG00000127955 GNAI1 -0.3953 -2.06718 0.0286 -0.2 [3] 0.2 [4]
ENSP00000398632 ENSG00000026508 CD44 0.3551 2.0612 0.0357 0.12 [8] -0.23 [8]
ENSP00000270625 ENSG00000142534 RPS11 0.429 2.05523 0.025 0.14 [7] -0.29 [3]
ENSP00000387286 ENSG00000138069 RAB1A -0.5775 -2.04975 0.0357 -0.28 [6] 0.29 [3]
ENSP00000472137 ENSG00000221983 UBA52 0.4032 2.04864 0.0068 0.17 [8] -0.24 [7]
ENSP00000428208 ENSG00000131504 DIAPH1 -0.3077 -2.03963 0.0238 -0.18 [6] 0.13 [5]
ENSP00000230050 ENSG00000112306 RPS12 0.3751 2.03733 0.0382 0.11 [10] -0.27 [9]
ENSP00000310226 ENSG00000174903 RAB1B -0.5708 -2.03638 0.0357 -0.28 [6] 0.29 [3]
ENSP00000264710 ENSG00000084733 RAB10 -0.3504 -2.02108 0.0364 0.02 [7] 0.37 [4]
ENSP00000348546 ENSG00000138069 RAB1A -0.5717 -2.02072 0.0357 -0.28 [6] 0.29 [3]
ENSP00000435195 ENSG00000174903 RAB1B -0.565 -2.00747 0.0357 -0.27 [6] 0.29 [3]
ENSP00000396397 ENSG00000228964 HLA-B 0.3539 1.98366 0.0429 0.21 [8] -0.14 [7]
ENSP00000463939 ENSG00000141522 ARHGDIA 0.2838 1.98314 0.0416 0.04 [8] -0.24 [9]
ENSP00000461956 ENSG00000141522 ARHGDIA 0.2838 1.98314 0.0416 0.04 [8] -0.24 [9]
ENSP00000431078 ENSG00000197043 ANXA6 0.3794 1.95532 0.0322 0.03 [9] -0.35 [4]
ENSP00000298556 ENSG00000165704 HPRT1 -0.2656 -1.95154 0.0476 -0.13 [6] 0.13 [4]
ENSP00000361878 ENSG00000131236 CAP1 0.3348 1.94592 0.0406 0.12 [9] -0.22 [9]
ENSP00000468041 ENSG00000126247 CAPNS1 0.2712 1.80847 0.0476 -0.16 [6] -0.43 [6]
ENSP00000362409 ENSG00000136830 FAM129B 0.3373 1.76892 0.0476 0.48 [7] 0.14 [8]
ENSP00000217426 ENSG00000101444 AHCY -0.4336 -1.64293 0.0152 -0.16 [5] 0.27 [6]
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Table B-7 Differentially abundant proteins from monocytes at Day 7. Proteins with the same ICCS-ratio were 
grouped together and represented by the longest protein in the group. *mean baseline log2 fold change. 
 
 
 
 
 
Protein ID Gene ID Gene Name Log2 Fold Change z-statistic P Mean [N] (AS03)* Mean [N] (PBS)*
ENSP00000466574 ENSG00000142657 PGD 0.281 2.74065 0.0017 0 [9] -0.28 [9]
ENSP00000466358 ENSG00000142657 PGD 0.2984 2.68614 0.0029 0.01 [10] -0.29 [9]
ENSP00000450538 ENSG00000258947 TUBB3 0.7249 2.66224 0.0016 0.45 [5] -0.27 [8]
ENSP00000397533 ENSG00000089820 ARHGAP4 -0.419 -2.54128 0.0064 -0.1 [6] 0.31 [7]
ENSP00000434565 ENSG00000109971 HSPA8 -0.3093 -2.5307 0.008 -0.45 [10] -0.15 [10]
ENSP00000464359 ENSG00000101608 MYL12A 0.2868 2.48336 0.0105 -0.11 [10] -0.4 [10]
ENSP00000456865 ENSG00000198848 CES1 -0.4919 -2.48095 0.0119 -0.2 [3] 0.29 [6]
ENSP00000428916 ENSG00000197043 ANXA6 -0.31 -2.38291 0.0134 -0.17 [9] 0.14 [7]
ENSP00000279227 ENSG00000149781 FERMT3 -0.3926 -2.37424 0.0079 -0.18 [10] 0.21 [10]
ENSP00000447068 ENSG00000197111 PCBP2 0.4153 2.33786 0.0065 -0.17 [5] -0.58 [6]
ENSP00000305556 ENSG00000169564 PCBP1 0.5279 2.2875 0.0134 0.18 [7] -0.35 [7]
ENSP00000432153 ENSG00000172757 CFL1 0.3889 2.21989 0.0186 -0.04 [8] -0.43 [5]
ENSP00000401820 ENSG00000163631 ALB 0.5148 2.19295 0.0261 0.45 [9] -0.06 [10]
ENSP00000247470 ENSG00000103490 PYCARD 0.5167 2.17885 0.0357 0.36 [3] -0.16 [5]
ENSP00000405325 ENSG00000148834 GSTO1 -0.5195 -2.17467 0.0022 -0.42 [9] 0.09 [8]
ENSP00000441488 ENSG00000148834 GSTO1 -0.5195 -2.17467 0.0022 -0.42 [9] 0.09 [8]
ENSP00000211372 ENSG00000096150 RPS18 0.2644 2.1405 0.0295 0.12 [8] -0.14 [5]
ENSP00000421421 ENSG00000164111 ANXA5 -0.2789 -2.13557 0.0292 -0.1 [10] 0.18 [10]
ENSP00000434883 ENSG00000175220 ARHGAP1 -0.3312 -2.10934 0.028 -0.21 [6] 0.13 [7]
ENSP00000432485 ENSG00000204397 CARD16 0.2667 2.10501 0.0238 -0.08 [3] -0.35 [6]
ENSP00000448079 ENSG00000197111 PCBP2 0.3552 2.09513 0.0286 -0.23 [4] -0.58 [6]
ENSP00000053867 ENSG00000030582 GRN 0.2784 2.0642 0.0328 0.43 [5] 0.15 [7]
ENSP00000465673 ENSG00000030582 GRN 0.2784 2.0642 0.0328 0.43 [5] 0.15 [7]
ENSP00000451646 ENSG00000198668 CALM1 -0.6001 -2.05969 0.0286 -0.7 [3] -0.1 [4]
ENSP00000431641 ENSG00000109971 HSPA8 -0.2736 -2.05108 0.0359 -0.32 [10] -0.05 [10]
ENSP00000395051 ENSG00000111144 LTA4H -0.3563 -2.04888 0.0321 -0.3 [6] 0.05 [7]
ENSP00000430970 ENSG00000169045 HNRNPH1 0.3406 2.04025 0.0343 0.17 [4] -0.17 [8]
ENSP00000456004 ENSG00000067225 PKM 0.4444 2.01955 0.0485 0.17 [4] -0.27 [7]
ENSP00000445778 ENSG00000149781 FERMT3 -0.3024 -2.01385 0.0364 -0.09 [10] 0.21 [10]
ENSP00000429374 ENSG00000008988 RPS20 -0.4147 -1.97847 0.0333 -0.3 [6] 0.12 [4]
ENSP00000339035 ENSG00000143549 TPM3 0.3558 1.97454 0.0459 -0.06 [10] -0.42 [10]
ENSP00000271850 ENSG00000143549 TPM3 0.3512 1.96791 0.0468 -0.07 [10] -0.42 [10]
ENSP00000449793 ENSG00000075415 SLC25A3 -0.3168 -1.95529 0.0498 -0.27 [6] 0.04 [6]
ENSP00000457033 ENSG00000103187 COTL1 0.7792 1.93028 0.0411 0.57 [6] -0.21 [5]
ENSP00000437303 ENSG00000178209 PLEC -0.3251 -1.89668 0.0357 -0.03 [5] 0.3 [3]
ENSP00000426433 ENSG00000167085 PHB 0.5472 1.87642 0.0179 0.12 [5] -0.43 [3]
ENSP00000349748 ENSG00000116560 SFPQ 0.3409 1.86095 0.0325 0.05 [6] -0.29 [5]
ENSP00000352438 ENSG00000197111 PCBP2 0.4035 1.85388 0.0215 0.02 [5] -0.38 [7]
ENSP00000358724 ENSG00000148834 GSTO1 -0.4471 -1.83363 0.041 -0.36 [9] 0.09 [8]
ENSP00000358727 ENSG00000148834 GSTO1 -0.4471 -1.83363 0.041 -0.36 [9] 0.09 [8]
ENSP00000383168 ENSG00000183570 PCBP3 0.42 1.7368 0.0364 0.04 [4] -0.38 [7]
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Table B-8 Differentially abundant proteins for monocytes at Day 28. Proteins with the same ICCS-ratio were 
grouped together and represented by the longest protein in the group. *mean baseline log2 fold change. 
 
 
 
 
Protein ID Gene ID Gene Name Log2 Fold Change z-statistic P Mean [N] (AS03)* Mean [N] (PBS)*
ENSP00000264202 ENSG00000077549 CAPZB 0.3408 2.89576 0.0018 0.06 [10] -0.29 [10]
ENSP00000401010 ENSG00000077549 CAPZB 0.3408 2.89576 0.0018 0.06 [10] -0.29 [10]
ENSP00000466574 ENSG00000142657 PGD 0.3377 2.7541 0.0032 0.05 [9] -0.29 [10]
ENSP00000300413 ENSG00000167088 SNRPD1 0.5412 2.73227 0.0038 0.33 [9] -0.21 [6]
ENSP00000374645 ENSG00000142168 SOD1 0.4292 2.6406 0.0043 0.31 [5] -0.12 [10]
ENSP00000270142 ENSG00000142168 SOD1 0.456 2.61662 0.0049 0.26 [7] -0.19 [10]
ENSP00000324422 ENSG00000159840 ZYX 0.4148 2.56262 0.0075 0.33 [9] -0.08 [7]
ENSP00000262030 ENSG00000110955 ATP5B -0.264 -2.50866 0.0087 0 [10] 0.26 [10]
ENSP00000394158 ENSG00000159840 ZYX 0.3584 2.41756 0.0061 0.33 [8] -0.03 [7]
ENSP00000446489 ENSG00000110955 ATP5B -0.2912 -2.39216 0.0137 -0.01 [10] 0.28 [10]
ENSP00000308165 ENSG00000135218 CD36 -0.4322 -2.34777 0.0159 -0.07 [5] 0.36 [4]
ENSP00000456865 ENSG00000198848 CES1 -0.7407 -2.34157 0.0119 -0.3 [3] 0.45 [6]
ENSP00000384695 ENSG00000163631 ALB 0.5104 2.33281 0.0147 0.4 [10] -0.11 [10]
ENSP00000356520 ENSG00000135829 DHX9 0.4609 2.30305 0.007 0.31 [5] -0.15 [8]
ENSP00000295897 ENSG00000163631 ALB 0.5141 2.30152 0.0163 0.39 [10] -0.12 [10]
ENSP00000422784 ENSG00000163631 ALB 0.5141 2.30152 0.0163 0.39 [10] -0.12 [10]
ENSP00000341885 ENSG00000140988 RPS2 -0.4399 -2.29651 0.0057 -0.22 [9] 0.22 [8]
ENSP00000305556 ENSG00000169564 PCBP1 0.5755 2.25579 0.0175 0.31 [7] -0.26 [7]
ENSP00000244534 ENSG00000124575 HIST1H1D 0.4037 2.24014 0.0132 0.07 [9] -0.34 [7]
ENSP00000401820 ENSG00000163631 ALB 0.5658 2.23835 0.0143 0.49 [10] -0.07 [10]
ENSP00000447571 ENSG00000110955 ATP5B -0.3174 -2.22556 0.0221 0.07 [10] 0.39 [10]
ENSP00000260985 ENSG00000138413 IDH1 -0.4728 -2.18566 0.026 -0.33 [6] 0.14 [5]
ENSP00000433982 ENSG00000178209 PLEC -0.6956 -2.17528 0.0286 -0.42 [4] 0.28 [3]
ENSP00000457643 ENSG00000149925 ALDOA 0.5378 2.17092 0.0228 0.04 [10] -0.5 [7]
ENSP00000261733 ENSG00000111275 ALDH2 -0.3089 -2.1499 0.0296 -0.19 [10] 0.12 [8]
ENSP00000463042 ENSG00000136450 SRSF1 0.6112 2.12592 0.0242 0.38 [3] -0.23 [8]
ENSP00000341072 ENSG00000070831 CDC42 -0.3646 -2.1149 0.0303 -0.13 [5] 0.24 [8]
ENSP00000270776 ENSG00000142657 PGD 0.267 2.10835 0.0324 -0.01 [10] -0.28 [10]
ENSP00000458298 ENSG00000262617 AC020766.1 -0.5044 -2.10102 0.0354 -0.2 [5] 0.3 [7]
ENSP00000431296 ENSG00000135218 CD36 -0.4002 -2.09542 0.0238 -0.04 [5] 0.36 [4]
ENSP00000467362 ENSG00000142657 PGD 0.3442 2.09522 0.0304 0.05 [10] -0.29 [10]
ENSP00000362924 ENSG00000148180 GSN 0.5966 2.09155 0.0317 0.19 [10] -0.41 [9]
ENSP00000341136 ENSG00000147813 NAPRT1 0.377 2.08657 0.0286 0.1 [7] -0.28 [6]
ENSP00000447068 ENSG00000197111 PCBP2 0.5079 2.07445 0.0333 0.05 [4] -0.46 [6]
ENSP00000448079 ENSG00000197111 PCBP2 0.5079 2.07445 0.0333 0.05 [4] -0.46 [6]
ENSP00000314458 ENSG00000070831 CDC42 -0.4172 -2.07371 0.0319 -0.21 [5] 0.2 [8]
ENSP00000418635 ENSG00000106526 ACTR3C -0.2867 -2.05299 0.0318 -0.1 [10] 0.18 [9]
ENSP00000396519 ENSG00000062598 ELMO2 0.2839 2.04572 0.0286 0.14 [3] -0.15 [4]
ENSP00000312185 ENSG00000155849 ELMO1 0.2839 2.04572 0.0286 0.14 [3] -0.15 [4]
ENSP00000219169 ENSG00000102898 NUTF2 -0.3061 -2.03085 0.0403 -0.28 [6] 0.03 [8]
ENSP00000211372 ENSG00000096150 RPS18 0.3517 2.01219 0.0404 0.17 [8] -0.19 [5]
ENSP00000451715 ENSG00000087302 C14orf166 -0.6742 -2.00162 0.0286 -0.24 [4] 0.44 [3]
ENSP00000352438 ENSG00000197111 PCBP2 0.51 1.98984 0.0424 0.17 [4] -0.34 [7]
ENSP00000383168 ENSG00000183570 PCBP3 0.51 1.98984 0.0424 0.17 [4] -0.34 [7]
ENSP00000364447 ENSG00000072506 HSD17B10 0.2779 1.9777 0.0476 0.32 [4] 0.04 [5]
ENSP00000460741 ENSG00000185624 P4HB -0.5743 -1.67413 0.019 -0.64 [4] -0.07 [6]
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Table B-9 Differentially abundant proteins from neutrophils at Day 1. Proteins with the same ICCS-ratio were 
grouped together and represented by the longest protein in the group. *mean baseline log2 fold change.  
 
 
 
 
 
 
 
 
Protein ID Gene ID Gene Name Log2 Fold Change z-statistic P Mean [N] (AS03)* Mean [N] (PBS)*
ENSP00000448648 ENSG00000123416 TUBA1B -0.5433 -2.4951 0.0055 -0.3 [8] 0.25 [10]
ENSP00000428916 ENSG00000197043 ANXA6 0.5892 2.49034 0.0025 0.46 [8] -0.13 [10]
ENSP00000449460 ENSG00000123416 TUBA1B -0.5419 -2.45127 0.007 -0.28 [8] 0.26 [10]
ENSP00000449325 ENSG00000123416 TUBA1B -0.4971 -2.41131 0.006 -0.27 [8] 0.23 [10]
ENSP00000448211 ENSG00000167553 TUBA1C -0.5147 -2.3802 0.0088 -0.28 [8] 0.23 [10]
ENSP00000336799 ENSG00000123416 TUBA1B -0.3654 -2.19522 0.0243 -0.11 [9] 0.26 [10]
ENSP00000221992 ENSG00000105388 CEACAM5 -0.6216 -2.16941 0.016 -0.51 [5] 0.12 [9]
ENSP00000431078 ENSG00000197043 ANXA6 0.493 2.15348 0.029 0.23 [5] -0.27 [9]
ENSP00000418340 ENSG00000163931 TKT -0.4987 -2.11328 0.0308 -0.45 [7] 0.05 [10]
ENSP00000262428 ENSG00000103187 COTL1 -0.4324 -2.10136 0.03 -0.37 [8] 0.06 [10]
ENSP00000415121 ENSG00000113648 H2AFY 0.2843 2.08407 0.035 0.07 [5] -0.22 [8]
ENSP00000354532 ENSG00000198805 PNP -0.5383 -2.07644 0.011 -0.42 [8] 0.12 [10]
ENSP00000450268 ENSG00000167552 TUBA1A -0.2643 -2.04036 0.0289 -0.08 [8] 0.18 [10]
ENSP00000366980 ENSG00000197043 ANXA6 0.3724 2.01243 0.0198 0.35 [9] -0.03 [10]
ENSP00000359045 ENSG00000089820 ARHGAP4 -0.3974 -2.01016 0.0416 -0.26 [6] 0.14 [10]
ENSP00000397533 ENSG00000089820 ARHGAP4 -0.3877 -1.99861 0.0422 -0.26 [6] 0.13 [10]
ENSP00000293831 ENSG00000161960 EIF4A1 0.4683 1.93987 0.0485 0.43 [3] -0.04 [8]
ENSP00000325875 ENSG00000096384 HSP90AB1 0.3163 1.92885 0.0476 0.28 [6] -0.03 [9]
ENSP00000296930 ENSG00000181163 NPM1 -0.4135 -1.92042 0.0492 -0.32 [6] 0.09 [9]
ENSP00000202773 ENSG00000089009 RPL6 0.4596 1.91374 0.0357 0.46 [3] 0 [5]
ENSP00000462823 ENSG00000184009 ACTG1 0.2764 1.9073 0.0477 0.17 [9] -0.11 [10]
ENSP00000386881 ENSG00000135636 DYSF 0.4526 1.89898 0.0476 0.08 [4] -0.38 [6]
ENSP00000431086 ENSG00000197043 ANXA6 0.515 1.89626 0.0382 0.39 [7] -0.13 [8]
ENSP00000247470 ENSG00000103490 PYCARD 0.3722 1.88754 0.0357 0.15 [3] -0.22 [5]
ENSP00000407473 ENSG00000075624 ACTB 0.2903 1.88553 0.0469 0.18 [9] -0.11 [10]
ENSP00000351646 ENSG00000168439 STIP1 0.3125 1.87325 0.0286 0.09 [3] -0.22 [4]
ENSP00000452421 ENSG00000198805 PNP -0.4844 -1.86253 0.0344 -0.39 [8] 0.09 [10]
ENSP00000198765 ENSG00000085719 CPNE3 0.5114 1.84918 0.0498 0.33 [6] -0.18 [6]
ENSP00000430420 ENSG00000197043 ANXA6 0.3254 1.82926 0.029 0.31 [9] -0.02 [10]
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Table B-10 Differentially abundant proteins from neutrophils at Day 3. Proteins with the same ICCS-ratio were 
grouped together and represented by the longest protein in the group. *mean baseline log2 fold change.  
 
 
Table B-11 Differentially abundant proteins from neutrophils at Day 7. Proteins with the same ICCS-ratio were 
grouped together and represented by the longest protein in the group. *mean baseline log2 fold change.  
 
 
 
Protein ID Gene ID Gene Name Log2 Fold Change z-statistic P Mean [N] (AS03)* Mean [N] (PBS)*
ENSP00000296435 ENSG00000164047 CAMP 0.392 2.18181 0.0255 0.03 [8] -0.36 [10]
ENSP00000450765 ENSG00000258947 TUBB3 -0.3835 -2.15157 0.0242 -0.25 [4] 0.14 [7]
ENSP00000472249 ENSG00000130755 GMFG -0.5138 -2.14947 0.0182 -0.24 [4] 0.27 [7]
ENSP00000428424 ENSG00000254087 LYN -0.2905 -2.12822 0.0242 -0.22 [4] 0.07 [7]
ENSP00000469681 ENSG00000099783 HNRNPM -0.2876 -2.11376 0.0286 -0.06 [3] 0.23 [4]
ENSP00000472599 ENSG00000099783 HNRNPM -0.2876 -2.11376 0.0286 -0.06 [3] 0.23 [4]
ENSP00000372819 ENSG00000204525 HLA-C 0.5043 2.11135 0.0265 0.19 [5] -0.31 [7]
ENSP00000413992 ENSG00000233841 HLA-C 0.5043 2.11135 0.0265 0.19 [5] -0.31 [7]
ENSP00000397867 ENSG00000228299 HLA-C 0.5043 2.11135 0.0265 0.19 [5] -0.31 [7]
ENSP00000428924 ENSG00000254087 LYN -0.2824 -2.0704 0.0303 -0.22 [4] 0.06 [7]
ENSP00000372975 ENSG00000206435 HLA-C 0.5249 2.05472 0.0281 0.24 [5] -0.29 [6]
ENSP00000407952 ENSG00000229644 NAMPTL -0.2966 -2.05414 0.0371 -0.2 [9] 0.09 [10]
ENSP00000471786 ENSG00000130755 GMFG -0.4639 -2.04815 0.0238 -0.18 [4] 0.29 [6]
ENSP00000295470 ENSG00000152795 HNRNPDL -0.3082 -2.03505 0.0281 -0.05 [6] 0.26 [6]
ENSP00000464265 ENSG00000263563 UBBP4 -0.3727 -2.03259 0.0339 -0.39 [7] -0.01 [10]
ENSP00000272317 ENSG00000143947 RPS27A -0.3696 -2.01993 0.0339 -0.42 [7] -0.05 [10]
ENSP00000344818 ENSG00000150991 UBC -0.3696 -2.01993 0.0339 -0.42 [7] -0.05 [10]
ENSP00000351108 ENSG00000197451 HNRNPAB -0.3518 -2.00787 0.0333 -0.03 [6] 0.32 [4]
ENSP00000391429 ENSG00000110047 EHD1 -0.3819 -1.96425 0.0461 -0.25 [7] 0.14 [10]
ENSP00000451525 ENSG00000197249 SERPINA1 -0.3583 -1.94923 0.0443 -0.39 [5] -0.03 [8]
ENSP00000376309 ENSG00000170144 HNRNPA3 0.2944 1.94279 0.0486 0.07 [6] -0.22 [8]
ENSP00000470308 ENSG00000160014 CALM3 0.5545 1.88653 0.0476 0.1 [3] -0.45 [6]
ENSP00000451646 ENSG00000198668 CALM1 0.5467 1.88112 0.0476 0.1 [3] -0.45 [6]
ENSP00000407431 ENSG00000225691 HLA-C 0.5257 1.85492 0.0417 0.27 [5] -0.25 [7]
ENSP00000401935 ENSG00000158517 NCF1 -0.3206 -1.84147 0.0417 -0.29 [3] 0.03 [7]
Protein ID Gene ID Gene Name Log2 Fold Change z-statistic P Mean [N] (AS03)* Mean [N] (PBS)*
ENSP00000408620 ENSG00000115271 GCA -0.325 -2.78446 0.0022 -0.12 [8] 0.2 [9]
ENSP00000394842 ENSG00000115271 GCA -0.3051 -2.71992 0.0027 -0.1 [8] 0.21 [9]
ENSP00000394690 ENSG00000160211 G6PD -0.3663 -2.52888 0.0056 -0.12 [7] 0.25 [9]
ENSP00000400648 ENSG00000160211 G6PD -0.3069 -2.37242 0.0092 -0.07 [7] 0.23 [9]
ENSP00000364212 ENSG00000158825 CDA -0.272 -2.32051 0.0091 -0.06 [7] 0.21 [9]
ENSP00000292432 ENSG00000160883 HK3 0.2864 2.30087 0.0044 0.21 [8] -0.08 [8]
ENSP00000433308 ENSG00000172757 CFL1 -0.5067 -2.26392 0.0208 -0.39 [7] 0.12 [9]
ENSP00000436899 ENSG00000172757 CFL1 -0.5067 -2.26392 0.0208 -0.39 [7] 0.12 [9]
ENSP00000456004 ENSG00000067225 PKM 0.376 2.23529 0.0182 0.21 [4] -0.17 [7]
ENSP00000446415 ENSG00000134333 LDHA -0.3277 -2.22834 0.0202 -0.4 [5] -0.08 [7]
ENSP00000446709 ENSG00000092841 MYL6 -0.3326 -2.21544 0.0232 -0.15 [8] 0.18 [9]
ENSP00000456756 ENSG00000102879 CORO1A -0.5378 -2.15625 0.0317 -0.3 [5] 0.24 [5]
ENSP00000391842 ENSG00000026025 VIM 0.3401 2.15219 0.026 0.3 [8] -0.04 [9]
ENSP00000475750 ENSG00000051620 HEBP2 -0.9247 -2.11205 0.0179 -0.75 [3] 0.17 [5]
ENSP00000393951 ENSG00000075624 ACTB 0.299 2.07269 0.03 0.06 [8] -0.24 [9]
ENSP00000401032 ENSG00000075624 ACTB 0.299 2.07269 0.03 0.06 [8] -0.24 [9]
ENSP00000419442 ENSG00000169764 UGP2 0.8591 2.00253 0.0397 0.71 [4] -0.15 [5]
ENSP00000412429 ENSG00000158710 TAGLN2 -0.322 -1.96932 0.0453 -0.26 [8] 0.06 [9]
ENSP00000386672 ENSG00000138069 RAB1A 0.693 1.91019 0.0397 0.19 [5] -0.51 [5]
ENSP00000314458 ENSG00000070831 CDC42 0.5174 1.85235 0.0495 0.19 [7] -0.33 [6]
ENSP00000394213 ENSG00000115091 ACTR3 -0.5107 -1.8179 0.0397 -0.13 [5] 0.38 [4]
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Table B-12 Differentially abundant proteins from neutrophils at Day 28. Proteins with the same ICCS-ratio were 
grouped together and represented by the longest protein in the group. *mean baseline log2 fold change. 
 
 
 
 
 
 
 
Protein ID Gene ID Gene Name Log2 Fold Change z-statistic P Mean [N] (AS03)* Mean [N] (PBS)*
ENSP00000391592 ENSG00000111679 PTPN6 -0.4089 -2.97017 0.0005 -0.35 [5] 0.06 [9]
ENSP00000415979 ENSG00000111679 PTPN6 -0.3472 -2.88239 0.0008 -0.32 [5] 0.03 [8]
ENSP00000400842 ENSG00000223532 HLA-B 0.6593 2.50607 0.0091 0.32 [4] -0.33 [7]
ENSP00000335153 ENSG00000080824 HSP90AA1 -0.3714 -2.50434 0.0085 -0.15 [8] 0.22 [10]
ENSP00000352656 ENSG00000206450 HLA-B 0.6153 2.47877 0.0091 0.28 [4] -0.33 [7]
ENSP00000392099 ENSG00000223532 HLA-B 0.6153 2.47877 0.0091 0.28 [4] -0.33 [7]
ENSP00000411954 ENSG00000206450 HLA-B 0.6153 2.47877 0.0091 0.28 [4] -0.33 [7]
ENSP00000450765 ENSG00000258947 TUBB3 -0.4258 -2.451 0.0038 -0.22 [5] 0.2 [7]
ENSP00000391250 ENSG00000228299 HLA-C 0.5432 2.3708 0.0079 0.48 [4] -0.06 [5]
ENSP00000400410 ENSG00000204525 HLA-C 0.5432 2.3708 0.0079 0.48 [4] -0.06 [5]
ENSP00000407494 ENSG00000237022 HLA-C 0.3056 2.36907 0.0079 0.22 [4] -0.08 [5]
ENSP00000399675 ENSG00000223532 HLA-B 0.4773 2.35741 0.0079 0.41 [4] -0.06 [5]
ENSP00000433363 ENSG00000206450 HLA-B 0.4333 2.31936 0.0079 0.37 [4] -0.06 [5]
ENSP00000300289 ENSG00000167004 PDIA3 0.3823 2.20357 0.0246 0.23 [5] -0.15 [10]
ENSP00000450712 ENSG00000080824 HSP90AA1 -0.4117 -2.19649 0.0171 -0.15 [5] 0.26 [8]
ENSP00000376309 ENSG00000170144 HNRNPA3 0.4374 2.15353 0.0266 0.14 [6] -0.3 [8]
ENSP00000373854 ENSG00000156886 ITGAD -0.4075 -2.13916 0.0242 -0.27 [3] 0.14 [8]
ENSP00000438260 ENSG00000167004 PDIA3 0.3467 2.12947 0.0286 0.23 [5] -0.11 [10]
ENSP00000343027 ENSG00000127955 GNAI1 -0.3691 -2.11803 0.0095 -0.24 [4] 0.13 [6]
ENSP00000410572 ENSG00000127955 GNAI1 -0.3671 -2.08544 0.019 -0.24 [4] 0.13 [6]
ENSP00000410661 ENSG00000206452 HLA-C 0.2956 2.03351 0.0286 0.25 [4] -0.05 [4]
ENSP00000398592 ENSG00000070831 CDC42 -0.5533 -2.02779 0.035 0.04 [7] 0.6 [8]
ENSP00000356022 ENSG00000112096 SOD2 0.3881 2.0131 0.0356 0.32 [5] -0.07 [10]
ENSP00000454623 ENSG00000140678 ITGAX -0.3569 -2.00162 0.0303 -0.22 [3] 0.14 [8]
ENSP00000403679 ENSG00000196419 XRCC6 0.4503 1.99906 0.0286 0.34 [3] -0.11 [4]
ENSP00000437098 ENSG00000177156 TALDO1 -0.3494 -1.96447 0.0413 -0.12 [7] 0.23 [10]
ENSP00000321259 ENSG00000177156 TALDO1 -0.3459 -1.95059 0.0427 -0.12 [7] 0.23 [10]
ENSP00000372819 ENSG00000204525 HLA-C 0.6948 1.94256 0.0394 0.47 [4] -0.22 [7]
ENSP00000413992 ENSG00000233841 HLA-C 0.6948 1.94256 0.0394 0.47 [4] -0.22 [7]
ENSP00000397867 ENSG00000228299 HLA-C 0.6948 1.94256 0.0394 0.47 [4] -0.22 [7]
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Table B-13 Differentially abundant proteins from NK cells at Day 1. Proteins with the same ICCS-ratio were 
grouped together and represented by the longest protein in the group. *mean baseline log2 fold change.  
 
 
 
 
 
 
 
 
 
Protein ID Gene ID Gene Name Log2 Fold Change z-statistic P Mean [N] (AS03)* Mean [N] (PBS)*
ENSP00000477441 ENSG00000147065 MSN 0.9323 2.67964 0.0079 0.73 [4] -0.2 [5]
ENSP00000366002 ENSG00000206503 HLA-A -0.3471 -2.4673 0.0093 0.04 [8] 0.39 [5]
ENSP00000463482 ENSG00000265434 HLA-ABC -0.3471 -2.4673 0.0093 0.04 [8] 0.39 [5]
ENSP00000410645 ENSG00000223980 HLA-A -0.3429 -2.44613 0.0101 0.04 [8] 0.39 [5]
ENSP00000448239 ENSG00000229215 HLA-A -0.4676 -2.38313 0.0114 0.01 [7] 0.47 [5]
ENSP00000327539 ENSG00000169045 HNRNPH1 -0.3935 -2.34234 0.0286 -0.18 [4] 0.21 [3]
ENSP00000373114 ENSG00000206505 HLA-A -0.4266 -2.33118 0.007 -0.13 [8] 0.3 [6]
ENSP00000317697 ENSG00000160255 ITGB2 -0.5493 -2.32988 0.014 -0.27 [5] 0.28 [8]
ENSP00000391897 ENSG00000002834 LASP1 -0.2817 -2.32049 0.0155 -0.16 [7] 0.12 [8]
ENSP00000392235 ENSG00000232126 HLA-B -0.424 -2.27137 0.0152 -0.12 [7] 0.3 [8]
ENSP00000388208 ENSG00000232126 HLA-B -0.407 -2.2568 0.0148 -0.12 [7] 0.29 [8]
ENSP00000401048 ENSG00000002834 LASP1 -0.425 -2.15595 0.0264 -0.25 [5] 0.17 [8]
ENSP00000316029 ENSG00000137076 TLN1 -0.3292 -2.14624 0.022 -0.14 [5] 0.19 [9]
ENSP00000442981 ENSG00000137076 TLN1 -0.4176 -2.13977 0.0185 -0.24 [5] 0.18 [9]
ENSP00000467037 ENSG00000152234 ATP5A1 0.7353 2.13443 0.0278 0.36 [5] -0.37 [7]
ENSP00000303242 ENSG00000160255 ITGB2 -0.4429 -2.12891 0.0295 -0.2 [5] 0.24 [8]
ENSP00000380952 ENSG00000160255 ITGB2 -0.4429 -2.12891 0.0295 -0.2 [5] 0.24 [8]
ENSP00000282050 ENSG00000152234 ATP5A1 0.6672 2.12268 0.0303 0.32 [6] -0.34 [7]
ENSP00000302935 ENSG00000172349 IL16 0.5059 2.05091 0.0357 0.48 [3] -0.03 [5]
ENSP00000431347 ENSG00000237022 HLA-C -0.4015 -2.04946 0.0379 0.01 [7] 0.41 [5]
ENSP00000408986 ENSG00000231834 HLA-A -0.2768 -2.00183 0.0427 0.04 [8] 0.32 [5]
ENSP00000216181 ENSG00000100345 MYH9 -0.3616 -1.98636 0.0389 -0.28 [8] 0.08 [8]
ENSP00000472469 ENSG00000233927 RPS28 -0.5729 -1.97626 0.0286 -0.21 [4] 0.36 [3]
ENSP00000301522 ENSG00000167815 PRDX2 0.4264 1.92593 0.0397 0.41 [4] -0.02 [5]
ENSP00000415121 ENSG00000113648 H2AFY -0.3794 -1.69394 0.0476 -0.11 [5] 0.26 [6]
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Table B-14 Differentially abundant proteins from NK cells at Day 3. Proteins with the same ICCS-ratio were 
grouped together and represented by the longest protein in the group. *mean baseline log2 fold change.  
 
 
Table B-15 Differentially abundant proteins from NK cells at Day 7. Proteins with the same ICCS-ratio were 
grouped together and represented by the longest protein in the group. *mean baseline log2 fold change.  
 
Protein ID Gene ID Gene Name Log2 Fold Change z-statistic P Mean [N] (AS03)* Mean [N] (PBS)*
ENSP00000380065 ENSG00000111640 GAPDH -0.505 -2.60099 0.0041 -0.15 [9] 0.36 [8]
ENSP00000438740 ENSG00000111679 PTPN6 -0.3582 -2.46857 0.0079 0.11 [5] 0.47 [4]
ENSP00000286788 ENSG00000156261 CCT8 0.4326 2.41856 0.0143 0.31 [4] -0.13 [6]
ENSP00000395153 ENSG00000142634 EFHD2 -0.4273 -2.41211 0.0097 -0.31 [9] 0.12 [8]
ENSP00000445646 ENSG00000111679 PTPN6 -0.3924 -2.40175 0.0286 0.08 [4] 0.47 [4]
ENSP00000475985 ENSG00000268954 PTPN6 -0.3924 -2.40175 0.0286 0.08 [4] 0.47 [4]
ENSP00000450297 ENSG00000110955 ATP5B 0.4671 2.35779 0.0096 0.27 [8] -0.2 [8]
ENSP00000442981 ENSG00000137076 TLN1 -0.477 -2.32866 0.0146 -0.29 [7] 0.18 [7]
ENSP00000264071 ENSG00000104833 TUBB4A 0.3226 2.29112 0.0183 0.27 [9] -0.05 [8]
ENSP00000193403 ENSG00000072110 ACTN1 -0.4345 -2.27265 0.0161 -0.23 [9] 0.2 [8]
ENSP00000377941 ENSG00000072110 ACTN1 -0.4345 -2.27265 0.0161 -0.23 [9] 0.2 [8]
ENSP00000414272 ENSG00000072110 ACTN1 -0.4345 -2.27265 0.0161 -0.23 [9] 0.2 [8]
ENSP00000439828 ENSG00000072110 ACTN1 -0.4345 -2.27265 0.0161 -0.23 [9] 0.2 [8]
ENSP00000316029 ENSG00000137076 TLN1 -0.4574 -2.24918 0.014 -0.31 [7] 0.15 [7]
ENSP00000229239 ENSG00000111640 GAPDH -0.4418 -2.24004 0.0188 -0.15 [9] 0.29 [8]
ENSP00000380067 ENSG00000111640 GAPDH -0.4418 -2.24004 0.0188 -0.15 [9] 0.29 [8]
ENSP00000372819 ENSG00000204525 HLA-C 0.3762 2.22815 0.0238 0.17 [8] -0.21 [7]
ENSP00000341289 ENSG00000188229 TUBB4B 0.3009 2.15077 0.028 0.25 [9] -0.05 [8]
ENSP00000472469 ENSG00000233927 RPS28 -0.6694 -2.1255 0.0357 -0.36 [5] 0.31 [3]
ENSP00000413992 ENSG00000233841 HLA-C 0.3516 2.11551 0.0337 0.17 [8] -0.18 [7]
ENSP00000445257 ENSG00000115091 ACTR3 -0.3052 -2.08108 0.0267 -0.24 [7] 0.06 [8]
ENSP00000408986 ENSG00000231834 HLA-A -0.3543 -2.07277 0.0333 0.22 [7] 0.58 [4]
ENSP00000410645 ENSG00000223980 HLA-A -0.3543 -2.07277 0.0333 0.22 [7] 0.58 [4]
ENSP00000442730 ENSG00000156261 CCT8 0.6711 2.06649 0.0397 0.34 [4] -0.33 [5]
ENSP00000429978 ENSG00000153310 FAM49B 0.7826 2.02824 0.0179 0.33 [3] -0.46 [5]
ENSP00000246554 ENSG00000126267 COX6B1 0.3945 2.01799 0.0283 0.26 [8] -0.13 [4]
ENSP00000326042 ENSG00000075886 TUBA3D 0.3605 1.99826 0.0394 0.23 [7] -0.13 [4]
ENSP00000342026 ENSG00000117592 PRDX6 -0.6719 -1.98867 0.0449 -0.28 [6] 0.39 [7]
ENSP00000373114 ENSG00000206505 HLA-A -0.3559 -1.98248 0.0424 0.06 [7] 0.42 [4]
ENSP00000365147 ENSG00000142634 EFHD2 -0.3486 -1.9663 0.0449 -0.31 [9] 0.04 [8]
ENSP00000467037 ENSG00000152234 ATP5A1 0.4339 1.95642 0.0454 0.17 [8] -0.26 [7]
ENSP00000244534 ENSG00000124575 HIST1H1D 0.6862 1.86118 0.0455 0.33 [5] -0.36 [7]
ENSP00000468618 ENSG00000152234 ATP5A1 0.3769 1.80027 0.0429 0.22 [4] -0.16 [6]
ENSP00000465259 ENSG00000152234 ATP5A1 0.6805 1.78399 0.0397 0.15 [4] -0.53 [5]
Protein ID Gene ID Gene Name Log2 Fold Change z-statistic P Mean [N] (AS03)* Mean [N] (PBS)*
ENSP00000228825 ENSG00000111229 ARPC3 -0.8939 -2.45638 0.0083 -0.23 [7] 0.66 [3]
ENSP00000467037 ENSG00000152234 ATP5A1 0.4979 2.28467 0.0095 -0.05 [8] -0.54 [7]
ENSP00000279146 ENSG00000110711 AIP -0.4026 -2.18037 0.0159 0.12 [4] 0.53 [5]
ENSP00000429978 ENSG00000153310 FAM49B 0.7391 2.13204 0.0357 0.4 [3] -0.34 [5]
ENSP00000282050 ENSG00000152234 ATP5A1 0.4737 2.1284 0.0218 -0.03 [8] -0.51 [7]
ENSP00000372819 ENSG00000204525 HLA-C 0.3972 2.09329 0.0317 0.16 [8] -0.24 [7]
ENSP00000309431 ENSG00000173213 RP11-683L23.1 0.5046 2.04368 0.0333 0.05 [7] -0.45 [3]
ENSP00000457610 ENSG00000261456 TUBB8 0.5046 2.04368 0.0333 0.05 [7] -0.45 [3]
ENSP00000467190 ENSG00000130402 ACTN4 -0.8218 -2.03613 0.0343 -0.58 [8] 0.24 [4]
ENSP00000364805 ENSG00000204390 HSPA1L 0.5643 2.01564 0.0373 0.35 [6] -0.21 [7]
ENSP00000249071 ENSG00000128340 RAC2 -0.5895 -1.96068 0.0368 -0.35 [5] 0.24 [6]
ENSP00000385590 ENSG00000128340 RAC2 -0.5895 -1.96068 0.0368 -0.35 [5] 0.24 [6]
ENSP00000263373 ENSG00000160460 SPTBN4 -0.4784 -1.73174 0.0476 -0.3 [5] 0.17 [4]
ENSP00000340741 ENSG00000160460 SPTBN4 -0.4784 -1.73174 0.0476 -0.3 [5] 0.17 [4]
ENSP00000438260 ENSG00000167004 PDIA3 -0.3385 -1.67852 0.0425 -0.2 [7] 0.14 [7]
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Table B-16 Differentially abundant proteins from NK cells at Day 28. Proteins with the same ICCS-ratio were 
grouped together and represented by the longest protein in the group. *mean baseline log2 fold change.  
 
 
Table B-17 Differentially abundant proteins from T cells at Day 1. Proteins with the same ICCS-ratio were 
grouped together and represented by the longest protein in the group. *mean baseline log2 fold change.  
 
Protein ID Gene ID Gene Name Log2 Fold Change z-statistic P Mean [N] (AS03)* Mean [N] (PBS)*
ENSP00000450297 ENSG00000110955 ATP5B 0.3247 2.92022 0.0019 0.27 [8] -0.05 [8]
ENSP00000446677 ENSG00000110955 ATP5B 0.4898 2.5298 0.0076 0.29 [8] -0.2 [7]
ENSP00000339035 ENSG00000143549 TPM3 -0.7335 -2.36213 0.0079 -0.4 [4] 0.33 [5]
ENSP00000271850 ENSG00000143549 TPM3 -0.7335 -2.36213 0.0079 -0.4 [4] 0.33 [5]
ENSP00000357520 ENSG00000143549 TPM3 -0.6285 -2.3076 0.0159 -0.3 [4] 0.33 [5]
ENSP00000357516 ENSG00000143549 TPM3 -0.6285 -2.3076 0.0159 -0.3 [4] 0.33 [5]
ENSP00000207437 ENSG00000196465 MYL6B 0.7145 2.24612 0.0079 0.61 [5] -0.1 [4]
ENSP00000340278 ENSG00000116288 PARK7 -0.4908 -2.17162 0.0273 -0.05 [7] 0.44 [4]
ENSP00000466242 ENSG00000116288 PARK7 -0.4908 -2.17162 0.0273 -0.05 [7] 0.44 [4]
ENSP00000369671 ENSG00000244734 HBB -1.1892 -2.15378 0.0246 -0.14 [8] 1.05 [7]
ENSP00000327539 ENSG00000169045 HNRNPH1 -0.6008 -2.12921 0.0333 -0.37 [7] 0.23 [3]
ENSP00000249071 ENSG00000128340 RAC2 -0.5127 -2.12691 0.0281 -0.29 [5] 0.22 [6]
ENSP00000385590 ENSG00000128340 RAC2 -0.5127 -2.12691 0.0281 -0.29 [5] 0.22 [6]
ENSP00000329219 ENSG00000184922 FMNL1 0.5882 2.072 0.0179 0.11 [5] -0.48 [3]
ENSP00000451560 ENSG00000198211 TUBB3 0.4275 2.05253 0.0366 0.18 [9] -0.25 [8]
ENSP00000219150 ENSG00000102879 CORO1A -0.3549 -2.04649 0.0195 -0.24 [9] 0.12 [8]
ENSP00000333994 ENSG00000244734 HBB -1.1241 -2.03948 0.0375 -0.24 [8] 0.88 [7]
ENSP00000392099 ENSG00000223532 HLA-B 0.4542 1.96558 0.0476 0.21 [5] -0.24 [4]
ENSP00000325875 ENSG00000096384 HSP90AB1 -0.5839 -1.93384 0.0429 -0.11 [7] 0.47 [5]
ENSP00000307940 ENSG00000167658 EEF2 -0.3722 -1.9202 0.0404 -0.2 [7] 0.17 [5]
ENSP00000270792 ENSG00000142669 SH3BGRL3 0.3552 1.85843 0.0148 0.28 [8] -0.07 [7]
Protein ID Gene ID Gene Name Log2 Fold Change z-statistic P Mean [N] (AS03)* Mean [N] (PBS)*
ENSP00000358224 ENSG00000198161 PPIAL4C -0.3172 -2.2544 0.02 -0.22 [7] 0.1 [8]
ENSP00000269576 ENSG00000186395 KRT10 1.3023 2.1991 0.0317 0.52 [4] -0.78 [5]
ENSP00000393764 ENSG00000250151 ARPC4-TTLL3 -0.5793 -2.18368 0.0238 -0.28 [5] 0.3 [5]
ENSP00000259818 ENSG00000137285 TUBB2B 0.6902 2.14351 0.0238 0.4 [6] -0.29 [6]
ENSP00000451560 ENSG00000198211 TUBB3 0.6902 2.14351 0.0238 0.4 [6] -0.29 [6]
ENSP00000388169 ENSG00000241553 ARPC4 -0.3506 -2.08212 0.0317 -0.27 [5] 0.08 [5]
ENSP00000216181 ENSG00000100345 MYH9 -0.306 -2.04984 0.0366 -0.34 [9] -0.04 [10]
ENSP00000440014 ENSG00000127314 RAP1B 0.3568 2.02429 0.0381 0.15 [4] -0.2 [6]
ENSP00000228825 ENSG00000111229 ARPC3 -0.4459 -2.01633 0.0411 -0.24 [5] 0.21 [6]
ENSP00000250559 ENSG00000127314 RAP1B 0.3413 1.99781 0.0333 0.15 [4] -0.19 [6]
ENSP00000348786 ENSG00000116473 RAP1A 0.3413 1.99781 0.0333 0.15 [4] -0.19 [6]
ENSP00000444467 ENSG00000127314 RAP1B 0.3413 1.99781 0.0333 0.15 [4] -0.19 [6]
ENSP00000399986 ENSG00000127314 RAP1B 0.3413 1.99781 0.0333 0.15 [4] -0.19 [6]
ENSP00000477441 ENSG00000147065 MSN 0.6398 1.91843 0.0429 -0.16 [6] -0.8 [4]
ENSP00000264335 ENSG00000108953 YWHAE -1.1652 -1.91077 0.0286 -0.74 [3] 0.42 [4]
ENSP00000248975 ENSG00000128245 YWHAH -0.8436 -1.87684 0.0286 -0.45 [3] 0.4 [4]
ENSP00000340989 ENSG00000175793 SFN -0.8436 -1.87684 0.0286 -0.45 [3] 0.4 [4]
ENSP00000238081 ENSG00000134308 YWHAQ -0.8436 -1.87684 0.0286 -0.45 [3] 0.4 [4]
ENSP00000396189 ENSG00000080824 HSP90AA1 -0.4531 -1.85351 0.0286 -0.44 [4] 0.02 [4]
ENSP00000449460 ENSG00000123416 TUBA1B 0.35 1.84981 0.0471 0.2 [7] -0.15 [9]
ENSP00000448648 ENSG00000123416 TUBA1B 0.35 1.84981 0.0471 0.2 [7] -0.15 [9]
ENSP00000306330 ENSG00000170027 YWHAG -1.0967 -1.72571 0.0286 -0.69 [3] 0.41 [4]
ENSP00000300161 ENSG00000166913 YWHAB -1.0814 -1.71639 0.0286 -0.69 [3] 0.4 [4]
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Table B-18 Differentially abundant proteins from T cells at Day 3.  Proteins with the same ICCS-ratio were 
grouped together and represented by the longest protein in the group. *mean baseline log2 fold change. 
 
 
Table B-19 Differentially abundant proteins from T cells at Day 7. Proteins with the same ICCS-ratio were 
grouped together and represented by the longest protein in the group. *mean baseline log2 fold change.  
 
 
Table B-20 Differnetially abundant proteins from T cells at Day 28. Proteins with the same ICCS-ratio were 
grouped together and represented by the longest protein in the group. *mean baseline log2 fold change.  
 
 
Protein ID Gene ID Gene Name Log2 Fold Change z-statistic P Mean [N] (AS03)* Mean [N] (PBS)*
ENSP00000468618 ENSG00000152234 ATP5A1 0.6825 2.24065 0.0286 0.15 [4] -0.53 [3]
ENSP00000465259 ENSG00000152234 ATP5A1 0.5901 2.23147 0.0286 0.14 [4] -0.45 [3]
ENSP00000270142 ENSG00000142168 SOD1 0.512 1.96036 0.0429 0.1 [6] -0.41 [4]
ENSP00000438740 ENSG00000111679 PTPN6 -0.4706 -1.86121 0.0286 -0.41 [4] 0.06 [3]
ENSP00000455584 ENSG00000067225 PKM 0.6226 1.70431 0.0346 0.26 [6] -0.36 [5]
Protein ID Gene ID Gene Name Log2 Fold Change z-statistic P Mean [N] (AS03)* Mean [N] (PBS)*
ENSP00000403679 ENSG00000196419 XRCC6 -0.8634 -2.41711 0.0159 -0.4 [4] 0.46 [5]
ENSP00000386929 ENSG00000163017 ACTG2 0.523 2.38555 0.0061 0.21 [10] -0.31 [9]
ENSP00000407473 ENSG00000075624 ACTB -0.94 -2.36984 0.0126 -0.96 [7] -0.02 [8]
ENSP00000462823 ENSG00000184009 ACTG1 -0.94 -2.36984 0.0126 -0.96 [7] -0.02 [8]
ENSP00000408649 ENSG00000146701 MDH2 -0.5929 -2.19489 0.0317 -0.35 [4] 0.24 [5]
ENSP00000259791 ENSG00000137259 HIST1H2AB -0.5639 -2.15511 0.0275 -0.48 [8] 0.09 [8]
ENSP00000452858 ENSG00000182718 ANXA2 0.672 2.14546 0.0317 0.08 [5] -0.59 [5]
ENSP00000453770 ENSG00000182718 ANXA2 0.672 2.14546 0.0317 0.08 [5] -0.59 [5]
ENSP00000453566 ENSG00000182718 ANXA2 0.672 2.14546 0.0317 0.08 [5] -0.59 [5]
ENSP00000327070 ENSG00000146701 MDH2 -0.4244 -2.14219 0.0286 -0.27 [4] 0.15 [6]
ENSP00000431696 ENSG00000172757 CFL1 -0.3807 -2.13111 0.0291 -0.09 [7] 0.29 [7]
ENSP00000416706 ENSG00000169067 ACTBL2 0.5229 1.95735 0.0445 0.3 [10] -0.22 [9]
ENSP00000262269 ENSG00000105357 MYH14 0.5881 1.95017 0.0494 0.1 [8] -0.49 [9]
ENSP00000440902 ENSG00000246705 H2AFJ -2.2355 -1.90964 0.0238 -1.53 [4] 0.7 [6]
ENSP00000362413 ENSG00000102144 PGK1 -0.5424 -1.86222 0.0368 -0.12 [5] 0.42 [6]
ENSP00000444708 ENSG00000102144 PGK1 -0.5503 -1.85639 0.0346 -0.13 [5] 0.42 [6]
Protein ID Gene ID Gene Name Log2 Fold Change z-statistic P Mean [N] (AS03)* Mean [N] (PBS)*
ENSP00000380033 ENSG00000100201 DDX17 0.3259 2.44908 0.0079 0.18 [5] -0.15 [5]
ENSP00000452858 ENSG00000182718 ANXA2 0.5248 2.2103 0.0065 0.13 [6] -0.39 [5]
ENSP00000453770 ENSG00000182718 ANXA2 0.5248 2.2103 0.0065 0.13 [6] -0.39 [5]
ENSP00000453566 ENSG00000182718 ANXA2 0.5248 2.2103 0.0065 0.13 [6] -0.39 [5]
ENSP00000452895 ENSG00000182718 ANXA2 0.3523 2.20641 0.0173 0.1 [6] -0.25 [5]
ENSP00000453663 ENSG00000182718 ANXA2 0.3523 2.20641 0.0173 0.1 [6] -0.25 [5]
ENSP00000346694 ENSG00000122566 HNRNPA2B1 0.6735 2.18942 0.0169 0.54 [6] -0.14 [7]
ENSP00000346032 ENSG00000182718 ANXA2 0.3959 2.10576 0.0281 0.07 [6] -0.33 [5]
ENSP00000453754 ENSG00000182718 ANXA2 0.3959 2.10576 0.0281 0.07 [6] -0.33 [5]
ENSP00000453859 ENSG00000182718 ANXA2 0.3959 2.10576 0.0281 0.07 [6] -0.33 [5]
ENSP00000305995 ENSG00000170950 PGK2 -0.6084 -2.09987 0.0368 -0.13 [6] 0.48 [5]
ENSP00000472249 ENSG00000130755 GMFG -0.6483 -2.08625 0.0368 -0.37 [6] 0.28 [5]
ENSP00000471786 ENSG00000130755 GMFG -0.6483 -2.08625 0.0368 -0.37 [6] 0.28 [5]
ENSP00000282050 ENSG00000152234 ATP5A1 0.4032 2.05407 0.0108 0.11 [5] -0.29 [6]
ENSP00000465477 ENSG00000152234 ATP5A1 0.4032 2.05407 0.0108 0.11 [5] -0.29 [6]
ENSP00000234590 ENSG00000074800 ENO1 0.2925 2.05008 0.0301 0.08 [9] -0.21 [10]
ENSP00000467037 ENSG00000152234 ATP5A1 0.3905 2.01856 0.0108 0.11 [5] -0.28 [6]
ENSP00000431696 ENSG00000172757 CFL1 -0.3909 -2.00154 0.0357 -0.13 [8] 0.26 [10]
ENSP00000349101 ENSG00000122566 HNRNPA2B1 0.6114 1.90079 0.0466 0.48 [6] -0.14 [7]
ENSP00000357721 ENSG00000143546 S100A8 -1.3285 -1.82553 0.0286 -0.31 [3] 1.02 [4]
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Table B-21 Significant protein family overlap between cell types. Proteins are ordered by the number of different cell types they are shared between 
Protein ID Gene ID Gene Name B-cells Monocytes Neutrophils NK-cells T-cells 
ENSP00000451560 ENSG00000198211 TUBB3 Day 1,7,28 Day 1,3,7 Day 3,28 Day 3,7,28 Day 1 
ENSP00000373123 ENSG00000206509 HLA-F Day 1,3,7 Day 3 Day 3,28 Day 1,3,7,28 0 
ENSP00000459921 ENSG00000262785 PKLR Day 7 Day 7 Day 7  Day 3 
ENSP00000346550 ENSG00000197043 ANXA6 Day 1,3 Day 3,7 Day 1   
ENSP00000353192 ENSG00000196419 XRCC6 Day 1  Day 28  Day 7 
ENSP00000310219 ENSG00000173110 HSPA6 Day 1,3 Day 1,7  Day 7  
ENSP00000441750 ENSG00000092841 MYL6 Day 1,3,7  Day 7 Day 28  
ENSP00000451920 ENSG00000197045 GMFB  Day 1 Day 3  Day 28 
ENSP00000388169 ENSG00000241553 ARPC4 Day 28 Day 1   Day 1 
ENSP00000327070 ENSG00000146701 MDH2 Day 7 Day 1   Day 7 
ENSP00000300289 ENSG00000167004 PDIA3  Day 1 Day 28 Day 7  
ENSP00000443475 ENSG00000167553 TUBA1C   Day 1 Day 3 Day 1 
ENSP00000391481 ENSG00000163931 TKT Day 3 Day 3 Day 1   
ENSP00000423563 ENSG00000113648 H2AFY   Day 1 Day 1 Day 7 
ENSP00000335153 ENSG00000080824 HSP90AA1   Day 1,28 Day 28 Day 1 
ENSP00000386786 ENSG00000196604 POTEF Day 28  Day 1,7  Day 7 
ENSP00000437301 ENSG00000137710 RDX  Day 3  Day 1 Day 1 
ENSP00000262030 ENSG00000110955 ATP5B Day 3,7 Day 28  Day 3,28  
ENSP00000330074 ENSG00000184357 HIST1H1B Day 3 Day 28  Day 3  
ENSP00000441543 ENSG00000150991 UBC Day 28 Day 3 Day 3   
ENSP00000376309 ENSG00000170144 HNRNPA3 Day 28  Day 3,28  Day 28 
ENSP00000391592 ENSG00000111679 PTPN6   Day 28 Day 3 Day 3 
ENSP00000263238 ENSG00000115091 ACTR3  Day 28 Day 7 Day 3  
ENSP00000431696 ENSG00000172757 CFL1  Day 7 Day 7  Day 7,28 
ENSP00000394496 ENSG00000110880 CORO1C Day 28  Day 7 Day 28  
ENSP00000228740 ENSG00000111144 LTA4H Day 1 Day 7    
ENSP00000368646 ENSG00000123131 PRDX4 Day 1,3,28   Day 1  
ENSP00000439828 ENSG00000072110 ACTN1 Day 1,7   Day 3,7  
ENSP00000363071 ENSG00000175084 DES Day 1,7,28  Day 7   
ENSP00000362413 ENSG00000102144 PGK1 Day 1    Day 7,28 
ENSP00000462209 ENSG00000141522 ARHGDIA Day 1 Day 3    
ENSP00000250559 ENSG00000127314 RAP1B  Day 1,3   Day 1 
ENSP00000344419 ENSG00000005381 MPO Day 7 Day 1    
ENSP00000246662 ENSG00000171403 KRT9  Day 1   Day 1 
ENSP00000446252 ENSG00000112096 SOD2  Day 1 Day 28   
ENSP00000369475 ENSG00000057608 GDI2 Day 7 Day 1    
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Table B-21 Continued. 
Protein ID Gene ID Gene Name B-cells Monocytes Neutrophils NK-cells T-cells 
ENSP00000302393 ENSG00000171989 LDHAL6B  Day 1 Day 7   
ENSP00000262428 ENSG00000103187 COTL1  Day 7 Day 1   
ENSP00000359045 ENSG00000089820 ARHGAP4  Day 7 Day 1   
ENSP00000247470 ENSG00000103490 PYCARD  Day 7 Day 1   
ENSP00000327539 ENSG00000169045 HNRNPH1  Day 7  Day 1,28  
ENSP00000453508 ENSG00000171914 TLN2  Day 3  Day 1,3  
ENSP00000381736 ENSG00000152234 ATP5A1    Day 1,3,7 Day 3,28 
ENSP00000302935 ENSG00000172349 IL16 Day 3   Day 1  
ENSP00000369315 ENSG00000133026 MYH10    Day 1 Day 1 
ENSP00000228825 ENSG00000111229 ARPC3    Day 7 Day 1 
ENSP00000264335 ENSG00000108953 YWHAE Day 28    Day 1 
ENSP00000365458 ENSG00000165119 HNRNPK Day 3 Day 3    
ENSP00000349748 ENSG00000116560 SFPQ Day 3 Day 3,7    
ENSP00000286788 ENSG00000156261 CCT8 Day 3   Day 3  
ENSP00000295470 ENSG00000152795 HNRNPDL Day 3  Day 3   
ENSP00000324105 ENSG00000108515 ENO3 Day 3    Day 28 
ENSP00000357076 ENSG00000158710 TAGLN2  Day 3 Day 7   
ENSP00000312999 ENSG00000114353 GNAI2  Day 3 Day 28   
ENSP00000386672 ENSG00000138069 RAB1A  Day 3 Day 7   
ENSP00000443053 ENSG00000150991 UBC Day 28  Day 3   
ENSP00000387065 ENSG00000143933 CALM2  Day 7 Day 3   
ENSP00000270142 ENSG00000142168 SOD1  Day 28   Day 3 
ENSP00000219169 ENSG00000102898 NUTF2 Day 7,28 Day 28    
ENSP00000455356 ENSG00000180209 MYLPF Day 7 Day 7    
ENSP00000295897 ENSG00000163631 ALB Day 28 Day 7,28    
ENSP00000350667 ENSG00000140416 TPM1  Day 7  Day 28  
ENSP00000398592 ENSG00000070831 CDC42  Day 28 Day 7,28   
ENSP00000380033 ENSG00000100201 DDX17 Day 28    Day 28 
 
 
 
 128 
 
Table B-22 Significantly enriched MSigDB Reactome Pathways for B cells at day 7. 
Category ID Category Genes # 
Significant Genes #(%) 
[#Protein Families] 
Genes Up (AS03 
vs. PBS) #(%) 
Genes Down (AS03 
vs. PBS) #(%) P FDR 
METABOLISM OF PROTEINS 409 5 (1.2) [2] 4 (1) 1 (0.2) <0.0001 0.0035 
ANTIGEN PRESENTATION FOLDING 
ASSEMBLY AND PEPTIDE LOADING OF 
CLASS I MHC 
20 2 (10) [2] 2 (10) 0 (0) 0.0001 0.0162 
SMOOTH MUSCLE CONTRACTION 23 2 (8.7) [2] 2 (8.7) 0 (0) 0.0002 0.0176 
SEMA4D INDUCED CELL MIGRATION 
AND GROWTH CONE COLLAPSE 24 2 (8.3) [2] 2 (8.3) 0 (0) 0.0002 0.0176 
SEMA4D IN SEMAPHORIN SIGNALING 29 2 (6.9) [2] 2 (6.9) 0 (0) 0.0003 0.023 
 
 
Table B-23 Significantly enriched MSigDB Reactome Pathways for B cells at day 28. 
Category ID Category Genes # 
Significant Genes #(%) 
[#Protein Families] 
Genes Up (AS03 
vs. PBS) #(%) 
Genes Down (AS03 
vs. PBS) #(%) P FDR 
CELL CYCLE 389 16 (4.1) [3] 0 (0) 16 (4.1) <0.0001 <0.0001 
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Table B-24 Significantly enriched MSigDB Reactome Pathways for monocytes at day 3. 
Category ID Category Genes # 
Significant Genes #(%) 
[#Protein Families] 
Genes Up (AS03 
vs. PBS) #(%) 
Genes Down (AS03 
vs. PBS) #(%) P FDR 
METABOLISM OF MRNA 207 8 (3.9) [8] 6 (2.9) 2 (1) <0.0001 <0.0001 
METABOLISM OF RNA 252 8 (3.2) [8] 6 (2.4) 2 (0.8) <0.0001 <0.0001 
ANTIGEN PROCESSING CROSS 
PRESENTATION 72 5 (6.9) [5] 5 (6.9) 0 (0) <0.0001 0.0002 
PEPTIDE CHAIN ELONGATION 82 5 (6.1) [5] 3 (3.7) 2 (2.4) <0.0001 0.0003 
INFLUENZA VIRAL RNA 
TRANSCRIPTION AND REPLICATION 99 5 (5.1) [5] 3 (3) 2 (2) <0.0001 0.0005 
3 UTR MEDIATED TRANSLATIONAL 
REGULATION 101 5 (5) [5] 3 (3) 2 (2) <0.0001 0.0005 
NONSENSE MEDIATED DECAY 
ENHANCED BY THE EXON JUNCTION 
COMPLEX 
101 5 (5) [5] 3 (3) 2 (2) <0.0001 0.0005 
SRP DEPENDENT 
COTRANSLATIONAL PROTEIN 
TARGETING TO MEMBRANE 
105 5 (4.8) [5] 3 (2.9) 2 (1.9) <0.0001 0.0005 
ER PHAGOSOME PATHWAY 59 4 (6.8) [4] 4 (6.8) 0 (0) <0.0001 0.001 
INFLUENZA LIFE CYCLE 134 5 (3.7) [5] 3 (2.2) 2 (1.5) <0.0001 0.0013 
TRANSLATION 140 5 (3.6) [5] 3 (2.1) 2 (1.4) <0.0001 0.0014 
REGULATION OF MRNA STABILITY 
BY PROTEINS THAT BIND AU RICH 
ELEMENTS 
83 4 (4.8) [4] 4 (4.8) 0 (0) <0.0001 0.0026 
IMMUNE SYSTEM 870 9 (1) [11] 9 (1) 0 (0) 0.0002 0.007 
CLASS I MHC MEDIATED ANTIGEN 
PROCESSING PRESENTATION 228 5 (2.2) [5] 5 (2.2) 0 (0) 0.0002 0.007 
HOST INTERACTIONS OF HIV 
FACTORS 118 4 (3.4) [4] 4 (3.4) 0 (0) 0.0002 0.007 
INTEGRATION OF ENERGY 
METABOLISM 113 4 (3.5) [3] 2 (1.8) 2 (1.8) 0.0002 0.007 
FORMATION OF THE TERNARY 
COMPLEX AND SUBSEQUENTLY THE 
43S COMPLEX 
46 3 (6.5) [3] 2 (4.3) 1 (2.2) 0.0002 0.007 
CDK MEDIATED PHOSPHORYLATION 
AND REMOVAL OF CDC6 47 3 (6.4) [3] 3 (6.4) 0 (0) 0.0002 0.007 
AUTODEGRADATION OF THE E3 
UBIQUITIN LIGASE COP1 48 3 (6.2) [3] 3 (6.2) 0 (0) 0.0002 0.007 
P53 INDEPENDENT G1 S DNA 
DAMAGE CHECKPOINT 49 3 (6.1) [3] 3 (6.1) 0 (0) 0.0002 0.007 
SCF BETA TRCP MEDIATED 
DEGRADATION OF EMI1 50 3 (6) [3] 3 (6) 0 (0) 0.0002 0.007 
 
      
 130 
 
Table B-24 Continued. 
Category ID Category Genes # 
Significant Genes #(%) 
[#Protein Families] 
Genes Up (AS03 
vs. PBS) #(%) 
Genes Down (AS03 
vs. PBS) #(%) P FDR 
VIF MEDIATED DEGRADATION OF 
APOBEC3G 50 3 (6) [3] 3 (6) 0 (0) 0.0002 0.007 
DESTABILIZATION OF MRNA BY 
AUF1 HNRNP D0 52 3 (5.8) [3] 3 (5.8) 0 (0) 0.0003 0.0075 
ACTIVATION OF THE MRNA UPON 
BINDING OF THE CAP BINDING 
COMPLEX AND EIFS AND 
SUBSEQUENT BINDING TO 43S 
54 3 (5.6) [3] 2 (3.7) 1 (1.9) 0.0003 0.0075 
P53 DEPENDENT G1 DNA DAMAGE 
RESPONSE 54 3 (5.6) [3] 3 (5.6) 0 (0) 0.0003 0.0075 
SCFSKP2 MEDIATED DEGRADATION 
OF P27 P21 54 3 (5.6) [3] 3 (5.6) 0 (0) 0.0003 0.0075 
CDT1 ASSOCIATION WITH THE CDC6 
ORC ORIGIN COMPLEX 55 3 (5.5) [3] 3 (5.5) 0 (0) 0.0003 0.0076 
REGULATION OF APOPTOSIS 56 3 (5.4) [3] 3 (5.4) 0 (0) 0.0003 0.0078 
AUTODEGRADATION OF CDH1 BY 
CDH1 APC C 57 3 (5.3) [3] 3 (5.3) 0 (0) 0.0004 0.0079 
ACTIVATION OF NF KAPPAB IN B 
CELLS 61 3 (4.9) [3] 3 (4.9) 0 (0) 0.0004 0.0091 
METABOLISM OF PROTEINS 409 6 (1.5) [6] 3 (0.7) 3 (0.7) 0.0005 0.0092 
CYCLIN E ASSOCIATED EVENTS 
DURING G1 S TRANSITION 63 3 (4.8) [3] 3 (4.8) 0 (0) 0.0005 0.0092 
SIGNALING BY WNT 63 3 (4.8) [3] 3 (4.8) 0 (0) 0.0005 0.0092 
INTERFERON SIGNALING 153 4 (2.6) [6] 4 (2.6) 0 (0) 0.0005 0.0093 
ASSEMBLY OF THE PRE 
REPLICATIVE COMPLEX 64 3 (4.7) [3] 3 (4.7) 0 (0) 0.0005 0.0093 
APC C CDH1 MEDIATED 
DEGRADATION OF CDC20 AND 
OTHER APC C CDH1 TARGETED 
PROTEINS IN LATE MITOSIS EARLY 
G1 
65 3 (4.6) [3] 3 (4.6) 0 (0) 0.0005 0.0093 
APC C CDC20 MEDIATED 
DEGRADATION OF MITOTIC 
PROTEINS 
66 3 (4.5) [3] 3 (4.5) 0 (0) 0.0006 0.0093 
ORC1 REMOVAL FROM CHROMATIN 66 3 (4.5) [3] 3 (4.5) 0 (0) 0.0006 0.0093 
M G1 TRANSITION 77 3 (3.9) [3] 3 (3.9) 0 (0) 0.0009 0.0138 
REGULATION OF MITOTIC CELL 
CYCLE 78 3 (3.8) [3] 3 (3.8) 0 (0) 0.0009 0.014 
ADAPTIVE IMMUNE SYSTEM 494 6 (1.2) [6] 6 (1.2) 0 (0) 0.0013 0.0173 
HIV INFECTION 190 4 (2.1) [4] 4 (2.1) 0 (0) 0.0012 0.0173 
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Table B-24 Continued. 
Category ID Category Genes # 
Significant Genes #(%) 
[#Protein Families] 
Genes Up (AS03 
vs. PBS) #(%) 
Genes Down (AS03 
vs. PBS) #(%) P FDR 
PLATELET ACTIVATION SIGNALING 
AND AGGREGATION 191 4 (2.1) [3] 2 (1) 2 (1) 0.0012 0.0173 
REGULATION OF INSULIN 
SECRETION 87 3 (3.4) [2] 1 (1.1) 2 (2.3) 0.0013 0.0173 
SYNTHESIS OF DNA 90 3 (3.3) [3] 3 (3.3) 0 (0) 0.0014 0.0187 
DOWNSTREAM SIGNALING EVENTS 
OF B CELL RECEPTOR BCR 91 3 (3.3) [3] 3 (3.3) 0 (0) 0.0014 0.0189 
METABOLISM OF CARBOHYDRATES 221 4 (1.8) [5] 3 (1.4) 1 (0.5) 0.0021 0.0262 
G1 S TRANSITION 104 3 (2.9) [3] 3 (2.9) 0 (0) 0.0021 0.0262 
S PHASE 106 3 (2.8) [3] 3 (2.8) 0 (0) 0.0022 0.0271 
CELL CYCLE CHECKPOINTS 113 3 (2.7) [3] 3 (2.7) 0 (0) 0.0027 0.0314 
SIGNALING BY THE B CELL 
RECEPTOR BCR 118 3 (2.5) [3] 3 (2.5) 0 (0) 0.003 0.0349 
CYTOKINE SIGNALING IN IMMUNE 
SYSTEM 258 4 (1.6) [6] 4 (1.6) 0 (0) 0.0036 0.0413 
MITOTIC G1 G1 S PHASES 127 3 (2.4) [3] 3 (2.4) 0 (0) 0.0037 0.0415 
APOPTOSIS 137 3 (2.2) [3] 3 (2.2) 0 (0) 0.0046 0.0496 
 
 
Table B-25 Significantly enriched MSigDB Reactome Pathways for monocytes at day 7. Results are sorted by FDR and number of significant protein 
families. 
Category ID Category Genes # 
Significant Genes #(%) 
[#Protein Families] 
Genes Up (AS03 
vs. PBS) #(%) 
Genes Down (AS03 
vs. PBS) #(%) P FDR 
SMOOTH MUSCLE CONTRACTION 23 4 (17.4) [3] 2 (8.7) 2 (8.7) <0.0001 <0.0001 
MUSCLE CONTRACTION 45 4 (8.9) [3] 2 (4.4) 2 (4.4) <0.0001 0.0003 
RESPONSE TO ELEVATED PLATELET 
CYTOSOLIC CA2 74 4 (5.4) [3] 2 (2.7) 2 (2.7) <0.0001 0.0017 
GLUCOSE METABOLISM 59 3 (5.1) [2] 1 (1.7) 2 (3.4) 0.0001 0.0185 
PLATELET ACTIVATION SIGNALING 
AND AGGREGATION 191 4 (2.1) [3] 2 (1) 2 (1) 0.0003 0.0211 
METABOLISM OF CARBOHYDRATES 221 4 (1.8) [3] 2 (0.9) 2 (0.9) 0.0005 0.0305 
MRNA SPLICING 103 3 (2.9) [2] 3 (2.9) 0 (0) 0.0007 0.0345 
PROCESSING OF CAPPED INTRON 
CONTAINING PRE MRNA 132 3 (2.3) [2] 3 (2.3) 0 (0) 0.0015 0.0456 
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Table B-26 Significantly enriched MSigDB Reactome Pathways for monocytes at day 28.  Results are sorted by FDR and number of significant protein 
families. 
Category ID Category Genes # 
Significant Genes #(%) 
[#Protein Families] 
Genes Up (AS03 
vs. PBS) #(%) 
Genes Down (AS03 
vs. PBS) #(%) P FDR 
APOPTOTIC EXECUTION PHASE 48 5 (10.4) [3] 4 (8.3) 1 (2.1) <0.0001 <0.0001 
MRNA SPLICING 103 5 (4.9) [4] 5 (4.9) 0 (0) <0.0001 0.0003 
PROCESSING OF CAPPED INTRON 
CONTAINING PRE MRNA 132 5 (3.8) [4] 5 (3.8) 0 (0) <0.0001 0.0005 
APOPTOSIS 137 5 (3.6) [3] 4 (2.9) 1 (0.7) <0.0001 0.0005 
MRNA PROCESSING 151 5 (3.3) [4] 5 (3.3) 0 (0) <0.0001 0.0007 
RESPONSE TO ELEVATED PLATELET 
CYTOSOLIC CA2 74 4 (5.4) [4] 3 (4.1) 1 (1.4) <0.0001 0.0008 
PLATELET ACTIVATION SIGNALING AND 
AGGREGATION 191 5 (2.6) [5] 3 (1.6) 2 (1) <0.0001 0.0017 
CASPASE MEDIATED CLEAVAGE OF 
CYTOSKELETAL PROTEINS 12 2 (16.7) [2] 1 (8.3) 1 (8.3) 0.0002 0.0146 
 
 
Table B-27 Significantly enriched MSigDB Reactome Pathways for neutrophils at day 1. Results are sorted by FDR and number of significant protein 
families. 
Category ID Category Genes # 
Significant Genes #(%) 
[#Protein Families] 
Genes Up (AS03 
vs. PBS) #(%) 
Genes Down (AS03 
vs. PBS) #(%) P FDR 
PROTEIN FOLDING 50 5 (10) [2] 2 (4) 3 (6) <0.0001 <0.0001 
PREFOLDIN MEDIATED TRANSFER 
OF SUBSTRATE TO CCT TRIC 27 4 (14.8) [2] 2 (7.4) 2 (7.4) <0.0001 <0.0001 
METABOLISM OF PROTEINS 409 7 (1.7) [4] 4 (1) 3 (0.7) <0.0001 <0.0001 
THE NLRP3 INFLAMMASOME 11 2 (18.2) [2] 2 (18.2) 0 (0) <0.0001 0.0062 
INFLAMMASOMES 16 2 (12.5) [2] 2 (12.5) 0 (0) 0.0001 0.0116 
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Table B-28 Significantly enriched MSigDB Reactome Pathways for neutrophils at day 3.  Results are sorted by FDR and number of significant protein 
families. 
Category ID Category Genes # 
Significant Genes #(%) 
[#Protein Families] 
Genes Up (AS03 
vs. PBS) #(%) 
Genes Down (AS03 
vs. PBS) #(%) P FDR 
SIGNALING BY THE B CELL 
RECEPTOR BCR 118 6 (5.1) [3] 3 (2.5) 3 (2.5) <0.0001 <0.0001 
ANTIGEN ACTIVATES B CELL 
RECEPTOR LEADING TO 
GENERATION OF SECOND 
MESSENGERS 
27 4 (14.8) [2] 3 (11.1) 1 (3.7) <0.0001 <0.0001 
SIGNALING BY ERBB2 96 5 (5.2) [2] 3 (3.1) 2 (2.1) <0.0001 <0.0001 
SIGNALING BY EGFR IN CANCER 103 5 (4.9) [2] 3 (2.9) 2 (1.9) <0.0001 <0.0001 
SIGNALING BY FGFR 107 5 (4.7) [2] 3 (2.8) 2 (1.9) <0.0001 <0.0001 
SIGNALING BY FGFR IN DISEASE 120 5 (4.2) [2] 3 (2.5) 2 (1.7) <0.0001 <0.0001 
ADAPTIVE IMMUNE SYSTEM 494 7 (1.4) [4] 4 (0.8) 3 (0.6) <0.0001 <0.0001 
RESPONSE TO ELEVATED PLATELET 
CYTOSOLIC CA2 74 4 (5.4) [2] 3 (4.1) 1 (1.4) <0.0001 <0.0001 
PLATELET ACTIVATION SIGNALING 
AND AGGREGATION 191 5 (2.6) [3] 3 (1.6) 2 (1) <0.0001 <0.0001 
SIGNALLING BY NGF 201 5 (2.5) [2] 3 (1.5) 2 (1) <0.0001 0.0001 
HEMOSTASIS 440 6 (1.4) [4] 3 (0.7) 3 (0.7) <0.0001 0.0002 
IMMUNE SYSTEM 870 7 (0.8) [4] 4 (0.5) 3 (0.3) <0.0001 0.0009 
ER PHAGOSOME PATHWAY 59 3 (5.1) [2] 1 (1.7) 2 (3.4) <0.0001 0.0009 
ANTIGEN PROCESSING CROSS 
PRESENTATION 72 3 (4.2) [2] 1 (1.4) 2 (2.8) <0.0001 0.0013 
CYTOKINE SIGNALING IN IMMUNE 
SYSTEM 258 4 (1.6) [3] 1 (0.4) 3 (1.2) 0.0002 0.0026 
INTERFERON SIGNALING 153 3 (2) [2] 1 (0.7) 2 (1.3) 0.0007 0.007 
CLASS I MHC MEDIATED ANTIGEN 
PROCESSING PRESENTATION 228 3 (1.3) [2] 1 (0.4) 2 (0.9) 0.0022 0.0169 
MRNA SPLICING 103 2 (1.9) [2] 1 (1) 1 (1) 0.0063 0.0355 
 
 
Table B-29 Significantly enriched MSigDB Reactome Pathways for neutrophils at day 7. Results are sorted by FDR and number of significant protein 
families. 
Category ID Category Genes # 
Significant Genes #(%) 
[#Protein Families] 
Genes Up (AS03 
vs. PBS) #(%) 
Genes Down (AS03 vs. 
PBS) #(%) P FDR 
SEMAPHORIN INTERACTIONS 62 3 (4.8) [3] 1 (1.6) 2 (3.2) <0.0001 0.0095 
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Table B-30 Significantly enriched MSigDB Reactome Pathways for neutrophils at day 28. Results are sorted by FDR and number of significant protein 
families. 
Category ID Category Genes # 
Significant Genes #(%) 
[#Protein Families] 
Genes Up (AS03 
vs. PBS) #(%) 
Genes Down (AS03 
vs. PBS) #(%) P FDR 
HEMOSTASIS 440 5 (1.1) [4] 0 (0) 5 (1.1) <0.0001 0.0097 
ANTIGEN PRESENTATION FOLDING 
ASSEMBLY AND PEPTIDE LOADING OF 
CLASS I MHC 
20 2 (10) [2] 2 (10) 0 (0) 0.0002 0.0162 
INTEGRATION OF ENERGY 
METABOLISM 113 3 (2.7) [2] 0 (0) 3 (2.7) 0.0002 0.0162 
PLATELET ACTIVATION SIGNALING 
AND AGGREGATION 191 3 (1.6) [2] 0 (0) 3 (1.6) 0.0008 0.0442 
 
 
Table B-31 Significantly enriched MSigDB Reactome Pathways for NK cells at day 3. Results are sorted by FDR and number of significant protein families. 
Category ID Category Genes # 
Significant Genes #(%) 
[#Protein Families] 
Genes Up (AS03 
vs. PBS) #(%) 
Genes Down (AS03 
vs. PBS) #(%) P FDR 
FORMATION OF TUBULIN FOLDING 
INTERMEDIATES BY CCT TRIC 21 5 (23.8) [3] 5 (23.8) 0 (0) <0.0001 <0.0001 
PREFOLDIN MEDIATED TRANSFER OF 
SUBSTRATE TO CCT TRIC 27 5 (18.5) [3] 5 (18.5) 0 (0) <0.0001 <0.0001 
PROTEIN FOLDING 50 5 (10) [3] 5 (10) 0 (0) <0.0001 <0.0001 
POST CHAPERONIN TUBULIN 
FOLDING PATHWAY 18 4 (22.2) [2] 4 (22.2) 0 (0) <0.0001 <0.0001 
METABOLISM OF PROTEINS 409 8 (2) [6] 7 (1.7) 1 (0.2) <0.0001 <0.0001 
RESPIRATORY ELECTRON 
TRANSPORT ATP SYNTHESIS BY 
CHEMIOSMOTIC COUPLING AND 
HEAT PRODUCTION BY UNCOUPLING 
PROTEINS 
91 3 (3.3) [3] 3 (3.3) 0 (0) 0.0001 0.0104 
FORMATION OF ATP BY 
CHEMIOSMOTIC COUPLING 15 2 (13.3) [2] 2 (13.3) 0 (0) 0.0001 0.0104 
TCA CYCLE AND RESPIRATORY 
ELECTRON TRANSPORT 124 3 (2.4) [3] 3 (2.4) 0 (0) 0.0003 0.0233 
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Table B-32 Significantly enriched MSigDB Reactome Pathways for T cells at day 1.  Results are sorted by FDR and number of significant protein families. 
Category ID Category Genes # 
Significant Genes #(%) 
[#Protein Families] 
Genes Up (AS03 
vs. PBS) #(%) 
Genes Down (AS03 
vs. PBS) #(%) P FDR 
POST CHAPERONIN TUBULIN 
FOLDING PATHWAY 18 4 (22.2) [2] 4 (22.2) 0 (0) <0.0001 <0.0001 
FORMATION OF TUBULIN FOLDING 
INTERMEDIATES BY CCT TRIC 21 4 (19) [2] 4 (19) 0 (0) <0.0001 <0.0001 
PROTEIN FOLDING 50 4 (8) [2] 4 (8) 0 (0) <0.0001 0.0001 
RAP1 SIGNALLING 16 3 (18.8) [2] 2 (12.5) 1 (6.2) <0.0001 0.0002 
LOSS OF NLP FROM MITOTIC 
CENTROSOMES 54 3 (5.6) [2] 0 (0) 3 (5.6) <0.0001 0.0051 
RECRUITMENT OF MITOTIC 
CENTROSOME PROTEINS AND 
COMPLEXES 
61 3 (4.9) [2] 0 (0) 3 (4.9) <0.0001 0.0063 
MITOTIC G2 G2 M PHASES 76 3 (3.9) [2] 0 (0) 3 (3.9) 0.0001 0.0097 
ARMS MEDIATED ACTIVATION 17 2 (11.8) [2] 1 (5.9) 1 (5.9) 0.0002 0.0131 
PROLONGED ERK ACTIVATION 
EVENTS 19 2 (10.5) [2] 1 (5.3) 1 (5.3) 0.0003 0.0139 
SIGNALLING TO ERKS 36 2 (5.6) [2] 1 (2.8) 1 (2.8) 0.001 0.0411 
 
 
Table B-33 Significantly enriched MSigDB Reactome Pathways for T cells at day 7.  Results are sorted by FDR and number of significant protein families. 
Category ID Category Genes # 
Significant Genes #(%) 
[#Protein Families] 
Genes Up (AS03 
vs. PBS) #(%) 
Genes Down (AS03 
vs. PBS) #(%) P FDR 
SEMAPHORIN INTERACTIONS 62 2 (3.2) [2] 1 (1.6) 1 (1.6) 0.001 0.0462 
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Table B-34 Combination of protein families differentiating between seroprotection status for monocytes at day 1. Sorted by descending absolute logistic 
regression coefficient (log odds ratio).  
Ensembl Protein ID Ensembl Gene ID Gene Name Ensemble Gene Description Coefficient 
ENSP00000459921 ENSG00000262785 PKLR pyruvate kinase, liver and RBC [Source:HGNC Symbol;Acc:9020] 2.2980 
ENSP00000250559 ENSG00000127314 RAP1B RAP1B, member of RAS oncogene family [Source:HGNC Symbol;Acc:9857] 1.4093 
ENSP00000358162 ENSG00000183941 HIST2H4A histone cluster 2, H4a [Source:HGNC Symbol;Acc:4794] 0.9855 
ENSP00000446252 ENSG00000112096 SOD2 superoxide dismutase 2, mitochondrial [Source:HGNC Symbol;Acc:11180] 0.8463 
ENSP00000344419 ENSG00000005381 MPO myeloperoxidase [Source:HGNC Symbol;Acc:7218] 0.6826 
ENSP00000381216 ENSG00000088247 KHSRP KH-type splicing regulatory protein [Source:HGNC Symbol;Acc:6316] 0.1670 
ENSP00000350667 ENSG00000140416 TPM1 tropomyosin 1 (alpha) [Source:HGNC Symbol;Acc:12010] 0.1489 
ENSP00000371982 ENSG00000100453 GZMB granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine 
esterase 1) [Source:HGNC Symbol;Acc:4709] 0.0671 
 
 
Table B-35 Combination of protein families differentiating between seroprotection status for monocytes at day 3.  Sorted by descending absolute logistic 
regression coefficient (log odds ratio). 
Ensembl Protein ID Ensembl Gene ID Gene Name Ensemble Gene Description Coefficient 
ENSP00000216802 ENSG00000100911 PSME2 proteasome (prosome, macropain) activator subunit 2 (PA28 beta) [Source:HGNC Symbol;Acc:9569] 1.0332 
ENSP00000373123 ENSG00000206509 HLA-F major histocompatibility complex, class I, F [Source:HGNC Symbol;Acc:4963] 0.8873 
ENSP00000324074 ENSG00000143401 ANP32E acidic (leucine-rich) nuclear phosphoprotein 32 family, member E [Source:HGNC Symbol;Acc:16673] 0.7787 
ENSP00000250559 ENSG00000127314 RAP1B RAP1B, member of RAS oncogene family [Source:HGNC Symbol;Acc:9857] 0.5431 
ENSP00000391481 ENSG00000163931 TKT transketolase [Source:HGNC Symbol;Acc:11834] 0.4869 
ENSP00000357076 ENSG00000158710 TAGLN2 transgelin 2 [Source:HGNC Symbol;Acc:11554] 0.3746 
ENSP00000229270 ENSG00000111669 TPI1 triosephosphate isomerase 1 [Source:HGNC Symbol;Acc:12009] -0.2424 
ENSP00000372155 ENSG00000092010 PSME1 proteasome (prosome, macropain) activator subunit 1 (PA28 alpha) [Source:HGNC Symbol;Acc:9568] 0.2143 
ENSP00000296181 ENSG00000082781 ITGB5 integrin, beta 5 [Source:HGNC Symbol;Acc:6160] 0.2064 
ENSP00000300026 ENSG00000166794 PPIB peptidylprolyl isomerase B (cyclophilin B) [Source:HGNC Symbol;Acc:9255] 0.1679 
ENSP00000245932 ENSG00000125753 VASP vasodilator-stimulated phosphoprotein [Source:HGNC Symbol;Acc:12652] 0.0888 
ENSP00000279227 ENSG00000149781 FERMT3 fermitin family member 3 [Source:HGNC Symbol;Acc:23151] 0.0695 
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Table B-36 Combination of protein families differentiating between seroprotection status for monocytes at day 7. Sorted by descending absolute logistic 
regression coefficient (log odds ratio). 
Ensembl Protein ID Ensembl Gene ID Gene Name Ensemble Gene Description Coefficient 
ENSP00000353129 ENSG00000183783 KCTD8 potassium channel tetramerization domain containing 8 [Source:HGNC Symbol;Acc:22394] 1.4593 
ENSP00000270776 ENSG00000142657 PGD phosphogluconate dehydrogenase [Source:HGNC Symbol;Acc:8891] 0.8716 
ENSP00000455356 ENSG00000180209 MYLPF myosin light chain, phosphorylatable, fast skeletal muscle [Source:HGNC Symbol;Acc:29824] 0.7378 
ENSP00000279227 ENSG00000149781 FERMT3 fermitin family member 3 [Source:HGNC Symbol;Acc:23151] -0.5299 
ENSP00000346550 ENSG00000197043 ANXA6 annexin A6 [Source:HGNC Symbol;Acc:544] -0.4512 
ENSP00000264932 ENSG00000073578 SDHA succinate dehydrogenase complex, subunit A, flavoprotein (Fp) [Source:HGNC Symbol;Acc:10680] 0.4453 
ENSP00000388169 ENSG00000241553 ARPC4 actin related protein 2/3 complex, subunit 4, 20kDa [Source:HGNC Symbol;Acc:707] -0.4105 
ENSP00000295897 ENSG00000163631 ALB albumin [Source:HGNC Symbol;Acc:399] 0.3807 
ENSP00000273398 ENSG00000114573 ATP6V1A ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A [Source:HGNC Symbol;Acc:851] 0.3463 
ENSP00000216802 ENSG00000100911 PSME2 proteasome (prosome, macropain) activator subunit 2 (PA28 beta) [Source:HGNC Symbol;Acc:9569] 0.2992 
ENSP00000346921 ENSG00000004455 AK2 adenylate kinase 2 [Source:HGNC Symbol;Acc:362] -0.2647 
ENSP00000262030 ENSG00000110955 ATP5B ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide [Source:HGNC Symbol;Acc:830] -0.1258 
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Table B-37 Combination of protein families differentiating between seroprotection status for neutrophils at day 1. Sorted by descending absolute logistic 
regression coefficient (log odds ratio). 
Ensembl Protein ID Ensembl Gene ID Gene Name Ensemble Gene Description Coefficient 
ENSP00000362089 ENSG00000148346 LCN2 lipocalin 2 [Source:HGNC Symbol;Acc:6526] -6.5855 
ENSP00000386786 ENSG00000196604 POTEF POTE ankyrin domain family, member F [Source:HGNC Symbol;Acc:33905] 6.2142 
ENSP00000216392 ENSG00000100504 PYGL phosphorylase, glycogen, liver [Source:HGNC Symbol;Acc:9725] -4.9844 
ENSP00000236826 ENSG00000118113 MMP8 matrix metallopeptidase 8 (neutrophil collagenase) [Source:HGNC Symbol;Acc:7175] -3.1220 
ENSP00000221992 ENSG00000105388 CEACAM5 carcinoembryonic antigen-related cell adhesion molecule 5 [Source:HGNC Symbol;Acc:1817] -2.9938 
ENSP00000443475 ENSG00000167553 TUBA1C tubulin, alpha 1c [Source:HGNC Symbol;Acc:20768] -2.5615 
ENSP00000250559 ENSG00000127314 RAP1B RAP1B, member of RAS oncogene family [Source:HGNC Symbol;Acc:9857] -2.1966 
ENSP00000380334 ENSG00000100365 NCF4 neutrophil cytosolic factor 4, 40kDa [Source:HGNC Symbol;Acc:7662] -2.1249 
ENSP00000295897 ENSG00000163631 ALB albumin [Source:HGNC Symbol;Acc:399] 2.0315 
ENSP00000222553 ENSG00000105835 NAMPT nicotinamide phosphoribosyltransferase [Source:HGNC Symbol;Acc:30092] -2.0269 
ENSP00000459921 ENSG00000262785 PKLR pyruvate kinase, liver and RBC [Source:HGNC Symbol;Acc:9020] -2.0072 
ENSP00000279227 ENSG00000149781 FERMT3 fermitin family member 3 [Source:HGNC Symbol;Acc:23151] 1.8581 
ENSP00000350667 ENSG00000140416 TPM1 tropomyosin 1 (alpha) [Source:HGNC Symbol;Acc:12010] -1.8502 
ENSP00000222286 ENSG00000105679 GAPDHS glyceraldehyde-3-phosphate dehydrogenase, spermatogenic [Source:HGNC Symbol;Acc:24864] -1.7305 
ENSP00000401010 ENSG00000077549 CAPZB capping protein (actin filament) muscle Z-line, beta [Source:HGNC Symbol;Acc:1491] -1.2546 
ENSP00000310219 ENSG00000173110 HSPA6 heat shock 70kDa protein 6 (HSP70B) [Source:HGNC Symbol;Acc:5239] -1.2306 
ENSP00000346550 ENSG00000197043 ANXA6 annexin A6 [Source:HGNC Symbol;Acc:544] 1.0741 
ENSP00000371982 ENSG00000100453 GZMB granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine 
esterase 1) [Source:HGNC Symbol;Acc:4709] -1.0695 
ENSP00000384678 ENSG00000189403 HMGB1 high mobility group box 1 [Source:HGNC Symbol;Acc:4983] -1.0413 
ENSP00000466090 ENSG00000197561 ELANE elastase, neutrophil expressed [Source:HGNC Symbol;Acc:3309] -1.0067 
ENSP00000263238 ENSG00000115091 ACTR3 ARP3 actin-related protein 3 homolog (yeast) [Source:HGNC Symbol;Acc:170] -0.7432 
ENSP00000354947 ENSG00000198898 CAPZA2 capping protein (actin filament) muscle Z-line, alpha 2 [Source:HGNC Symbol;Acc:1490] -0.5263 
ENSP00000369315 ENSG00000133026 MYH10 myosin, heavy chain 10, non-muscle [Source:HGNC Symbol;Acc:7568] -0.5010 
ENSP00000283195 ENSG00000153201 RANBP2 RAN binding protein 2 [Source:HGNC Symbol;Acc:9848] 0.2982 
ENSP00000241052 ENSG00000121691 CAT catalase [Source:HGNC Symbol;Acc:1516] 0.1718 
ENSP00000394496 ENSG00000110880 CORO1C coronin, actin binding protein, 1C [Source:HGNC Symbol;Acc:2254] 0.0231 
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 APPENDIX C 
 
ASSESSMENT OF INSTRUMENT STABILITY 
 
     Due to requiring the LTQ mass spectrometer to run 700 samples for quality control, a stability 
test was performed to determine the stability of it and the Thermo PAL autosampler. Ten aliquots 
of Pepmix (Table C-1) were loaded into the autosampler and run in triplicate using a 60 min 
gradient (5-45% acetonitrile).  The raw files were converted to mxzml format and analyzed using 
X!Tandem. The number of peptides identified and the glufib peak area were plotted to observe 
any trends between the samples (Figure C-1).  
 
Table C-1 Components of Pepmix Samples 
Concentration 
(fmol/µL) 
Peptide/Protein Digest Company 
50 BSA Digest Standard Protea 
50 Yeast (S. cerevisiae) alcohol 
dehydrogenase 
Protea 
50 Yeast (S. cerevisiae) enolase Protea 
50 Glu-1-Fibrinopeptide B Prote 
100 Angiotensin II Sigma Aldrich 
100 ACTH Sigma Aldrich 
 
 
Figure C-1 Assessment of stability in LTQ.(A) Glufib peptide peak area and (B) number of peptides identified in 
triplicate experiments of 10 pepmix samples shows some variability across samples, but overall no significant 
differences between samples. 
 
 140 
 
     Glufib was chosen as the peptide to monitor for stability, as it is added to each sample prior to 
MS analysis to monitor the chromatography and instrument response. The peak area of glufib 
and the total number of peptides tracked similar patterns over the 10 pepmix samples. While there 
is variability across samples, there is no significant differences due to the overlap of the error 
bars. The high standard deviation was determined to be due to an issue in the autosampler picking 
up such a small volume (1 µL). Overall, it was determined that the instrument and autosampler 
was stable enough to run the QC samples. Additional pepmix samples and blanks were run during 
QC experiments to ensure continued stability of the instrument.
Allison C. Galassie 
263 Wildberry Lane, Nashville, TN 37209 ·  Phone: 803-413-7871 
Email: allison.c.galassie@gmail.com · Web: https://www.linkedin.com/in/allisoncgalassie 
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• Galassie, A. C., Samir, P., Hoek, K. L., Niu, X., Link, A. J. Quantitative Proteomic and Systems 
Analysis of Cells in Response to External Stimuli. 62nd ASMS Conference on Mass Spectrometry 
and Allied Topics, Baltimore, MD, June 2014. 
• Samir, P., Hoek K.L., Howard, L. M., Allos, T., Galassie, A. C., Niu, X., Creech, C. B., Joyce, 
S., Edwards, K. M., Link, A. J. Optimizing the iTRAQ Multiplexing Strategy for Quantitative 
Proteomics Analysis of Immune Cell Subsets Fractionated from Whole Blood of Human 
Subjects.  61st ASMS Conference on Mass Spectrometry and Allied Topics, Minneapolis, MN, 
2013.  
• Galassie, A. C., Wieliczo, M. B., Smith, D. L. In situ Analysis of the Synthesis of Ergovaline 
using Direct Analysis in Real Time Mass Spectrometry (DART-MS). American Chemical 
Society National Meeting, San Diego, CA, April 2012 and Undergraduate Presentation 
Showcase, Richmond, KY, April 2012. 
• Galassie, A. C., Wieliczko, M. B., Smith, D. L. Synthetic Developments towards Ergovaline. 
Kentucky Academy of Sciences Meeting, Murray, KY, Nov. 2011. 
• Galassie, A. C., Jones, N., Van Zant, S., Wheeler, B. Learning Outcomes of Interdisciplinary 
Projects. National Collegiate Honors Council Conference, Phoenix, AZ, Oct 2011.   
    
TEACHING EXPERIENCE 
     
Teaching Assistant, Analytical Chemistry       Aug. 2016 – Dec 2016 
Department of Chemistry, Vanderbilt University         Nashville, TN 
 
Teaching Assistant, Forensic Analytical Chemistry                                                  Jan 2013- May 2013 
Department of Chemistry, Vanderbilt University                                                                     Nashville, TN 
 
Teaching Assistant, General Chemistry Lab                          Aug 2012- Dec 2012 
Department of Chemistry, Vanderbilt University                                                                     Nashville, TN 
 
Teaching Assistant, Forensic and Chemical Instrumental Analysis                        Aug 2011-May 2012 
Department of Chemistry, Eastern Kentucky University                                                        Richmond, KY 
 
Teaching Assistant, Forensic Microscopy                                  Aug 2011-Dec. 2011 
Department of Chemistry, Eastern Kentucky University                                                        Richmond, KY 
 
 144 
 
Tutor and Grader                                   Aug 2010-May 2011 
Department of Chemistry, Eastern Kentucky University                                                        Richmond, KY 
 
AWARDS AND FUNDING 
     
Top Poster at the Vanderbilt Institute for Chemical Biology Student Research Symposium                 2016 
NIH Training Grant: Immunobiology of Blood and Vascular Systems Training Program         2013 – 2016  
ASMS Student Travel Award                 2015, 2016 
Vanderbilt Graduate School Travel Grant                2014, 2015, 2016 
Top Senior in Forensics Award              2012 
Top Junior in Forensics Award               2011 
Top Junior in Chemistry Award              2010 
Thomas Herndon Scholarship              2010 
President’s List            Fall 2008 – Spring 2010, Spring 2011 – Spring 2012 
Dean’s List                      Fall 2008 – Spring 2012 
 
AFFILIATIONS 
     
American Chemical Society 
American Society for Mass Spectrometry 
Mu Sigma Rho National Statistics Honorary Society  
 
LEADERSHIP 
    
Chemistry Department Student Representative for the Dean                                    August 2011-May 2012 
 
COMMUNITY SERVICE AND OUTREACH 
Adventure Science Center: Nanoday and Making Stuff Volunteer         March 2014 
Vanderbilt Center for Science Outreach: Young Scientist Journal Editor             Fall 2014 
Vanderbilt Center for Science Outreach: Poster Judge         July 2015, July 2016 
Nashville Zoo Adult Volunteer Corps         August 2016 - Present 
 
